

Lymphoma

Effective date: August 2025



Table of Contents

Background

Guideline Questions

Search Strategy

Target Population

Discussion

I. Diagnosis and Pathologic Classifications (Last reviewed: Oct 2024)

II. Staging (Last reviewed Oct 2024)

III. Treatment of Non-Hodgkin Lymphomas (Last reviewed: Aug 2025)

IV. Cutaneous Lymphoma (Last reviewed: Jul 2021)

V. Hodgkin Lymphoma (Last reviewed: Jul 2025)

VI. HDCT and Hematopoietic Stem Cell Transplantation for Lymphoma (Last reviewed: Oct 2024)

VII. Prevention and Management of Toxicities of Bispecific Antibodies in Lymphoma (Last reviewed: Oct 2024)

VIII. Supportive Care in the Treatment of Lymphoma (Last reviewed: Oct 2024)

IX. Follow-Up Care in the Treatment of Lymphoma (Last reviewed: Sep 2023)

Appendix A (Chemotherapy Regimens)

Appendix B: General Radiotherapy Guidelines

Appendix C: Prognostic Models

Appendix D: Lymphoma Response Criteria

Appendix E: New Lymphoma Patient Data Sheet

Appendix F: Ideal Body Weight

Glossary of Abbreviations

Dissemination

Maintenance

Background

Lymphomas encompass a group of lymphoproliferative malignant diseases that originate from T- and B-cells in the lymphatic system. Traditionally, lymphomas have been subcategorized into two groups: Hodgkin lymphoma and non-Hodgkin lymphoma. It is now known however, that Hodgkin lymphoma is simply one of the numerous varieties of lymphoma, and that non-Hodgkin lymphoma is a fairly meaningless term, representing all of the other subtypes of this disease.

Non-Hodgkin lymphoma involves a heterogeneous group of over 40 lymphoproliferative malignancies with diverse patterns of behaviours and responses to treatments. Non-Hodgkin lymphoma is much less predictable than Hodgkin lymphoma and prognosis depends on the histologic type, stage, and treatment. In Canadian males and females, the incidence rates for non-Hodgkin lymphoma showed a marked increase by approximately 50% between 1978 and the late 1990s, but have since stabilized¹. Mortality rates have followed a similar pattern. The clearest risk factor for the disease is immunosuppression associated with HIV infection, or medications used to prevent rejection in organ transplantation. Other factors that increase risk of non-Hodgkin lymphoma are poorly understood but may include occupational exposures to pesticides, herbicides, and dioxins, as well as chronic immune stimulation associated with autoimmune disorders (e.g. thyroiditis, Sjogren's Syndrome, SLE) or infections (e.g. *Helicobacter pylori* gastritis, hepatitis C virus)². In 2015, it is estimated that 8200 new cases of non-Hodgkin lymphoma will be diagnosed in Canada, and 2650 deaths will occur, making non-Hodgkin lymphoma the sixth most common cause of cancer-related death in Canada³.

Hodgkin lymphoma is a malignancy characterized histopathologically by the presence of Reed-Sternberg cells in the appropriate cellular background. Although rare, Hodgkin lymphoma is one of the best-characterized malignancies of the lymphatic system and one of the most readily curable forms of malignant disease.² The incidence rate has remained fairly steady over time, it is estimated that approximately 1000 new cases of Hodgkin lymphoma are diagnosed in Canada each year³. It is important to note that lymphoma also represents the most commonly diagnosed non-epithelial cancers in adolescents and young adults in Canada. Between 1992 and 2005, 5577 new cases of Hodgkin and non-Hodgkin lymphoma were diagnosed in Canadians aged 15-29 years¹. ***The following guidelines do not address lymphoma in the pediatric or adolescent populations.***

Guideline Questions

- What are the diagnostic criteria for the most common lymphomas?
- What are the staging and re-staging procedures for Hodgkin and non-Hodgkin lymphomas?
- What are the recommended treatment and management options for Hodgkin and non-Hodgkin lymphomas?
- What are the recommended follow-up procedures for patients with malignant Hodgkin and non-Hodgkin lymphoma?

Search Strategy

Medical journal articles were searched using Medline (1950 to October Week 1, 2015), EMBASE (1980 to October Week 1, 2015), Cochrane Database of Systematic Reviews (3rd Quarter, 2015), and PubMed electronic databases. An updated review of the relevant existing practice guidelines for lymphoma was also conducted by accessing the websites of the National Comprehensive Cancer Network (NCCN), Cancer Care Ontario (CCO), the British Columbia Cancer Agency (BCCA), the European Society for Medical Oncology (ESMO), and the British Committee for Standards in Haematology.

Target Population

The following guidelines apply to adults over 18 years of age. Different principles may apply to pediatric and adolescent patients.

References

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics. In. *Special Topic: Cancer in Adolescents and Young Adults*. Available at: <http://www.cancer.ca/Canadawide/About%20cancer/Cancer%20statistics/~media/CCS/Canada%20wide/Files%20List/English%20files%20heading/pdf%20not%20in%20publications%20section/Stats%202009E%20Special%20Topics.ashx>2009.
2. Marcus R. *Lymphoma: pathology, diagnosis, and treatment*. 14th ed: Cambridge University Press; 2007.
3. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics. In. Available at: <http://www.cancer.ca/Canadawide/About%20cancer/~media/CCS/Canada%20wide/Files%20List/English%20files%20heading/PDF%20%20Policy%20-%20Canadian%20Cancer%20Statistics%20%20English/Canadian%20Cancer%20Statistics%202011%20-%20English.ashx>.2011.

I. Diagnosis and Pathologic Classification ¹⁻⁶

Sufficient tissue is required for the diagnosis of lymphoma. Fine needle aspirates are not sufficient and only lead to diagnostic delays. Historically, a surgical biopsy was recommended but more recent data, including a comparative study, have demonstrated that a well-performed radiology-guided core needle biopsy provides equivalent diagnostic accuracy with less complications⁷. Cancer Care Alberta now supports diagnostic pathways for many cancers including lymphoma ([Lymphoma Diagnosis Program](#)). All patients who are considered highly likely to have lymphoma should be referred to the LDP to expedite appropriate diagnostic and staging investigations.

Table 1 describes the histologic subclassification of the malignant lymphomas, and is an **adaptation** of the most recent WHO classification⁶. This classification is based on the light microscopic interpretation complemented by special stains, immunophenotyping, cytogenetics and other ancillary information as available. The specific lymphomas are divided into three major groups, according to the degree of clinical aggressiveness, for treatment planning. All B-cell lymphomas should be immuno-phenotyped to determine if they are CD20 positive.

Table 1. Lymphoma classification⁶.

	B-cell	T-cell
Indolent	Follicular, grades 1-2, 3a Small lymphocytic Lymphoma/Chronic Lymphocytic Leukemia Marginal zone, extranodal (MALT) Splenic marginal zone Marginal zone, nodal (monocytoid B-cell) Lymphoplasmacytic (Waldenström's macroglobulinemia) Primary cutaneous, follicle centre Hairy cell leukemia Nodular lymphocyte predominant Hodgkin Lymphoma Mantle cell (can be aggressive)	Mycosis fungoides /Sezary syndrome Primary cutaneous, CD30+ Primary cutaneous perioheral T-cell lymphoma PTCL, CD30- T-cell large granular lymphocytic leukemia
Aggressive	Diffuse large B-cell - o T-cell/histocyte-rich DLBCL - o Primary DLBCL of the CNS - o Primary cutaneous DLBCL, leg-type - o EBV-positive DLBCL of the elderly DLBCL associated with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal large B-cell Intravascular large B-cell ALK positive large B-cell Plasmablastic lymphoma LBCL in HHV8-associated Castleman disease Primary effusion lymphoma Follicular grade 3b (large cell) Classical Hodgkin lymphoma ⇒ Nodular sclerosis ⇒ Mixed cellularity ⇒ Lymphocyte rich ⇒ Lymphocyte depleted	Peripheral T-cell, unspecified Angioimmunoblastic (AITL, formerly AILD) Enteropathy associated T-cell Hepatosplenic T-cell Subcutaneous panniculitis-like Anaplastic large cell (CD30+) ALK+ Anaplastic large cell (CD30+) ALK- Extranodal NK/T-cell, nasal type
Special	Burkitt lymphoma Intermediate between DLBCL and BL Intermediate between DLBCL and Hodgkin lymphoma B lymphoblastic leukemia/lymphoma B prolymphocytic leukemia Lymphomas associated with HIV infection Lymphomas associated with primary immune disorders Post-transplant lymphoproliferative disorders (PTLD) - o Plasmacytic hyperplasia and infectious mononucleosis-like PTLD - o Polymorphic PTLD - o Monomorphic PTLD - o Classical Hodgkin-type PTLD Other iatrogenic immunodeficiency-associated lymphomas	T lymphoblastic leukemia/lymphoma Adult T-cell leukemia/lymphoma (ATLL) T prolymphocytic leukemia

Required Immunohistochemical and Ancillary Testing for Lymphoma

In general, guidelines for using the various ancillary methods, including immunohistochemical and fluorescence in situ hybridization (FISH) testing as outlined in the most recent version of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues should be followed so as to confirm a specific diagnosis and provide necessary prognostic and/or predictive information⁶. In addition, the following are recommended by the Alberta Provincial Hematology Tumour Team^{8, 9}:

1. **Classical Hodgkin Lymphoma:** The immunohistochemical panel may include CD45/CD3/CD20/CD30/CD15/ PAX5/MUM1 and should be selected on a case by case basis at the discretion of the hematopathologist. EBV studies by in situ hybridization (EBER) may be considered if difficulty exists diagnostically, as most cases of the mixed-cellularity subtype of classical Hodgkin lymphoma are EBER positive.
2. **Diffuse Large B-Cell Lymphoma (DLBCL):**
 - Immunohistochemical (IHC) panels to distinguish between Activated B Cell (ABC) type and Germinal Centre B-cell (GCB) cell of origin (COO) types have limitations (regardless of which algorithm is employed) when compared to gene expression profiling^{9, 10}. However, GCB vs non-GCB COO by IHC does correlate with survival rates following RCHOP chemotherapy, and therefore adds prognostic information when managing DLBCL. The Alberta hematopathologists currently use a simple algorithm published by Hans et al, requiring IHC stains for CD10, BCL6 and MUM1, in which CD10+ or BCL6+/ MUM1- cases are designated as GCB COO, whereas cases negative for negative/BCL6+/MUM1+ phenotype are considered to have a non-GCB COO.
 - EBER and CD5 expression confer worse prognosis, and may be used to identify various clinical-pathological entities with distinct implications. Determining CD5 expression should be considered on all DLBCL cases. EBER should be performed in patients with immune suppression related lymphomas, or those who possibly have EBV-related DLBCL (consider past the age of 50)¹¹.
 - Rearrangements of the C-MYC gene as determined by FISH, especially in association with *BCL2* and/or *BCL6* (so called "double hit" or "triple hit" disease) are associated with very poor outcomes following R-CHOP therapy, as well as high rates of central nervous system relapse. Patients with a double-hit or triple-hit lymphoma under age 70 years should receive more aggressive therapy and possibly stem cell transplantation. Though it represents approximately only 5-10% of DLBCL cases¹², it is very important to recognize these patients, and therefore, *MYC* rearrangement testing by FISH is to be performed on all patients younger than 70 y.o. with the appropriate lymphoma histology, i.e. DLBCL or lymphoma that are so called "unclassifiable" with intermediate morphological features between DLBCL and Burkitt. If *MYC* is rearranged, the case should also undergo *BCL2* and *BCL6* rearrangement testing by FISH. *MYC* and *BCL2* test results are required within 2 weeks of diagnoses for all new patients within the appropriate diagnostic category and age group. FISH testing may also be performed in select instances at

the discretion of the reporting hematopathologist if such studies are deemed diagnostically useful.

- Immunohistochemical studies cannot be used as a surrogate for MYC rearrangement.
- However, the detection of MYC and BCL2 concurrent overexpression by IHC in so-called “dual expressor” DLBCL, identifies a numerically significant subset of the DLBCL with potentially similar aggressive behavior compared to double-hit lymphoma cases, but representing a distinct group of patients (more often an ABC subtype as opposed to double hit DLBCL which are usually GCB). This group is also associated with a high rate of CNS relapse¹². Therefore, provided adequate benchmarks and interpretation standards can be established for reproducibility, IHC for MYC and BCL2 expression should also be strongly considered on all DLBCL cases^{10, 13}.

3. **Follicular Lymphoma:** must document grade (1-2, 3a or 3b), because all grade 3b should receive R-CHOP rather than other chemotherapy regimens. Also, if a diffuse pattern is present, this should be specified and a relative proportion noted, as outlined in the WHO Classification.
4. **Peripheral T-Cell Lymphoma:** cytotoxic T-cell markers (CD8/CD57/Granzyme B) correlate with poor prognosis and should be considered. Notably, however, peripheral T cell lymphomas are not classified on the basis of these phenotypic markers. EBV studies by in situ hybridization (EBER) should be performed in cases where angioimmunoblastic T cell lymphoma (AITL) and extranodal T/NK cell lymphoma, nasal type enter in the differential diagnosis.
5. **Mantle Cell Lymphoma:** Evidence of CyclinD1 deregulation confirmed by IHC (positive staining for CyclinD1) and/or FISH (positive for t(11;14)) is needed to confirm the diagnosis, provided other morphophenotypic findings are consistent with the diagnosis. Poor prognostic features must be mentioned in the report, including blastoid and pleomorphic morphologic variants. The proliferation index as measured by Ki67 or Mib-1 (used to calculate MIPI score) is to be reported. In cases where it is difficult to differentiate MCL from CLL, flow cytometry for CD200 and IHC for SOX11 may be performed¹⁴. For patients who are deemed transplant-eligible (i.e. age <65 and fit for intensive therapy), *TP53* mutational testing should be performed at time of diagnosis to identify high-risk patients more appropriate for allogeneic stem cell transplantation¹⁵.

References

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood*. 1994;84(5):1361-1392.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1998;16(8):2780-2795.
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. 1997;89(11):3909-3918.
4. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. *The New England journal of medicine*. 1993;329(14):987-994.
5. Armitage JO. Treatment of non-Hodgkin's lymphoma. *The New England journal of medicine*. 1993;328(14):1023-1030.
6. Swerdlow SH, Campo E, Harris NL. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed. Lyon: International Agency for REsearch on Cancer. 2008;
7. Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Zeppa P, et al. Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. *Annals of hematology*. 2017 Apr 2017;96(4)
8. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(2):200-207.
9. Gutierrez-Garcia G, Cardesa-Salzmänn T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Blood*. 2011;117(18):4836-4843.
10. Savage KJ, Sehn LH, Villa D, Kansara RR, Mottok A, Ennishi D, et al. The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*. 2014;124(21):495.
11. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5+ diffuse large B cell lymphoma. *Am J Hematol*. 2013;88(9):798-802.
12. Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. *Cancer*. 2014;120(24):3884-3895.
13. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. *Blood*. 2013;121(20):4021-31; quiz 4250.
14. Wasik AM, Priebe V, Lord M, Jeppsson-Ahlberg A, Christensson B, Sander B. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. *Leuk Lymphoma*. 2015;56(5):1425-1431.
15. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. *Blood*. 2017;130(17):1903-1910.

II. Staging ¹⁻¹²

Mandatory Staging Procedures

- Pathology review whenever possible (essential for core needle biopsies)
- Complete history and physical examination stating ECOG Performance Score, B symptoms
- CBC & differential, creatinine, electrolytes, Alk P, ALT, LDH, bilirubin, total protein, albumin, calcium
- Hepatitis B Surface Antigen (HBsAg), Hepatitis B Surface Antibody (anti-HBs), and Hepatitis B Core Antibody (total anti-HBc) must be done prior to initiating chemo/immunotherapy. Patients who are HBsAg positive are either acutely or chronically infected and require consultation with Hepatology. Patients who are HBsAg negative/anti-HBc positive (regardless of anti-HBs titre levels) and are going to be treated with B-cell depleting therapy (e.g. rituximab) should receive prophylactic therapy with entecavir or tenofovir. Those who are HBsAg negative/anti-HBc positive and fall under low or moderate risk as per Table 1 do not require prophylaxis and should undergo serial HBV DNA testing q6-12 months and serial ALT testing q3 months while on immunosuppressive therapy (see Figure 1). Hepatitis B prophylactic therapy should be continued for at least 6 months following the completion of immunosuppressive therapy, except for those treated with anti-CD20 agents who should continue for at least 12-18 months due to the lag in B-cell function recovery.¹³⁻¹⁷

Table 1: Risk of HBV reactivation with immunosuppression and chemotherapy in HBsAg-positive and HBsAg-negative/anti-HBc-positive patients.

Risk group and HBV serology	Immunosuppressive or chemotherapy
High-risk group (>10%)	
HBsAg positive OR HBsAg negative and anti-HBc positive (high risk regardless of anti-HBs titre levels)	• B-cell depleting agents such as rituximab and obinutuzumab
HBsAg positive	• Anthracycline derivatives such as doxorubicin and epirubicin • Corticosteroid therapy for ≥ 4 weeks (prednisone equivalent > 10-20 mg/day)
Moderate-risk group (1%-10%)	
HBsAg positive OR HBsAg negative and anti-HBc positive (may be lower risk and monitoring may be sufficient if high anti-HBs titres > 100 IU/L)	• TNF-α inhibitors: etanercept, adalimumab, certolizumab, infliximab • Other cytokine inhibitors and integrin inhibitors: abatacept, ustekinumab, natalizumab, vedolizumab • Tyrosine kinase inhibitors: imatinib,

nilotinib, ibrutinib	
HBsAg positive	Corticosteroid therapy for ≥ 4 weeks (prednisone equivalent < 10 mg/day)
HBsAg negative and anti-HBc positive (may be lower risk and monitoring may be sufficient if high anti-HBs titres > 100 IU/L)	- Corticosteroid therapy for ≥ 4 weeks (prednisone equivalent > 10-20 mg/day) - Anthracycline derivatives: doxorubicin and epirubicin
Low-risk group (<1%)	
HBsAg positive OR HBsAg negative and anti-HBc positive (low risk especially if high anti-HBs titres > 100 IU/L)	- Traditional immunosuppressive agents: azathioprine, 6-mercaptopurine, methotrexate - Intra-articular corticosteroids - Corticosteroid therapy for ≤ 1 week
HBsAg negative and anti-HBc positive (low risk especially if high anti-HBs titres > 100 IU/L)	Corticosteroid therapy for ≥ 4 weeks (prednisone equivalent < 10 mg/day)

Adapted from Coffin, Carla S., et al. ¹³

Anti-HBc = antibody to HBV core; anti-HBs = antibody to HBsAg; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; TNF = tumour necrosis factor.

- ESR (for early stage Hodgkin lymphoma)
- Beta-2-microglobulin (for follicular lymphoma)
- Serum protein electrophoresis and quantitative IgG, IgA, and IgM for indolent B-cell lymphomas
- Pregnancy test: if at risk
- Bone marrow biopsy in iNHL (nodal MZL, FL) can be reserved for situations of confirming limited stage or investigating unexplained cytopenias. Bone marrow biopsy may be deferred altogether in MALT lymphoma unless for investigating unexplained cytopenias.
- Bone marrow biopsy is not required for Hodgkin lymphoma or DLBCL if a staging PET/CT is performed. PET scan does not reliably predict bone marrow involvement in histologies other than HL or DLBCL.
- Bone marrow biopsy is discretionary for full staging of other aggressive histologies (e.g. PTCL-NOS) as it provides prognostic information but seldomly influences treatment selection
- PET/CT is the preferred staging modality for most FDG-avid nodal lymphomas. PET/CT is especially important for patients who otherwise have non-bulky, stage I-IIA lymphoma, and are

being considered for involved field radiation (IFRT) following abbreviated (or no) chemotherapy. PET/CT is not necessarily required for follicular lymphoma if the results will not change management, particularly for a patient who will likely undergo watchful waiting

- There are circumstances where a contrast enhanced CT alone is adequate or the preferred imaging modality:
 - Variably FDG avid histologies (chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, mycosis fungoides, and marginal zone lymphoma)
 - urgent treatment is indicated, and PET/CT is not readily available
 - patient unable to access PET/CT due to travel distance
 - to accurately distinguish bowel from lymphadenopathy when clinically relevant
 - for identifying compression/thrombosis of central/mediastinal vessels if clinical suspicion
 - for accurate measurements of nodal size, particularly for clinical trial

Table 2. Selected non-routine tests and required presentation

Test	Required Presentation/Condition
CSF and MRI Brain with gad	Brain, intraocular, epidural, testicular, paranasal sinus, kidney, adrenal, or symptoms referable to CNS or nerve roots. Consider for elevated LDH, ECOG 2-4, and >1 ENS.
ENT exam	Suprahyoid cervical lymph node or stomach
UGI & SBFT	Waldeyer's ring involvement
Ophthalmologic (slit lamp) exam	Primary brain lymphoma
HIV serology	If any HIV risk factors. Lymphomas with unusual presentations or aggressiveness including Primary CNS.
Cardio-oncology imaging (MR or Echocardiogram)	All patients who are planned to receive anthracycline or high dose chemotherapy (esp, > 50 years of age, or with history of hypertension or cardiopulmonary disease)
Pulmonary function tests	if bleomycin chemotherapy is planned

Table 3. Staging system

Stage	Description
Stage I	Single lymph node region (I) or one extralymphatic organ (IE)
Stage II	Two or more lymph node regions, same side of the diaphragm (II), or local extralymphatic extension plus lymph nodes, same side of the diaphragm (IIE)
Stage III	Lymph node regions on both sides of the diaphragm either alone (III) or with local extra-lymphatic extension (IIIE)

Stage IV	Diffuse involvement of one or more extralymphatic organs or sites • A: No B symptoms • B: at least one of the following: unexplained weight loss >10% baseline within 6 months of staging, unexplained fever >38°C, or drenching night sweats
----------	--

*Suffix A or B used only for Hodgkin lymphoma (Lugano, 2014)

For treatment planning, patients are divided into two groups by stage:

1. Limited Stage: Non-bulky stage IA(E) or IIA(E) (≤ 3 adjacent lymph node regions)
2. Advanced Stage:
 - Stage II involving >3 or non-adjacent lymph node regions
 - or stage III or IV
 - or B symptoms
 - or bulky tumour mass ($\geq 10\text{cm}$)

Restaging Schedule

1. The following are to be performed prior to each chemotherapy treatment:
 - Clinical parameters: brief history and physical examination, toxicity notation, ECOG status
 - Bloodwork:
 - CBC/differential/platelet
 - also consider EP/creatinine and LFTs
2. Requirements for CT scanning of chest/ abdomen/ pelvis:
 - Routine CT scanning:
 - after 3 months (4 cycles) of therapy and again after completion of all therapy for Non-Hodgkin Lymphomas
 - if a residual mass is seen on the CT after completion of all therapy, then repeat a PET/CT for aggressive lymphoma to determine partial or complete remission.
 - a repeat CT scan should be considered 6-12 months post-treatment; otherwise, no further routine CT scans are required
 - Hodgkin lymphoma patients should undergo a PET/CT after 2 cycles ABVD (rather than CT after 4 cycles) as outlined below in the Hodgkin Lymphoma treatment guidelines.
 - Consider a surveillance CT after 1 year of diagnosis of iNHL on watch and wait
 - Other requirements for CT scanning:
 - as indicated to investigate clinical signs or symptoms, or abnormal laboratory tests
3. Bone marrow aspirate & biopsy (with sample sent for flow cytometry):
 - Repeat for transplant-eligible patients with aggressive histology lymphomas who otherwise are in complete remission after completion of chemotherapy, if marrow was positive at diagnosis
4. PET/CT Imaging:
 - Assessment of residual radiographic or clinical abnormalities of uncertain significance at the time of re-staging following completion of therapy.
 - Hodgkin lymphoma patients should undergo a PET/CT after 2 cycles ABVD (rather than CT after 4 cycles) as outlined below in the Hodgkin Lymphoma treatment guidelines.

Table 4. PET result significance and treatment recommendations.

PET Result	Final Response	Treatment Recommendation
Negative	Complete	Observation
Positive	Partial	Consider biopsy, IFRT, or HDCT/ASCT versus observation

References

1. Cheson BD. Staging and evaluation of the patient with lymphoma. *Hematol Oncol Clin North Am.* 2008;22(5):825-viii.
2. Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. *Radiol Clin North Am.* 2008;46(2):213-23, vii.
3. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 1999;17(4):1244.
4. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol.* 2007;25(5):579-586.
5. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, et al. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. *Leuk Lymphoma.* 2007;48(8):1539-1547.
6. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2007;25(5):571-578.
7. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. *Blood.* 1998;91(4):1178-1184.
8. Naughton MJ, Hess JL, Zutter MM, Bartlett NL. Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test? *Cancer.* 1998;82(6):1154-1159.
9. Johnson PW, Whelan J, Longhurst S, Stepniewska K, Matthews J, Amess J, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. *Br J Cancer.* 1993;67(4):792-797.
10. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemester FB, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. *Ann Intern Med.* 1991;114(10):855-860.
11. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. *Blood.* 2008;112(10):3989-3994.
12. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2014;32(27):3059-3068.
13. Coffin C, Fung S, F A, CL C, Doucette K, Fournier C, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. research-article. *Canadian Liver Journal.* 2018-12-01 2018;1(4):156-217.
14. Hwang J, Feld J, Hammond S, Wang S, Alston-Johnson D, Cryer D, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 11/01/2020 2020;38(31)
15. Kusumoto S, Tobinai K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. *Hematology American Society of Hematology Education Program.* 12/05/2014 2014;2014(1)
16. Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology.* 2015 Jan 2015;148(1)
17. Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology (Baltimore, Md).* 2018 Apr 2018;67(4)

III. Treatment of Non-Hodgkin Lymphomas¹⁻⁴⁹

Treatment of non-Hodgkin lymphomas is based on histologic subtype, extent of disease, and age of the patient. In the case of discordant (2 separate sites of disease with differing types of lymphoma), composite (1 site of disease with 2 discrete types of lymphoma at that site) or transformed (a second lymphoma developing out of a background of previously known lymphoma) lymphoma, treatment must be directed at the most aggressive phase of the disease. Approaches outlined for aggressive lymphomas are generally applicable to both B- and T-cell types. However, treatments for lymphomas presenting at special sites, poor prognosis lymphomas in younger patients, and lymphomas arising in association with immunodeficiency (HIV, post-organ transplant) are outlined in the section titled “Special Problems in Lymphoma Management” below.

Diffuse Large B-Cell Lymphoma (DLBCL)^{4,45-47,50-52}

Table 1. Initial therapy of DLBCL/aggressive CD20+ lymphomas without MYC and BCL2 rearrangement by FISH.

Stage	# Risk Factors ^{1,2}	Treatment ³
Limited stage defined by PET with bulk <10cm	- sm-IPI = 0 - sm-IPI = 1 due to age >60 or stage II	- R-CHOP x4 cycles if CR by PET/CT 14-21 days after 3rd cycle - R-CHOP x 6 with IFRT (30-35Gy) if PR by PET/CT after 3rd cycle - RCHOP x 3 plus IFRT for patients unable to tolerate more than 3 cycles - R-CHOP x 6 for patients unable to undergo interim PET or R-CHOP x4 for patients meeting FLYER criteria (age 18-60, stage I-II, normal LDH, ECOG 0-1, bulk <7.5cm)
Limited stage with bulk <10cm	- sm-IPI = 2-4 - sm-IPI = 1 due to elevated LDH or ECOG >1	- R-CHOP x 6 cycles with no IFRT if CR by PET/CT 14-21d after 3rd cycle - R-CHOP x 6 cycles plus IFRT (30-35Gy) if only PR by PET/CT after 3rd cycle - RCHOP x 3 plus IFRT for patients unable to tolerate more than 3 cycles
Advanced ^{4,5} , or limited stage with bulk ≥10 cm		R-CHOP x 6 cycles possibly followed by IFRT (30-35Gy) if localized non-progressing PET+ residual disease by PET/CT 21-28d after 6th cycle

1. Stage-modified IPI (sm-IPI) Risk Factors for Limited Stage: increased LDH, stage II, ECOG performance status 2-4, age>60 years.

2. IPI Risk Factors for Advanced Stage: increased LDH, stage III/IV, >1 Extranodal Site, ECOG 2-4, age>60 years.

3. R-CEOP (with etoposide 50mg/m² IV day 1 and 100mg/m² PO days 2-3) can be used for DLBCL patients who have reduced left ventricular ejection fraction or prior maximum cumulative anthracycline exposure (Blood Adv 2021;5(5):1483). The use of R-CEOP should be limited to patients with an absolute contraindication to anthracyclines, as an Alberta-based retrospective chart review found that R-CEOP was associated with inferior 4-year PFS (32% vs 52%) and OS (39% vs 59%) compared to R-CHOP⁵³

4. For patients >age 60 years, 3-7 days of prednisone 100mg/day pre-R-CHOP as well as G-CSF prophylaxis are recommended to decrease toxicity.

5. Pola-R-CHP has superior 2-year PFS with similar OS and toxicity profile as R-CHOP among patients with DLBCL with IPI score 2-5 but is not currently funded in Alberta⁵⁴.

Treatment of Limited-Stage DLBCL

Limited-stage DLBCL is associated with favorable outcomes with long-term survival rates up to 80%, although a persistent pattern of late relapses has been described in up to 20-30% of patients. The stage-modified IPI score risk stratifies patients according to the following factors: age >60, stage II, elevated LDH, ECOG >1. In the pre-rituximab era, the phase III SWOG S8736 trial reported superior PFS and OS with CHOP×3 plus RT versus CHOP×8;⁵⁵ however, due to the occurrence of late relapses and treatment complications, there was no difference in PFS or OS between the two strategies with long-term follow-up.⁵⁶ In the rituximab era, the MInT trial established R-CHOP x6 as the standard of care for most patients with limited-stage DLBCL.⁵⁷ Given the favorable outcomes of limited-stage DLBCL, recent studies have assessed the role for treatment de-escalation to minimize toxicity while preserving efficacy. The LYSA/GOELAMS 02-03 trial of 334 patients with stage I-II non-bulky (<7cm) DLBCL demonstrated that R-CHOP alone is non-inferior to R-CHOP + RT if CR is achieved on interim PET after cycle 4; in addition, 4 cycles of R-CHOP was found to be sufficient for interim PET-negative patients with 0 sm-IPI risk factors⁵². The phase III FLYER trial found that 4 cycles of R-CHOP has reduced toxicity and non-inferior efficacy compared to 6 cycles for patients with stage I-II non-bulky (<7.5cm) DLBCL with no other sm-IPI risk factors.⁵⁸ In addition, the phase II SWOG S1001 trial and real-world data from BC Cancer demonstrated excellent PFS rates with 4 cycles of R-CHOP if CR is achieved after cycle 3, even in patients with up to 2 sm-IPI risk factors^{59,60}. Finally, the LYSA LNH 09-1B trial found that R-CHOP×4 is non-inferior to R-CHOP×6 if CR is achieved on interim PET after cycle 2 for patients with stage I-II DLBCL up to age 80 with normal LDH and ECOG 0-1.⁶¹

In summary:

1. These studies demonstrate that patients with 0 or 1 sm-IPI risk factors (age >60 or stage II disease) can be treated with 4 cycles of R-CHOP if they achieve CR on interim PET. Patients being considered for treatment de-escalation should undergo baseline PET rather than CT to ensure accurate staging.
2. Higher-risk limited-stage patients with sm-IPI 2-4 or those with elevated LDH or ECOG >1 were not well-represented in the above trials and should continue to receive 6 cycles of R-CHOP even if CR is achieved on interim PET. The optimal treatment of patients with PR on interim PET is unknown, but our preferred approach is R-CHOPx6 plus RT as this was shown to result in similar outcomes as interim PET-negative patients in the LYSA/GOELAMS 02-03 trial.

Role for Consolidative Radiation Therapy in DLBCL

As mentioned above, the only randomized trial of combined modality therapy versus chemoimmunotherapy alone in limited-stage DLBCL (LYSA/GOELAMS 02-03) found the addition of RT did not improve outcomes over R-CHOP alone among patients achieving CR on interim PET.⁵² However, the administration of RT after 6 cycles of R-CHOP appeared to overcome the poor prognostic impact of a positive interim PET, as these patients experienced similar outcomes as interim PET-negative patients. For advanced-stage DLBCL, a large retrospective analysis from BC Cancer of 723 patients treated with R-CHOP x6 +/- consolidative RT to focal sites of PET+ disease at end-of-treatment found that patients achieving negative PET have excellent outcomes without RT, including those with bulky disease and skeletal involvement at diagnosis.⁶² In addition, patients with non-progressing PET+ disease treated with RT had outcomes approaching those of PET-negative patients, suggesting a potential benefit of RT.

In summary:

1. We recommend consolidative RT only for patients with (1) limited-stage DLBCL with positive interim PET or (2) advanced-stage DLBCL with localized non-progressing PET+ residual disease on end of treatment PET. There is no evidence for improved PFS or OS when RT is used for patients who achieve CMR on restaging PET and therefore, it is not recommended.

HDCT/ASCT as Part of Initial Therapy for DLBCL

High dose therapy and ASCT is no longer recommended as consolidation of first line treatment for DLBCL in the era of CAR-T cell therapy.

Recommendations for CNS Prophylaxis^{23,48,49,63-66}:

For DLBCL, factors associated with high risk (>10%) for relapse in the central nervous system include 4-6 of the following factors: 1) Age >60 years, 2) elevated LDH, 3) ECOG=2-4, 4) Stage 3-4, 5) >1 extranodal site of involvement, and 6) kidney or adrenal involvement. Other high risk situations include double hit lymphoma (MYC + BCL2 and/or BCL6 translocations) and testicular lymphoma. Prophylactic intrathecal chemotherapy does not penetrate the brain parenchyma and has not been proven to decrease meningeal or parenchymal brain relapse of lymphoma in well-designed studies. Similarly, multiple studies (including local retrospective review) have demonstrated no benefit from incorporating high dose methotrexate into R-CHOP for patients at high risk of CNS progression⁶⁷⁻⁶⁹. To date, there are no confident strategies to reduce CNS progression risk except for patients with primary testicular lymphoma and intravascular large B-cell lymphoma, who are at particularly high risk of CNS relapse. In these rare diagnoses, there is prospective phase II evidence suggesting a possible benefit of CNS prophylaxis with high dose methotrexate; hence, this strategy may be considered on a case-by-case basis after informed discussion with these patients^{70,71}.

1. Given the lack of documented efficacy of intravenous HD-MTX and the associated inconvenience and toxicities, we no longer recommend prophylactic intravenous HD-MTX for most DLBCL patients at high risk of CNS relapse.

Treatment of Relapsed/Refractory DLBCL

Patients fit for intensive therapy:

Please refer to the ABMTP Standard Practice Manual chapter “Hodgkin and Non-Hodgkin Lymphoma: Indications for Cellular Therapy” for full details on indications and eligibility.

Note: Bendamustine and tafasitamab should be avoided in patients planned to receive CAR-T cell therapy due to the respective risks of lymphodepletion and CD19 downregulation.

In summary:

Approach to R/R DLBCL ***patients fit for intensive therapy:***

1. *Relapsed/Refractory DLBCL <12 months from completion of R-CHOP chemotherapy: patients should be referred for CAR T-cell therapy as second line therapy*
 - Phase III trials with axi-cel and liso-cel as second line therapy compared to the standard salvage chemotherapy approach in patients with poor prognosis relapsed/refractory DLBCL <12 months from RCHOP chemotherapy have demonstrated superior event-free survival, progression-free survival, and overall survival outcomes with 2L CAR-T.^{72,73}
2. *Relapsed DLBCL >12 months from completion of RCHOP chemotherapy – Patients should be offered salvage platinum-containing chemotherapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation in chemo-sensitive patients*
 - All patients, ECOG 0-2, with adequate organ function and absence of active infections with relapsed disease >12 months after initial RCHOP chemotherapy should be referred to the HSCT program as soon as possible.
 - Consider RGDP over RDICEP as the preferred salvage in this population^{74,75}
 - Potential transplant candidates should receive rituximab with salvage chemotherapy to maximize the chance of response, and *in-vivo* purge blood of tumour cells
3. *Relapsed/Refractory DLBCL after two or more lines of therapy*

Any fit r/r DLBCL patient who has not received CAR-T in second-line should be considered for 3rd line CAR-T cell therapy. Phase II trials of axi-cel, tisa-cel, and liso-cel demonstrates CR rates 40-56% with long-term PFS rates in the range of 30-40%. The main toxicities of these therapies are cytokine release syndrome, neurotoxicity, cytopenias, and B-cell aplasia/hypogammaglobulinemia and as such this therapy is administered only at centers approved for cellular therapy treatments. Patients who have previously received or are unable to receive CAR-T should be considered for therapy with bispecific antibodies (glofitamab or epcoritamab) or other palliative therapies

Patients unfit for intensive therapy:

The prognosis of patients with relapsed/refractory DLBCL who are not candidates for cellular therapy has been historically poor. Palliative-intent regimens including R-GemOx, polatuzumab vedotin with bendamustine/rituximab, and tafasitamab with lenalidomide have been studied in phase II trials of patients with r/r DLBCL who are unfit for intensive therapy:

	R-GemOx	Pola + BR	Tafa + Len
Mechanism	Chemoimmunotherapy	Chemoimmunotherapy + antibody-drug conjugate	Monoclonal antibody + immunomodulator
Study population	49 ASCT-ineligible patients with r/r DLBCL and ECOG 0-2	106 ASCT-ineligible patients with r/r DLBCL and ECOG 0-2	80 ASCT-ineligible patients with r/r DLBCL and ECOG 0-2 (excluding primary refractory)
Administration	Time-limited therapy with simpler dosing	Time-limited therapy with simpler dosing	Indefinite therapy with frequent dosing
Efficacy	ORR 61% with CR 44% Median DOR 10 mos Median OS 11 mos	ORR 42% with CR 39% Median DOR 10 mos Median OS 13 mos	ORR 58% with CR 40% Median DOR 44 mos Median OS 34 mos
Notable toxicities	Myelosuppression Neurotoxicity	Myelosuppression Neuropathy	Myelosuppression Rash Thrombosis
Cost	Lower cost	High cost	High cost

References	Haematologica 2013; 98(11):1726	J Clin Oncol 2020; 38(2):155 Blood Adv 2022; 6(2):533	Lancet 2020; 21(7):978 Haematologica 2021; 106(9):2417
-------------------	---------------------------------	--	---

Epcoritamab and glofitamab are bispecific antibodies targeting CD20 and CD3 which are funded for patients with relapsed/refractory large B-cell lymphoma after ≥ 2 lines of therapy who have already received or are unable to receive CAR-T cell therapy^{76,77}. Bispecific antibodies produce complete responses in approximately 40% of patients with a median time to response of 6 weeks. Response assessment is therefore recommended 6-8 weeks after C1D1 of epcoritamab or glofitamab. Although some delayed responses have been observed as late as 8-10 months after treatment initiation, these are unlikely to occur in patients with progressive disease at the time of first response assessment. See chapter on “Prevention and Management of Toxicities of Bispecific Antibodies in Lymphoma” for detailed recommendations on supportive care.

	Epcoritamab	Glofitamab
Indication	Relapsed/refractory DLBCL after ≥ 2 LOT Relapsed after or unable to receive CAR-T	Relapsed/refractory DLBCL after ≥ 2 LOT Relapsed after or unable to receive CAR-T
Schedule	Frequent and indefinite dosing C1D1: 0.16mg, C1D8: 0.8mg, C1D15+22: 48mg C2 to C3: 48mg weekly C4 to C9: 48mg q2 weeks C10+: 48mg q4 weeks	Less frequent fixed-duration treatment C1D1: obinutuzumab, C1D8: 2.5mg, C1D15: 10mg C2 to C12: 30mg q3 weeks
Administration	Subcutaneous	Intravenous (2-4h)
Efficacy	ORR 63% and CR rate 39%	ORR 52% and CR rate 39%
Toxicity	CRS in 50% Grade 2 CRS in 17% and grade ≥ 3 in 3%	CRS in 63% Grade 2 CRS in 12% and grade ≥ 3 in 3%

Recommendations for treatment:

1. R-GemOx is the preferred second-line treatment because it is a well-established outpatient platinum-based regimen that is better tolerated in older patients than other regimens such as GDP, DHAP, or ICE, although it is associated with significant myelosuppression.
2. Epcoritamab or glofitamab are recommended for patients with relapsed/refractory large B-cell lymphoma after ≥ 2 lines of therapy who have already received or are unable/decline to receive CAR-T cell therapy.
3. Polatuzumab, bendamustine, and rituximab can also be considered for second or later relapses, and for patients who are unfit for, or intolerant of, R-GemOx or bispecific antibodies. Patients should have reasonable performance status (ECOG 0-2) and adequate hematologic function to be expected to benefit from and tolerate polatuzumab with BR. Tafasitamab-lenalidomide is not approved or funded in Alberta.
4. Some palliative patients at or beyond second relapse may have symptomatic benefit from prednisone alone, or low dose daily oral chemotherapy with chlorambucil 0.1mg/kg/day or etoposide 50mg/day, or combination oral therapy such as PEPC. Involved field radiotherapy (IFRT) to symptomatic sites or localized relapses may also benefit these palliative patients. Addressing goals of care and ensuring timely integration of palliative care should be a priority for all patients with r/r DLBCL who are unfit for intensive therapy.

Secondary CNS Lymphoma⁷⁸⁻⁸¹


Selected patients with CNS relapse/progression may be candidates for intensive therapy as outlined in Appendix A, subheading VIII. Favorable outcomes were reported in an Alberta study of 62 SCNSL patients with median age 58 years (range 20-75) intended for transplant, with ASCT rates of 84%, 5-year PFS 53% and OS 65% for all patients, and 5-year PFS 62% and OS 73% for those undergoing R-TBuM conditioning and ASCT. One of 3 induction regimens is recommended for transplant-eligible patients and one of two options for transplant ineligible patients, based on presentation:

- 1) Isolated CNS lymphoma: HDMTX-based induction then RDHAP for stem cell mobilization and collection, then R-TBuM/ASCT for transplant eligible (table A) or MATRix for patients who decline ASCT but are fit for intensive induction therapy or Cytarabine/Rituximab/Thiotepa outpatient regimen for transplant ineligible (PCNSL table C).
- 2) Early Systemic and CNS lymphoma (prior to completing RCHOP x6): RCHOP and HDMTX x4 cycles and early referral to Cellular Therapy for discussion around R-TBuM/ASCT vs CAR-T cell therapy for transplant eligible (table B) or RCHOP/MTX followed by AraC then ifosfamide in transplant ineligible (table E).
- 3) Late relapse (prior RCHOP x6) with systemic and CNS lymphoma: HDMTX-Ifosfamide-etoposide x2 then RDHAP for stem cell mobilization and collection, then R-TBuM/ASCT for transplant eligible (table C) or palliation for transplant ineligible (table F)

Of note, patients with concurrent CNS and systemic relapse have inferior outcomes with HD-MTX-based chemotherapy and ASCT compared to those with SCNSL at diagnosis or isolated CNS relapse^{82,83}. The optimal treatment of patients with concurrent CNS and systemic relapse within 12 months from the end of first-line therapy is unclear, and these patients should be considered for ASCT or second-line CAR-T cell therapy on a case-by-case basis. Patients with SCNSL undergoing CAR-T cell therapy should receive appropriate CNS-directed bridging therapy before infusion since outcomes appear poor with active CNS disease at the time of infusion⁸⁴.

Unfortunately, most patients with multiple-relapsed secondary CNS lymphoma experience poor response to subsequent therapy and are best managed with palliative intent, including consideration of palliative cranial radiotherapy.

Figure 1. Treatment algorithm for diffuse large B-cell lymphoma with no double hit (MYC/BCL2 rearrangements)



Treatment of special DLBCL entities ^{24-27,63}.

High-grade B-cell lymphoma with MYC and BCL2 rearrangements by FISH:

High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double hit lymphoma or DHL) is associated with a poor prognosis, with a large multicenter retrospective analysis of 311 patients reporting an OS rate <50% if IPI=2-5 vs 65% for IPI=0-1⁸⁵. The optimal treatment of DHL is unknown, but intensive induction regimens such as da-EPOCH-R or R-CODOX-M/R-IVAC are commonly used and have demonstrated PFS benefit over R-CHOP in some retrospective studies⁸⁵ but not others⁸⁶. In addition, the use of consolidative HDT/ASCT has been associated with superior outcomes among patients achieving CR after R-CHOP induction but not after intensive induction regimens.⁸⁷ This

suggests that DHL patients treated with R-CHOP can be considered for ASCT consolidation, especially if IPI=2-5 at diagnosis, however other patients who achieve CR after an intensive induction regimen probably should not receive ASCT consolidation. A retrospective analysis of 99 patients with DHL in Alberta found relatively favorable outcomes with 4-year PFS 59% and OS 66%, with no significant difference in PFS or OS between patients treated with intensive induction regimens vs intention-to-transplant following R-CHOP induction. Among the 48 patients intended for ASCT, outcomes were excellent for the 75% of patients undergoing upfront ASCT with 4-year PFS 80-90%, whereas there were no survivors among the 25% of patients with primary refractory disease. This suggests that upfront ASCT can achieve durable remissions in the majority of DHL patients with chemosensitive disease, whereas alternative strategies such as CAR-T cell therapy should be strongly considered for patients with chemorefractory disease.

Of note, the 2023 WHO and ICC lymphoma classifications consider MYC and BCL6 rearranged cases to be an indistinct and biologically heterogeneous group. Given that the prognosis and best management of these cases is also uncertain, it is now recommended that patients with MYC and BCL6 rearrangements (but no BCL2 rearrangement) should be treated as high-risk DLBCL NOS rather than as double-hit lymphoma.

Alberta recommendations for high-grade B-cell lymphoma with MYC and BCL2 rearrangements:

- IPI=0-1: R-CHOP x 6 cycles or DA-EPOCH-R x 6 cycles
- IPI=2-5: Options include:
 - A. R-CHOP x 3-4 cycles then restaging PET with responding patients proceeding to R-BuMel/ASCT. Patients refractory to R-CHOP are unlikely to respond to second-line chemotherapy and should be planned for CAR-T cell therapy as soon as possible. Consider PET scan for interim response assessment for best assessment of chemosensitivity.
 - B. DA-EPOCH-R or R-CODOX-M/R-IVAC

DLBCL with MYC single-hit translocation by FISH

1. MYC-rearranged DLBCL (or high-grade B-cell lymphoma NOS) but no translocation of BCL2 : Patients should be treated with R-CHOP x 6 cycles given the lack of evidence of a superior treatment approach.

Transformed indolent B-cell lymphoma

Patients with transformed treatment-naïve indolent B-cell lymphoma have a similar prognosis as de novo DLBCL and should be treated with R-CHOP without consolidative ASCT or maintenance rituximab^{88,89}. Patients who have previously received chemotherapy for indolent lymphoma have an inferior prognosis at transformation⁹⁰. As such, ASCT is recommended for chemosensitive transformed DLBCL arising from chemotherapy-exposed iNHL⁹¹, although outcomes appear suboptimal in the bendamustine era (Stewart et al. submitted). CAR-T cell therapy is recommended for r/r transformed lymphoma after at least 2 lines of therapy (e.g. 1 for iNHL and 1 for DLBCL).

Second-line CAR-T may be available for those transforming within 12 months of first-line therapy with R-CHOP (e.g. for clinically suspected transformation at diagnosis).

B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (mediastinal gray-zone lymphoma):

- R-CHOP x 6 cycles for most patients

Primary Mediastinal B-Cell Lymphoma

Primary mediastinal B-cell lymphoma (PMBCL) of thymic origin represents 6-10% of all DLBCLs, and most commonly affects young adults (median age ~35), women more than men.⁹² It is frequently associated with a bulky mediastinal mass that directly extends into extranodal thoracic tissues such as pleura, pericardium and chest wall. Patients with distant lymphadenopathy or extranodal involvement outside the thorax should likely be diagnosed and treated as systemic DLBCL with secondary mediastinal involvement, rather than as PMBCL.⁹³ Overall, PMBCL is associated with a better prognosis than other DLBCLs, including GCB DLBCLs. The IPI score tends not to work well for PMBCL because most patients are young with fairly well-preserved performance status, and have elevated LDH. Therefore, limited vs advanced stage, and number extranodal sites (esp pleural effusions) tend to be the only factors that subdivide patients into excellent vs good prognosis. Likewise, because most patients have a very good prognosis, interim restaging PET imaging is associated with very high negative predictive value, but relatively low positive predictive value.⁹⁴ These findings were confirmed in 20 patients treated with R-CHOP in Alberta, where the PPV of a positive interim PET scan was only 20% for disease progression/relapse whereas a negative interim PET had NPV 100%. Therefore, a positive interim PET scan should probably not be used alone to guide further therapy.

Treatment of PMBCL with RCHOP +/- RT is associated with cure rates of approximately 75-80% and overall survival rates of 90%. Phase II studies have reported that intensifying chemotherapy (eg. dose adjusted EPOCH-R) maintains excellent outcomes while avoiding RT. However, the prospective phase III CALGB/Alliance 50303 study randomized 464 DLBCL patients (including 35 with PMBCL) to RCHOP or DA-EPOCH-R, and found no difference in PFS or OS between regimens, although there was substantially more toxicity with DA-EPOCH-R. A large retrospective study from 11 centres compared outcomes of 132 PMBCL patients treated with R-CHOP (n=56) or with dose-adjusted R-EPOCH (n=76), and found similar survival rates of approximately 90% with both regimens, but with more RT use in the R-CHOP group (59% vs 13%).⁹⁵ There is no phase III evidence that RT after R-CHOP improves survival rates relative to R-CHOP alone, but this is being studied in the ongoing IELSG-37 clinical trial. Real-world data from the BCCA demonstrates that omitting RT for PET-negative patients at the end of R-CHOP therapy achieves similar TTP (80%) and OS (89%) as historical cohorts treated routinely with RT, with a reduction in RT use from 78% in the historical cohort to 28% in the PET-directed era.⁹⁶ Similarly, retrospective data for 91 consecutive patients in Alberta treated with R-CHOP from 2004-2020 found a 5-year overall survival rate of 86%, with similar

outcomes for patients with advanced versus limited stage (86% vs 92%, $p=0.31$) or bulky versus non-bulky disease (83% vs 96%, $p=0.12$). For patients responding to R-CHOP, the 5-year OS rate was 93% with RT versus 100% without RT ($p=0.17$). Among 40 patients with a PET-defined complete metabolic response after R-CHOP, 5-year OS was 100% for all patients treated with ($n=9$) or without ($n=31$) RT.

Management of patients with partial metabolic response after R-CHOP is uncertain. Prospective data show that the majority of Deauville 4 end-of-treatment (EOT) PET scans after DA-EPOCH-R are false-positives which can be monitored with surveillance PET without RT, with progressive disease occurring in only 1/16 patients with Deauville.⁹⁷ Among the 34 patients in BC and Alberta with Deauville 4 EOT PET after R-CHOP (the majority of whom received RT), survival outcomes were excellent and similar to EOT PET-negative patients. It is likely that many cases of partial metabolic response after R-CHOP are false positives as well; indeed, 5 patients in Alberta and BC with Deauville 4 after R-CHOP were observed without RT and none relapsed. Extrapolating from this data, it has been proposed that surveillance imaging without radiation may be reasonable for young patients with Deauville 4 EOT PET after R-CHOP given the likely low risk of progression and long-term risks of toxicity from RT.⁹⁸

In conclusion, available evidence supports the use of R-CHOP for patients with PMBCL, with less toxicity but similar excellent outcomes as DA-EPOCH-R. End of treatment PET should be done 6-8 weeks after day 1 of the final cycle of chemoimmunotherapy to allow time for the post-treatment inflammatory response to resolve.⁹⁹ In view of the long-term risk of secondary malignancy and premature heart disease from RT in young patients, RT can probably be safely omitted for patients with PET-negative disease after R-CHOP. Omitting RT in favour of surveillance imaging in 6-8 weeks (CT is the preferred modality in Alberta) may be reasonable for patients <60 years old with Deauville 4 on EOT PET after R-CHOP, while older patients and those with Deauville 5 should receive RT. For the 10-20% of patients with suspected relapsed/refractory PMBCL, the diagnosis of progressive disease should be confirmed with biopsy or clear progression on CT, and not based on FDG uptake on PET alone. Treatment options at relapse include radiation for localized disease, salvage chemotherapy and autotransplant, radiation therapy, axicabtagene ciloleucel (funded only after 2 prior lines of therapy), and pembrolizumab.


Follicular Lymphoma¹⁰⁰⁻¹⁴⁵

Throughout the following suggested treatment approach, three over-riding principles should be considered:

1. These are guidelines only. This disease often carries a long, incurable, remitting/relapsing natural history and, therefore, several treatment approaches are reasonable.
2. The mere presence of disease does not alone imply the need for treatment.
3. If therapy is required for predominantly localized disease, IFRT should be considered in lieu of systemic pharmacological treatment as long as the radiotherapy can be done with minimal early or delayed side-effects (e.g., xerostomia, severe nausea/vomiting) and without eliminating future

treatment options (e.g., should not radiate $\geq 25\%$ bone marrow). Figure 2 outlines the treatment algorithm for follicular lymphoma.

Figure 2. Treatment algorithm for follicular lymphoma.



Initial therapy of stage IA and contiguous stage IIA:

IFRT 24Gy/12-30Gy/20 fractions is recommended for newly diagnosed patients with peripheral stage IA or contiguous non-bulky stage IIA follicular lymphoma, even if the patient is asymptomatic.

Initial therapy of advanced stage disease (stage III/IV, B symptoms, or bulky stage I/II):

Indications for systemic therapy (usually stage III/IV or bulky stage I/II) include any one of the following:

- Patient symptoms (fever, night sweats, weight loss, malaise, pain, nausea)
- Significant lymphadenopathy (> 7 cm mass, ≥ 3 sites and ≥ 3 cm, rapidly progressive)
- Splenomegaly ≥ 6 cm below costal margin, or hypersplenism, or pain
- Impending organ compromise (compression, pleural/pericardial effusions, ascites)
- Cytopenias secondary to bone marrow infiltration
- Patient preference because of anxiety and poor quality of life without treatment

For patients who do not have any of the above indications for therapy:

The recommended approach is to observe with (or arrange) follow-up clinical assessments every 3-6 months (“watchful waiting”), and a CT CAP 1 year after diagnosis. For patients not meeting treatment criteria 1 year after diagnosis, another CT 1-2 years later could be considered. Patients who have progressive disease on follow-up should generally be treated, even if they do not fulfill any of the other indications for therapy to prevent the risk of clinical deterioration in the setting of known progressing lymphoma. A retrospective study of 238 Alberta follicular lymphoma patients managed with watchful waiting found that 24% developed transformed disease or significant organ dysfunction (at a median of 30 months) prior to initiating initial therapy, and these patients had inferior survival rates compared to other patients requiring therapy who were initially managed with watchful waiting (10 yr OS 67.9% vs 85.7%, HR 3.000 (95%CI 1.696-7.126), $p=0.0007$). These watchful waiting patients did not undergo routine follow-up CT scans at 1 or 2 years to identify progression. It is possible that these adverse outcomes might have been avoided with closer monitoring by CT imaging and earlier initiation of chemoimmunotherapy¹⁴⁶.

Alternatively, a select population of advanced stage II-IV, asymptomatic patients could be considered for treatment with rituximab monotherapy (weekly x4) based on the long term follow up of the Ardeshtna/Northend trial. This phase III trial randomized 379 patients with asymptomatic low tumour burden follicular lymphoma to (1) watch & wait (W&W) (2) rituximab induction (RI) or (3) RI followed by rituximab maintenance (RM). The median time to next treatment (TTNT) was 2.7 years (W&W), 9.9 years (RI) and not reached (RM). No significant differences in OS, histological transformation, or response to next line treatment were observed¹⁴⁷. This group may include elderly patients (age 70+ who will likely not require another treatment within their lifetime) or patients with profound anxiety regarding their diagnosis. This treatment needs to be weighed with the risk of immunosuppression during and at least 6 months post-therapy. Patients need to be made aware that there is no survival benefit by using this approach. Additionally, the AB drug benefit list includes rituximab monotherapy for FL only for those “who have contraindications to, or who cannot tolerate chemotherapy” so these conditions would need to be met in individuals selected for treatment with RI.

For grades 1,2,3a follicular lymphoma who have an indication for therapy:

The recommended therapy involves 6 cycles of B-R (bendamustine-rituximab) chemotherapy, followed in responding patients by 2 years of maintenance rituximab (every 3 months for total of eight doses).

Patients who have an indication for treatment but are unable to tolerate BR due to significant comorbidities or frailty can be considered for dose reduced bendamustine (ie. 70mg/m² on D1 and D2 or 50% bendamustine, keeping D1 at 90mg/m² and omitting D2). This may help to reduce infectious and cytopenia risks. Alternatively, rituximab monotherapy may be used, for 4 weekly doses, to debulk their disease and provide an element of disease control. Rare patients who have very limited life-expectancy from serious comorbid illness and who wish to avoid intravenous therapy could be treated with palliative oral fludarabine or chlorambucil or targeted radiotherapy.

The GALLIUM clinical trial investigated the value of obinutuzumab in combination with chemotherapy followed by maintenance therapy compared to standard therapy with rituximab chemo-immunotherapy plus maintenance in the firstline treatment of follicular lymphoma. The study demonstrated superiority of obinutuzumab over rituximab in terms of PFS (3-year PFS was 81.9% (95%CI: 77.9-85.2%) vs. 77.9% (95%CI: 73.8-81.4%), with acceptable increased toxicity. As no OS advantage has yet been demonstrated, obinutuzumab is not funded in Canada for this indication and we continue to recommend rituximab.¹⁴⁸

Note: Grade 3b follicular lymphoma should be treated as DLBCL with R-CHOP. Rituximab maintenance has not been proven effective following R-CHOP therapy for large B-cell lymphoma, and therefore is not recommended.

Management of relapsed follicular lymphoma:

Note: treatment indications at relapse are the same as the indications for upfront treatment. Relapse and progression are expected for indolent lymphomas and again, only require treatment if meeting the criteria listed above.

Prior to moving to next line therapy for FL, if there is suspicion of transformation to aggressive lymphoma (ie. less than PR to initial therapy, systemic symptoms, or very early relapse), biopsy of the fastest growing (or most FDG-avid, if PET is performed) lesion should be done to rule out DLBCL.

Therapeutic recommendations for recurrent follicular lymphoma need to be individualized, and no one recommendation is suitable for all patients. Numerous factors need to be taken into consideration before recommending therapy for recurrent follicular lymphoma, including:

- Patient Factors: Age, co-morbidity, symptoms, short vs. long-term goals, preservation of future options, reimbursement/ability to pay for expensive treatments, acceptance of risks/toxicities of treatment option relative to potential benefit (RR, PFS, OS).
- Disease Factors: Stage, sites of involvement, grade, transformation, prior therapy, time from prior therapy (disease-free interval).

Autologous stem cell transplant:

For healthy patients, younger than 75 years old, HDCT/SCT maximizes the length of disease control, regardless of length of initial remission, and as such is a reasonable treatment option at first or second relapse for those who accept potential risks/toxicities.

This benefit of ASCT is most pronounced for patients who relapse within 2 years of initial chemotherapy (POD24) have more aggressive disease and higher rates of transformation to aggressive lymphoma. Their OS is < 5 years with standard therapy and several studies have shown improved PFS along with OS with ASCT for these patients.

A large retrospective study of consecutively treated relapsed follicular lymphoma patients in Alberta and BC reported 5 year overall survival rates following relapse of ~90% for those who received ASCT vs ~60% for those who did not receive ASCT. This marked difference in survival retained significance in multivariate as well as instrumental variable analyses¹⁴⁹. Another long-term follow-up study from Alberta demonstrated that up to 50% of ASCT recipients may be functionally cured of FL¹⁵⁰.

Lenalidomide/rituximab:

For patients not suitable HDCT/SCT, lenalidomide and rituximab, based on the AUGMENT trial is approved for patients with relapsed/refractory disease. Progression-free survival was estimated at a median duration of 39.4 months (95% CI, 22.9 months to not reached) in this phase III trial¹⁵¹.

CAR-T cellular therapy:

CAR-T is funded for patients with r/r FL grade 1-3A after ≥ 2 lines of therapy based on the ZUMA-5 and the ELARA trials^{152,153}. ORR and CR rates were upwards of 85% and 69% in both trials, respectively. Infection and cytopenias were the most common adverse effects. Patients need to be monitored for CRS and ICANS, though rates of same are generally lower than for DLBCL.

Repeat chemo-immunotherapy:

Some patients may be managed with repeating chemo-immunotherapy if they have achieved a long remission to first therapy. Rituximab maintenance should only be used once in the course of a patient's disease (first remission or first relapse).

A phase 3, open-label, two-arm parallel, randomized trial (GADOLIN), compared obinutuzumab and bendamustine followed by obinutuzumab maintenance to bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma (failure to respond or progress during or within 6 months of a rituximab containing regimen). Both PFS (HR[95%CI]: 0.52[0.39,0.69]; $p < 0.0001$) and OS (HR[95%CI]: 0.58[0.39,0.86]; $p = 0.0061$) were improved in the FL group treated with obinutuzumab. While there was no significant advantage reported for patients with other subtypes of iNHL, this was deemed to be based purely on the small numbers in other subgroups. Based on these results, it is recommended that obinutuzumab chemo-immunotherapy be considered in patients with rituximab-refractory iNHL. While the study used bendamustine as a chemotherapy backbone, few patients on the study had received bendamustine as their frontline therapy. Given current practice of BR for the frontline treatment of FL and the fact that there is no biological reason that the same clinical benefit of obinutuzumab would not be seen in combination with other chemotherapies, alternate NHL chemotherapy backbones can be considered for patients deemed inappropriate for bendamustine retreatment. Relatively frequent infections were noted so prophylactic antibiotics and antivirals should be considered, especially when obinutuzumab is combined with bendamustine.

Idelalisib:

Idelalisib, a PI3K δ inhibitor has also shown efficacy in a Phase 2 study of double-refractory FL patients (patients with lack of response or progression within 6 months of both rituximab and an

alkylator). Idelalisib can lead to durable remissions in a minority of patients and is currently funded. Infectious complications and immune toxicities are frequent and prophylactic antibiotics and anti-virals are required to reduce the risk of serious infections.¹⁵⁴ Due to these risks and general poor tolerability, we recommend considering other therapeutic options first.

Palliative, symptomatic care (possibly including palliative IFRT 4Gy/2 fractions):

This is usually the best option for patients who were refractory to their two most recent treatment regimens, those with CNS involvement, or those with an ECOG score of 3-4.

Indolent Lymphomas (Excluding Follicular Histology)^{1,155-163}

Indolent lymphomas should generally be treated similarly to follicular grade 1-2 lymphomas.

Table 2. Treatment of Indolent Lymphomas¹⁵⁵

Stage	Treatment
Limited	IFRT (24Gy/12 - 30Gy/20)
Advanced	Asymptomatic: observation until treatment indication Symptomatic: - majority should receive B-R, then rituximab maintenance - alternatives in special situations include IFRT, fludarabine, or chlorambucil

Marginal Zone Lymphomas (MZL)

The management of nodal marginal zone lymphoma should follow the same treatment principles as other indolent lymphoma, with the use of BR for frontline therapy when treatment indications are present.

Bone marrow biopsy may be deferred altogether in MALT lymphoma (ie gastric, orbital) or other stage I EMZL. Bone marrow biopsy is still often useful for SMZL (for diagnosis) and NMZL, especially for investigating unexplained cytopenias.

Special topics in MZL

Splenic Marginal Zone Lymphoma

Splenic marginal zone lymphoma is an uncommon type of non-Hodgkin lymphoma characterized by splenomegaly, cytopenias, lymphocytosis, and less commonly lymphadenopathy. Revised diagnostic criteria now specify the typical blood and bone marrow findings of SMZL and splenic biopsy is not

usually required to establish the diagnosis¹⁶⁴. It is still reasonable, however, to proceed with splenectomy if the cause of splenomegaly is not determined following peripheral blood and bone marrow evaluation.

The disease course is indolent and many patients can be managed expectantly until symptomatic splenomegaly or pronounced cytopenias develop. SMZL prognostic scoring systems have been described, with low hemoglobin, low platelets, elevated lactate dehydrogenase and extra-hilar lymphadenopathy as adverse markers¹⁶⁵.

In rare cases, SMZL has been associated with hepatitis C infection (HCV), so all patients should be screened at diagnosis. Those who are HCV+ should first be offered HCV-directed therapy, as the lymphoma may regress avoiding the immediate need for further therapy^{166,167}. Splenectomy has previously been the standard approach to treat SMZL for over two decades¹⁶⁸. The role of splenectomy as frontline treatment of SMZL is now controversial^{169,170 171 172}. Risks posed by splenectomy include operative morbidity and mortality, particularly in the elderly, or those with multiple comorbidities. However, surgical outcomes are improving at experienced centres. The risk of infection with encapsulated organisms is a serious concern, but may be mitigated with timely vaccination and long-term antibiotic prophylaxis¹⁷³.

Monotherapy with rituximab has recently emerged as a non-operative alternative¹⁷⁰⁻¹⁷⁴ with reports suggesting survival outcomes similar to historical patients treated with splenectomy. Chemo-immunotherapy such as rituximab-bendamustine (BR) is also a rational approach for SMZL given the recent favourable results of a large scale RCT of iNHL, including marginal zone histology¹⁴⁴.

Although existing evidence is inadequate to conclude which treatment approach is superior, we propose the following strategy for managing SMZL:

1. Rituximab monotherapy is recommended as frontline therapy for most patients. A standard regimen is rituximab weekly for 4 weeks, followed by a response assessment 4-6 weeks later.
 - a. Those achieving at least a partial response, defined by conventional response criteria¹⁶⁴, should subsequently receive maintenance rituximab as per other iNHL subtypes.
 - b. Non-responders or those with progressive disease should proceed with either:
 - i. Splenectomy if the spleen is the major site of disease or
 - ii. BR for those with additional nodal disease, extensive bone marrow involvement, or non-operative candidates, then followed by maintenance rituximab in responding patients.
2. Select patients who require a splenectomy to establish the diagnosis and have no bone marrow, peripheral blood, or nodal involvement, do not require maintenance rituximab and may simply be observed.

Gastric MALT lymphoma:

For complete staging evaluation, patients with gastric MALT lymphoma require cross-sectional imaging plus upper GI endoscopy with multiple mucosal biopsies for *Helicobacter pylori*. Gastric MALT lymphoma should be staged according to the Lugano or Paris staging systems for GI lymphomas:

Lugano GI staging system ¹⁷⁵		Paris staging system ¹⁷⁶	
Stage I	Confined to GI tract (single primary or multiple, non-contiguous)	T1m N0 M0 T1sm N0 M0 T2 N0 M0 T3 N0 M0	Mucosa Submucosa Muscularis propria Serosa
Stage II	Extending into abdomen		
Stage II ₁	Local nodal involvement	T1e3 N1 M0	Perigastric lymph nodes
Stage II ₂	Distant nodal involvement	T1e3 N2 M0	More distant regional nodes
Stage IIE	Penetration of serosa to involve adjacent organs or tissues	T4 N0e2 M0	Invasion of adjacent structures with or without abdominal lymph nodes
Stage IV	Disseminated extranodal involvement or concomitant supra-diaphragmatic nodal involvement	T1e4 N3 M0 T1e4 N0e3 M1 T1e4 N0e3 M2	Extra-abdominal lymph nodes Distant (non-contiguous) GI sites involvement Non-GI sites of involvement

3. Adapted from "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"¹⁷⁷

1) Localized (stage I-II₁) *H. pylori* positive gastric MALT lymphoma: Stage I-II₁ *H. pylori* positive gastric MALT lymphoma should be treated with quadruple antibiotic *H. pylori* eradication therapy (e.g. PAMC or PBMT) in accordance with current guidelines ¹⁷⁸. This achieves responses in up to 70-80% of patients with excellent long-term event-free survival, although response rates are lower for patients with t(11;18) ¹⁷⁹⁻¹⁸³. *H. pylori* eradication should be confirmed with stool antigen or urea breath test once off antibiotics for ≥4 weeks and off PPIs for ≥2 weeks, and an alternative second-line regimen should be given to patients with persistent *H. pylori*. After treatment with antibiotics, patients should undergo repeat gastroscopy at 3 months, then every 6 months for 2 years, then annually for 3 years. Biopsies should be taken for lymphoma and *H. pylori* each time. Gastric MALT lymphoma may respond within several weeks or slowly regress over 12-18 months after *H. pylori* eradication. Referral to the cancer centre is not required unless persistence of disease is documented after successful *H. pylori* eradication. If lymphoma recurs or persists more than 12-18 months after *H. pylori* eradication, the patient should receive moderate dose (e.g. 24-30 Gy) upper abdominal ISRT which results in excellent outcomes ¹⁸⁴⁻¹⁸⁷. Patients could also be considered for initial ISRT in addition to *H. pylori*

therapy if the tumour is associated with t(11;18). Rituximab or chemoimmunotherapy may be considered for patients ineligible for or relapsing after RT ¹⁸⁸⁻¹⁹⁰.

2) Localized (stage I-II₁) H. pylori negative gastric MALT lymphoma: For the minority of patients whose gastric biopsies are negative for H. pylori, non-invasive testing (e.g. stool antigen test, urea breath test, and/or serology) should be performed to confirm H. pylori status. H. pylori-negative gastric MALT lymphoma is more likely to be associated with t(11;18) ^{191,192}. A trial of H. pylori eradication may still be considered as up to 38% of cases of H. pylori negative gastric MALT lymphoma can respond to antibiotics ¹⁹³, presumably due to false negative testing or infection with other helicobacter species ¹⁹⁴; these patients should receive ISRT if there is no evidence of lymphoma regression after 3-6 months on repeat endoscopy. Alternatively, initial treatment with ISRT can be considered since the majority will not respond to H. pylori eradication, whereas ISRT achieves complete responses in >95% of patients with long-term event-free survival rates of 80-90% ^{176,195-198}. Repeat endoscopy should be done 3-6 months after ISRT to confirm response. The decision to treat with initial ISRT versus a trial of H. pylori eradication should be individualized and made in conjunction with patient wishes.

3) Advanced (stage II₂, IIE or IV) gastric MALT lymphoma: These patients should be managed as advanced stage indolent B-cell lymphoma with active surveillance if asymptomatic or chemoimmunotherapy if symptomatic disease. These patients should also receive H. pylori eradication therapy.

Management of Relapsed MZL

Relapsed disease (all MZL entities) is most often managed with a BTK inhibitor (via compassionate access) but repeat chemoimmunotherapy (if prolonged time since first therapy) is also an option. Autologous stem cell transplant is rarely used for this disease, but could be considered in a young, healthy patient who relapses quickly after BR. Clinical trials should be considered when available. Finally, CAR-T is currently available for 3rd line therapy, after failing 2 or more lines of therapy.

Small Lymphocytic Lymphoma (SLL)

SLL and chronic lymphocytic leukemia (CLL) are considered to be biologically the same disease and the management of SLL should follow CLL treatment guidelines (not guidelines for other indolent non-Hodgkin lymphoma subtypes. [[CLL Guideline link](#)])

Lymphoplasmacytic Lymphoma (LPL)

Diagnostic criteria for Waldenström macroglobulinemia (WM):

- IgM monoclonal gammopathy of any concentration
- Bone marrow infiltration by small lymphocytes showing plasmacytoid/plasma cell differentiation, usually with intertrabecular pattern of bone marrow infiltration
- LPL immunophenotype:

- surface IgM+ CD5- CD10- CD19+ CD20+ CD22+ CD23- CD25+ CD27+ FMC7+ CD103- CD138-
- Recent findings documented a strong association between WM and the MYD88 L265P variant, which might serve as an additional tool to diagnose WM and to separate it from other entities such as multiple myeloma, monoclonal gammopathy of undetermined significance, splenic marginal zone lymphoma and MALT lymphoma

Diagnostic approach to confirm a suspected case of WM:

1. Serum protein electrophoresis with immunofixation: to characterize the type of light and heavy chains.
2. 24-Hour urine for protein electrophoresis: 40%-80% have detectable Bence Jones proteinuria.
3. Serum B2-microglobulin: for prognostic evaluation.
4. Bone marrow biopsy: intratrabecular monoclonal lymphoplasmacytic infiltrate, ranging from predominantly lymphocytic to lymphoplasmacytic to overt plasma cells.
5. CT of the abdomen and pelvis: to detect organomegaly and lymphadenopathy (skeletal surveys and bone scans are not necessary in absence of symptoms).
6. Blood or plasma viscosity: if signs and symptoms of hyperviscosity syndrome (HVS) or IgM > 50 g/L.
7. Direct antiglobulin test and cold agglutinin titre if positive.
8. Cryoglobulins.

IgM monoclonal protein response assessment in WM¹⁶³.

Serum IgM monoclonal protein should be measured by serum protein electrophoresis. The use of nephelometry to determine total serum IgM should be discouraged because this method is unreliable, especially when the levels of monoclonal protein are high. The presence of cryoglobulin or cold agglutinin may affect determination of IgM; therefore, testing of cryoglobulin and cold agglutinin at baseline should be considered, and if present, serum samples should be reevaluated at 37°C to ensure accurate and consistent determination of the monoclonal protein levels.

Hyperviscosity syndrome (HVS) in LPL

Symptoms and signs of hyperviscosity include spontaneous bleeding, neurological symptoms and retinopathy. Patients with HVS have an expanded plasma volume and cardiac failure may also occur. There are several published reports demonstrating the efficacy of plasmapheresis in HVS although randomised data are lacking. There is not, however, a simple linear relationship between paraprotein concentration and either plasma viscosity, whole blood viscosity or symptoms. An increase in IgM concentration from 20 to 30 g/L results in an increase in plasma viscosity of <2 centipoise (cP) but an increase from 40 to 50 g/L increases the plasma viscosity by around 5 cP. Indeed, a 1-volume plasma exchange results in a 35-40% decrease in IgM concentration but in up to a 60% reduction in plasma viscosity. In patients with WM the actual plasma volume may exceed that calculated and, given the data above, a 1–1.5 volume exchange is therefore advisable.

General treatment guidelines for LPL/WM¹⁶³.

The usual indications for starting patients with LPL/WM on active therapy consist of clinical evidence of adverse effects of the paraprotein (HVS with neurological or ocular disturbance, peripheral neuropathy, amyloidosis, symptomatic cryoglobulinemia), symptomatic anemia (Hb<100g/L beware of pseudo-anemia from hemodilution), platelets <100, progression to high-grade lymphoma, significant adenopathy or organomegaly, or constitutional symptoms.

- Plasmapheresis: 1-2 procedures, exchanging 1-1.5 calculated plasma volumes, are advised for the treatment of HVS in WM, followed by chemotherapy to prevent paraprotein re-accumulation. In patients who are drug-resistant, plasmapheresis may be indicated for long-term management. Although there are few studies that consider the role of plasma exchange in the treatment of cryoglobulinemia, there is a clear rationale for its use. The treatment room should be warm and blood warmers used in the cell separator circuit to prevent precipitation during the procedure.
- Chemotherapy: The most common initial chemotherapy for LPL is B-R (Bendamustine-Rituximab) similar to other indolent B-cell lymphomas. Maintenance rituximab after BR did not appear to confer significant benefit in a randomized trial in LPL, although the final study results have not yet been published (Rummel et al., ASH 2019). For patients who do not tolerate B-R, CDR (Cyclophosphamide, Decadron, Rituximab) or Bortezomib-based therapy (eg. R-Bortezomib, R-CyBorD) could be considered¹⁹⁹. Rituximab is active in the treatment of WM but associated with the risk of transient exacerbation of disease-related complications and should be used with caution in patients with symptoms of hyperviscosity and/or IgM levels >40 g/L. In patients with hyperviscosity and/or IgM levels >40 g/L, it is advised to hold rituximab for cycle 1, and start rituximab with cycle 2 chemotherapy. In retrospective studies, purine analogue therapy is associated with higher rates of prolonged cytopenias, infections, secondary MDS/AML, and transformation to large cell lymphoma when compared to therapy with alkylating agents.
- BTK inhibitors, ibrutinib and zanubrutinib are both highly effective in LPL (both first line and for relapsed/refractory disease)²⁰⁰. Zanubrutinib is now funded for relapsed LPL in AB and is the preferred second line therapy for r/r LPL.^{201,202} Ibrutinib +/- rituximab is also anticipated to be funded for r/r LPL but has not been compared to zanubrutinib. Additionally, ibrutinib has not been investigated without rituximab and there is no data to support the added benefit of rituximab. Ibrutinib should thus be reserved for patients who are intolerant but not resistant to zanubrutinib²⁰³.
- Patients who have obtained lengthy first remissions can be considered for re-treatment with chemo-immunotherapy with or without the addition of bortezomib (eg. R-Bortezomib, R-CyBorD)
- ASCT may be considered for younger fit patients with early or aggressive relapses or who prioritize the possibility of a long-term treatment-free interval

Hairy Cell Leukemia

Hairy cell leukemia (HCL) and HCL variant (HCL-V) are mature lymphoid B-cell disorders, characterized by the identification of hairy cells and a specific genetic profile. HCL-v has recently been reclassified by the WHO as splenic B cell lymphoma/leukemia with prominent nucleoli (SBLPN) and is not treated as HCL.²⁰⁴ Diagnosis of HCL is based on morphological evidence of hairy cells,

immunophenotypic positivity for CD11C, CD103, CD123, and CD25 expression and the presence of *BRAF* V600E somatic mutation. *BRAF*-V600E has not been identified in other B-cell chronic lymphoproliferative disorders except very rarely so the mutation is now considered as the molecular hallmark of the disease. Absence of the *BRAF* gene mutation is reported in approximately 10% of patients with HCL and appears to constitute a subgroup with a poor prognosis, many of these likely to be reclassified in the modern era²⁰⁵.

Patients with asymptomatic HCL may be managed with active observation (watch & wait strategy). Symptomatic patients should be treated and most guidelines agree that even asymptomatic patients with marked cytopenias should be treated including at least one of the following: hemoglobin < 110 mg/dL, platelet count <100 000/ μ L, or an absolute neutrophil count <1000/ μ L.

In the first-line setting, purine analogs (cladribine or pentostatin) have been demonstrated to result in long overall survival. No randomized trials have been performed in HCL with no studies to suggest superiority of either drug but cladribine is available in Canada and is the most frequently used drug worldwide for HCL. Early studies used continuous intravenous dosing over 7 days²⁰⁶ but more recent studies (non-comparative) have investigated subcutaneous or intravenous bolus dosing over 5-7 days with excellent responses²⁰⁷. We previously recommended cladribine subcutaneously at 0.1-0.14mg/kg daily for 5-7 days though this is associated with multiple subcutaneous injections for most normal-weight adults so has been replaced by a recommendation for intravenous bolus dosing. Infection prophylaxis is recommended as with other purine analogues (PJP and viral prophylaxis for 6-12 months) and patients with active infections should have control of infection prior to therapy initiation if possible.

The addition of rituximab to cladribine in the frontline setting was shown to improve depth of response in HCL. HCL patients treated with concurrent cladribine and 8 weekly doses of rituximab had higher MRD-free complete remission rates than patients treated without rituximab or with delayed rituximab.²⁰⁸ As improved responses are predicted to lead to longer remissions and given the proven benefit of rituximab in combination with chemotherapy frontline for other indolent NHLs, we recommend consideration of cladribine + rituximab for frontline HCL treatment. Infectious risks and lack of survival data should be considered with cladribine monotherapy favoured for frailer patients and those at high risk of infection. Unpublished Alberta data has demonstrated that patients with HCL have a high incidence of injection site reactions to subcutaneous rituximab with as many as 1/3 of patients being intolerant to sc rituximab and requiring a switch back to intravenous formulation. These severe injection site reactions can lead to frequent emergency room presentations (for concerns of cellulitis) and as such, we recommend intravenous rituximab for all 8 doses for patients with HCL to reduce morbidity and high healthcare resource utilization.

For relapsed HCL, cladribine can result in a second durable remission. Synergy has also been demonstrated with rituximab such that we recommend combination therapy with rituximab and cladribine for relapsed disease for individuals who have experienced a lengthy remission to cladribine +/- R firstline²⁰⁹. Careful attention for and prophylaxis against infection is recommended.

Given the importance of *BRAF* V600E in this disease, BRAF inhibitors have also been investigated in relapsed patients with high response rates. Low dose vemurafenib at 240mg twice daily was reported to result in complete remissions in 40% of patients. Unfortunately, results do not appear durable after drug discontinuation and re-treatment or chronic treatment are commonly required²¹⁰. An intensive short-course therapy with high dose vemurafenib and concurrent rituximab was reported in a Phase 2 study of 30 patients with relapsed/refractory HCL.²¹¹ Although deep responses were obtained, the toxicity of high dose vemurafenib is very high and this therapy is unlikely to be feasible for most patients. We recommend BRAF inhibition for patients who are refractory to cladribine (relapse < 24 months)²¹². Vemurafenib has also been used successfully in previously untreated patients with active infections as a bridge to cladribine therapy during treatment of the infection.

Moxetumumab pasudotox is a recombinant CD22-targeting immunotoxin, which was also proven efficacious in highly refractory HCL patients. Moxetumumab is not marketed in most countries and is unlikely to be an option for patients in Canada.

Splenic B cell lymphoma/leukemia with prominent nucleoli (SBLPN)

SBLPN encompasses the previous diagnoses of B prolymphocytic leukemia and Hairy Cell Leukemia- variant. Given the recent classification of this entity, there is very limited evidence of the best treatment approach. Responses to purine analogue monotherapy are poor. The disease presents with small cells in keeping with an indolent B cell lymphoproliferative disorder but with cases reported of more aggressive presentations in keeping with “transformation”. In the absence of data to guide therapeutic strategies, we would recommend treatment following iNHL guidelines including consideration of RCHOP for clinical transformation.

Mantle cell lymphoma^{144,145,213-228}:

Characteristics of mantle cell lymphoma include: male predominance, median age approximately 65 years, advanced stage with multiple extranodal sites (marrow, blood, and intestinal tract), and relative chemoresistance.

Recommendation regarding Watchful Waiting for MCL

Although most patients with MCL have relatively aggressive disease, and even those asymptomatic patients initially managed with watchful waiting have median times to first systemic therapy of 11-12 months, a small proportion of patients can be managed expectantly for over 5 years^{229,230}. Features suggestive of indolent MCL include leukemic non-nodal presentations, predominantly hypermutated immunoglobulin heavy chain variable regions, non complex karyotypes and absence of SOX11 expression by immunohistochemistry²³¹. Occasionally, nodal MCL can also follow an indolent course^{229,230}. Prognostic indices such as the MIPI have not been shown to identify indolent MCL²²⁹. Poor prognostic features associated with shorter survivals and response durations, for which expectant management is not appropriate, include high burden nodal disease, Ki-67 positivity >20-

30%, blastoid histology, *TP53* mutation²³². No prospective randomized trials, or properly designed retrospective comparative effectiveness research studies have compared immediate treatment versus watch-and-wait for MCL patients. Poorly designed retrospective studies suggest similar survival outcomes to immediate therapy, however these studies were biased because patients were selected for watchful waiting based upon better prognostic factors (eg. younger age, better performance status) and did not routinely administer immediate aggressive therapy according to current standards to all patients in the control groups^{229,230}. Prospective randomized trials have demonstrated that more aggressive therapy improves PFS and OS rates relative to less aggressive therapy for MCL. Extrapolating these data to the hypothetical question of aggressive therapy vs no immediate therapy leads to the logical conclusion that immediate therapy is likely the superior approach for most MCL patients.

Given the lack of high-quality evidence from properly conducted comparative studies to prove the W&W is non-inferior to immediate therapy, W&W should only be considered for patients who present with all of the following features:

- 1) Non-nodal disease such as CLL-like presentation (lymphocytosis without associated cytopenias) or stage IAE marginal zone-like presentation. Patients presenting with nodal disease should generally receive immediate chemo-immunotherapy as indicated in treatment sections below unless they have significant co-morbidity that will limit life-expectancy, low tumor burden, and meet other criteria listed in this section below.
- 2) No disease-related symptoms
- 3) No adverse pathology features such as blastoid variant, Ki67>20% of cells, or complex cytogenetic changes. Other adverse features include SOX11 expression and complex cytogenetic changes, however, SOX11 immunohistochemistry is not routinely available in Alberta.
- 4) Patient consent to forgo immediate therapy despite knowledge of demonstrated survival benefits of aggressive vs less aggressive therapy. Patient agreement to surveillance disease monitoring.

Treatment – Transplant Eligible Patients (Up to approximately age 65 years)

The accepted standard of care for newly diagnosed MCL patients up to approximately 65 years of age without major co-morbidities was previously demonstrated to be chemoimmunotherapy followed by high dose therapy with ASCT and then 3 years of rituximab maintenance administered every 2 months. ASCT has thus been an integral part of therapy for younger MCL patients for several decades^{225,226,233}. The recently published TRIANGLE study compared the standard of care of chemoimmunotherapy induction (RCHOP/RDHAP) followed by ASCT with the same therapy but with the inclusion of ibrutinib in induction (with RCHOP only) and as maintenance for 2 years following ASCT versus chemoimmunotherapy (RCHOP/RDAP) with ibrutinib added to the RCHOP cycles plus 2 years of ibrutinib maintenance and omission of ASCT. This study has demonstrated an improvement in PFS and OS with the addition of ibrutinib²³⁴ in induction and maintenance and a lack of inferiority with the omission of ASCT for the groups receiving ibrutinib. Given this OS advantage,

the standard of care for MCL should now include a BTK inhibitor with induction and maintenance. ASCT consolidation is not required unless longer f/u data suggests that this provides added benefit. Ibrutinib and other BTKi inhibitors are not yet funded in Alberta for previously untreated patients with MCL and as such, drug access is recommended to be via Compassionate Access Programs until funding can be confirmed

The addition of high dose cytarabine to RCHOP-like regimens was associated with improved rates of CR, PFS, and OS relative to RCHOP alone in the historical ASCT studies. This is supported by studies from the *GELA* and the European MCL Network with R-CHOP/R-DHAP induction prior to ASCT (RCHOP-21 x 3 followed by R-DHAP x3 , or alternating RCHOP/RDHAP x 6 cycles)²²⁷, as well as the Nordic regimen published as a phase II trial involving RCHOP-21 alternating with Ara-C [3gm² for patients under age 60 years or 2g/m² for patients over 60 years, repeated every 12 hours for a total of 4 doses], for a total of 6 cycles, then ASCT²³⁵. Long-term follow-up of the European MCL Younger Trial demonstrated 10-year TTF 46% with R-CHOP/R-DHAP/ASCT, with a plateau on the curve demonstrating that a significant proportion of patients achieve durable remissions lasting >10 years²³⁶.

TP53 mutation is an uncommon (11%) but significant poor prognostic finding in patients with MCL, highly associated with blastoid morphology, Ki-67 >30%, and high risk MIPI²³⁷. All patients who are potentially eligible for stem cell transplant or CAR-T cell therapy should undergo *TP53* mutation testing. Of note, *TP53* mutations should be assessed by next-generation sequencing (NGS), since the prognostic value of FISH or immunohistochemistry staining has not been as well established²³⁸. Unfortunately, intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of *TP53* mutations, with a median OS of 1.8 years, compared to 12.7 years for *TP53*-unmutated²³⁷. Response to ibrutinib at relapse is also less favorable in patients with mutated versus wild-type *TP53*, with median PFS of only 4 months²³⁹. CAR-T cell therapy has shown high response rates in *TP53*-mutated MCL although longer follow-up is needed to confirm durability of responses and Alberta approval of CAR-T for MCL is still as third line therapy in these patients^{240,241}. Of note, bendamustine exposure within 6 months before leukapheresis has been associated with impaired CAR-T cell manufacturing and reduced efficacy, hence the use of bendamustine should be avoided in patients with *TP53* mutations who are likely to require early access to CAR-T cell therapy^{240,241}. The optimal treatment approach for patients with *TP53* mutations is unknown, but immune and cellular therapies are the most promising strategies. The option of an allogeneic SCT in first response may be discussed with younger, fit patients, although this is associated with significant toxicity and there is limited evidence to support the efficacy of allogeneic SCT in *TP53*-mutated MCL²⁴². Given the reduced risks of GVHD and non-relapse mortality, CAR-T cell therapy at second disease progression is likely to be a preferred strategy for most patients with *TP53*-mutated MCL. Close monitoring while on a BTK inhibitor is essential to detect relapse early and quickly refer for CAR-T before loss of disease control²⁴³.

Although maintenance rituximab has been shown to improve PFS and OS (4 year OS 87% vs. 63%) in the elderly population (age > 60) after induction with R-CHOP²⁴⁴, the role of rituximab maintenance after ASCT for younger patients was uncertain until results of the phase III trial (LyMa) were reported²²⁴. In the LyMa trial, 299 patients <66years of age with mantle cell lymphoma received 4 courses of R-DHAP followed by R-BEAM/ASCT (patients who did not achieve at least PR after R-DHAP could receive 4 additional courses of R-CHOP to facilitate ASCT) and 240 responders were

then randomly assigned to receive 3 years of rituximab maintenance therapy (375 mg/m², one injection every two months) or watch and wait. The median follow-up from randomization after transplantation was 50.2 months (range, 46.4 to 54.2). Progression-free survival at 4 years was improved at 83% (95% CI, 73 to 88) in the rituximab group versus 64% (95% CI, 55 to 73) in the observation group (P<0.001) and overall survival was improved at 89% (95% CI, 81 to 94) in the rituximab group versus 80% (95% CI, 72 to 88) in the observation group (P=0.04). In support of the LyMa trial, a retrospective review of 72 patients previously enrolled in a phase II trial showed a progression free survival benefit in patients who received maintenance Rituximab vs those who did not (2 year PFS 90% vs. 65%)²⁴⁵.

Treatment – Transplant Ineligible Patients (Age over approximately 65yrs)

For patients with mantle cell lymphoma over approximately 65 years of age, B-R induction x6 cycles is our standard of care. Results from an open-label, multicentre, randomized, phase 3 non-inferiority trial found a significant benefit for progression-free survival in patients with mantle cell lymphoma treated with B-R versus R-CHOP (HR 0.61, 95%CI 0.42-0.87, p=0.0072)¹⁴⁴. In addition, the trial confirmed the improved toxicity profile of BR over RCHOP. The phase III SHINE trial demonstrated that the addition of continuous ibrutinib to BR improved PFS over BR alone in older patients with MCL, although the ibrutinib arm had increased toxicity and treatment-related mortality with no improvement in overall survival²⁴⁶. The Phase ENRICH study examined ibrutinib and rituximab (ibrutinib until progressive disease) versus chemoimmunotherapy and did not demonstrate a PFS or PFS advantage compared to BR [[link](#)]. As such, first-line BTK inhibitors are not currently approved or recommended for transplant ineligible patients with MCL.

Regarding rituximab maintenance, there is no published trial examining its benefit following BR induction. The European Mantle Cell Lymphoma Elderly trial confirmed a benefit of rituximab q2 months until progression (vs. interferon-α 2a or 2b) following RCHOP induction. After a median follow-up of 30 months, rituximab maintenance was associated with a significantly longer remission duration compared to interferon maintenance (51 vs. 24 months; HR=0.56, 95% CI 0.36-0.88; p=0.0117). While there was no difference in overall survival between the two groups, a subcohort of patients treated with R-CHOP appeared to show an advantage in 3-year overall survival with rituximab versus interferon maintenance (85% vs. 70%, p=0.0375). The StiL group investigated the value of R maintenance following BR and reported a lack of benefit in terms of PFS or OS.²⁴⁷ However, the study was underpowered to detect a difference. Further, a multicentre retrospective study reported superior outcomes of patients given R maintenance (vs. observation) after achieving CR or PR with BR, with an OS advantage for those who achieved PR only.²⁴⁸ We favour following BR x 6 cycles with R maintenance but with a maximum duration of 4 years of rituximab maintenance given the balance between efficacy, toxicity and cost. Given the lack of strong data to support this approach, R maintenance could be omitted or truncated in patients for whom the benefits of extending a remission do not outweigh the inconvenience of maintenance therapy.

The rare patient who has stage I-IIA, non-bulky mantle cell lymphoma could be considered for B-R + IFRT, or even IFRT alone if they are older than 70 years of age or have significant co-morbidities.

Summary Initial Treatment Recommendations for Mantle Cell Lymphoma:

Immediate chemoimmunotherapy is recommended for most patients.

Transplant Eligible Patients (Age up to approximately 65yrs)

- 1) Induction: RCHOP + ibrutinib Days 1-18 alternating with RDAOx (3 cycles each, no ibrutinib with RDAOx)
 - a. High dose cytarabine dosing
 - i. 2 g/m² BID daily x2 days for age <60, CrCl >60 ml/min, and no pre-existing neurotoxicity
 - ii. 1.5 g/m² BID for age >60, or CrCl 46-60 ml/min, or pre-existing neurotoxicity
 - iii. 1 g/m² BID for CrCl 31-45 ml/min
- 2) Maintenance ibrutinib 560 mg daily x 24 months + rituximab 1400mg sc every 2 months x 3 years

Fit patients with TP53-mutated MCL

- 1) Induction with RCHOP x 6 cycles + BTK inhibitor followed by 24 months of ibrutinib monotherapy + 3 years of R maintenance
- 2) Discuss allogeneic SCT in first response versus plan for CAR-T cell therapy at disease progression after chemotherapy + BTK inhibitor.

Transplant Ineligible Patients (Age over approximately 65yrs)

- 1) Induction: Bendamustine-Rituximab x6 cycles
- 2) Rituximab maintenance q2mo until progression or for maximum 4 years

Treatment Relapsed Mantle Cell Lymphoma.

There is no standard treatment for relapsed MCL but there are many options, including chemotherapy and novel agents²⁴⁹. In general, treatment choice should take into consideration the duration of response to previous treatment.

The Bruton's tyrosine kinase (BTK) inhibitors have shown the most promise as therapeutic agents for relapsed MCL and are the preferred second line therapy. A phase 3 trial that randomized relapsed or refractory MCL patients who previously received at least one rituximab-containing regimen showed superior PFS using ibrutinib over temsirolimus (mPFS 14.6 vs. 6.2 months, p<0.0001) but no significant advantage in OS²⁵⁰. Acalabrutinib has also been investigated in relapsed/refractory MCL in a Phase 2 study with 12 month PFS and OS of 67% and 87% respectively.²⁵¹ Similarly, in a phase 1/2 trial with zanubrutinib the median PFS was 21.1 months and median DOR was 18.5 months.²⁵²

Patients who have received BTKi as a part of their first-line therapy as maintenance and have not progressed on BTKi can be rechallenged with BTKi. Response rates and durability of responses are not known.

Most patients treated with chemoimmunotherapy for MCL respond poorly and with short remissions to re-treatment with chemoimmunotherapy. Some regimens that have shown responses and could be considered in rare patients with r/r MCL include (R-bendamustine or R-BAC if previous (R) CHOP, or vice versa^{249,253,254} or combinations including bortezomib (ex R-cyBorD)^{255,256}. Maintenance rituximab prolongs PFS and OS in relapsed MCL²⁵⁷ but has not been studied in patients that received it after first-line therapy. Lenalidomide also has reported responses in this setting, particularly in combination with rituximab +/- chemotherapy^{256,258}.

The non-covalent BTK inhibitor pirtobrutinib is not yet funded but achieves ORR 58%, CR rate 20%, and median PFS 7.4 months in r/r MCL²⁵⁹.

Brexucabtagene autoleucel (brexu-cel) is a CAR T therapy that is funded for patients with relapsed or refractory mantle cell lymphoma who have received at least 2 lines of therapy including a BTKi. In the ZUMA-2 phase 2 trial, the estimated PFS was 61% and OS 83% at 12 months.²⁶⁰

Allogeneic stem cell transplant has the potential to cure MCL, as is evident from a plateau in the survival curves that is often seen post transplant. Because most patients present over the age of 60 and with multiple comorbidities, allogeneic stem cell transplant is not often offered. It may be considered in relapsed disease for those patients who are young and fit, although CAR-T cell therapy is now preferred before allogeneic SCT for most patients with relapsed MCL given the reduced risks of toxicity and non-relapse mortality.

Summary - Approach to Relapsed/Refractory MCL

1. Treatment with BTKi second line is standard of care
2. For patients not fit for intensive cellular therapy and who have failed BTKi, palliative options include non-covalent BTKi (not yet funded in AB), bortezomib-based therapies, lenalidomide, and clinical trials. Survival for these patients is expected to be very short.
3. For patients fit for intensive cellular therapy (ECOG 0-2 and meeting eligibility criteria) and progressing on BTKi should be referred for CAR-T cell therapy
4. Patients with high-risk features (e.g. *TP53* mutation, blastoid/pleomorphic, Ki67 >30-50%, bulk, POD24) should be started on a BTKi and discussed with the CAR-T centre so that planning and preparation for CAR-T cell therapy can be commenced. Patients should be assessed monthly and imaging should be done within 2-3 months or sooner if evidence of poor response. Imaging should be done again by 6 months for patients achieving an initial PR. Patients with stable or progressing

disease should be referred urgently for CAR-T cell therapy. BTKi should generally not be stopped abruptly due to the risk of rapid tumor progression.

- i. Patients intolerant to ibrutinib should be trialed on alternative BTKi (if possible) prior to referral for cellular therapy.
- ii. If responding to second-line therapy (PR/CR), fit and eligible for allogeneic SCT, particularly if high risk disease (e.g. *TP53* mutation), consider referral for opinion regarding allogeneic SCT. However, CAR-T cell therapy is now preferred before allogeneic SCT for most patients with relapsed MCL given the reduced risks of toxicity and non-relapse mortality.
- iii. If not responding to therapy, OR progressing on BTKi, refer urgently for CAR-T cell therapy

Lymphoblastic lymphoma²⁶¹⁻²⁶⁷:

Patients with lymphoblastic lymphoma require aggressive combination chemotherapy, similar to regimens used in acute lymphoblastic leukemia (ALL), involving induction, consolidation, prophylactic intrathecal chemotherapy and either maintenance therapy or first remission allogeneic SCT (occasionally autologous SCT). Refractory or relapsed patients should be considered for allogeneic SCT if not done previously.

Burkitt lymphoma²⁶⁸⁻²⁷⁰:

Patients with *classical Burkitt Lymphoma* require aggressive combination chemotherapy with prophylactic intrathecal chemotherapy. Acceptable regimens such as *R-CODOX-M/IVAC* are described in Appendix A. First-remission autologous SCT should be considered for patients who cannot tolerate timely administration of full dose *R-CODOX-M/IVAC* (particularly with adverse prognostic features). *DA-EPOCH-R* is an alternative intensive chemotherapy regimen that is easier to tolerate than *R-CODOX-M/IVAC* and could be considered in fit, older patients or patients with comorbidities who are deemed appropriate for curative intent therapy.^{271,272}

Patients who do not have classical Burkitt Lymphoma (eg. Double hit DLBCL, Unclassifiable with features intermediate between DLBCL and Burkitt Lymphoma, etc) do not seem to achieve high cure rates with *R-CODOX-M/IVAC*, and instead should receive different induction therapy, often with first remission ASCT (see section on DLBCL above).

Special Problems in Lymphoma Management

Testicular lymphoma²⁷³⁻²⁷⁶:

In contrast to other patients with localized large B-cell lymphoma, patients with stage IAE or IIAE testicular lymphoma are cured less than 50% of the time using brief chemotherapy and irradiation. Thus, the recommended treatment for all stages of testicular lymphoma is a full course of chemotherapy (*R-CHOP* x 6 cycles). An additional problem often seen in these patients is relapse in the opposite testicle. This can be prevented by scrotal irradiation (25-30Gy/10-15 fractions). Finally, these patients are at high risk for CNS relapse. Although some experts recommend prophylactic

intrathecal chemotherapy, especially for stage 3-4 disease, this has not been proven effective. Unfortunately, many of the CNS relapses occur within the brain parenchyma, and are not prevented by intrathecal chemotherapy. For this reason, CNS prophylaxis should involve high dose intravenous methotrexate 3.5g/m² every 14-28 days x 2-3 doses after completion of all 6 cycles of R-CHOP if this strategy is considered (though there is a paucity of data to support the value of CNS prophylaxis even in this DLBCL subtype).

Primary CNS lymphoma (PCNSL)^{273,277-288}:

Diagnosis of PCNSL is based on a biopsy of the brain lesion, or pathological examination of a vitrectomy or CSF specimen. A bone marrow biopsy and CT scan of the chest, abdomen, and pelvis is required to rule out systemic disease. Additional staging tests include CSF cytology (only if lumbar puncture is not contraindicated because of intracranial hypertension and midline shift). HIV serology should also be obtained.

Treatment of PCNSL involves induction chemotherapy including high dose methotrexate 3.5g/m² every 2 weeks for 4 to 5 doses. Intrathecal methotrexate has not been shown to be beneficial if high-dose methotrexate is used. In a phase II trial, 79 patients aged 18 to 75 years with ECOG 0-3 and mostly low-to-intermediate IELSG risk were randomized to treatment with high dose methotrexate plus cytarabine or high-dose methotrexate alone for 4 cycles every 3 weeks, followed by whole brain radiotherapy (WBRT)²⁷⁷. The investigators reported superior CR (18% vs. 46%, $p=0.006$), ORR (40% vs. 69%, $p=0.009$) and 3 year EFS (24% vs. 35%, $p=0.02$) for patients treated with high-dose methotrexate and cytarabine versus high-dose methotrexate alone. It is therefore recommended to include high-dose methotrexate and cytarabine during induction therapy for PCNSL²⁷⁷.

Whole brain radiotherapy (WBRT) has fallen out of favour for PCNSL, based in part upon high rates of severe neurotoxicity following high-dose methotrexate, and in part due to the results of the G-PCNSL-SG1 randomized controlled trial, in which 551 immunocompetent PCNSL patients (median age 63 years) were randomized to chemotherapy followed by WBRT (arms A1, B1) or chemotherapy alone (arms A2, B2)²⁸⁹. 411 patients entered the post-high dose methotrexate phase, and 318 of these patients were treated per protocol. For this per protocol population, there were no differences in median OS (32.4 vs. 37.1 months, $p=0.8$) or median PFS (18.3 vs. 12 months, $p=0.13$) between the chemotherapy plus WBRT arms (A1+B1, n=154) or chemotherapy alone arms (A2+B2, n=164), respectively²⁸⁹. A recent study suggests neurotoxicity can be reduced by decreasing WBRT dose to 23.4Gy after CR to induction HDMTX-based chemotherapy. The 2-year PFS was 78% in these patients²⁸⁸.

Although patients with refractory or relapsed PCNSL typically have dismal outcomes, autologous stem cell transplantation (ASCT) has shown promising results in this setting. Soussain *et al.* (2001) have reported a 3-year event-free survival (EFS) rate of 53% for patients with relapsed/refractory PCNSL undergoing ASCT following high dose thiotepa, busulfan and cyclophosphamide (TBC) conditioning²⁸⁷.

Small studies have demonstrated durable remissions with ASCT for PCNSL, however, the optimal conditioning regimen remains undefined²⁹⁰⁻²⁹³. With the knowledge of our initial encouraging experience with TBC/ASCT²⁹⁰, and the lack of any widely accepted standard treatment for PCNSL, TBC/ASCT consolidation was considered an acceptable option to treat consenting PCNSL patients at our centre. Review of our data proved the efficacy of this therapy (PFS 52% at 5 years post TBC/ASCT) but with significant toxicity (5 treatment-related deaths, all occurring in patients over 60 yrs). To reduce the TRM, we modified our protocol to omit cyclophosphamide starting in 2011. We recently completed a retrospective review of the outcomes of this protocol for patients treated between Nov 2011 and Dec 2017. In total, 42 patients with a median age of 61 yrs (42-82) were diagnosed with PCNSL from November 2011 – December 2017 in Alberta. Of these 42 patients, 26 patients with a median age of 56.5 years (42-63) were initially deemed to be transplant-eligible and achieved a 3 year PFS rate of 78.3%, even though only 21 (81%) actually received ASCT. Of the 5 who did not proceed to ASCT, 2 had progressive disease on induction and 2 had toxicity to induction preventing ASCT. There was no transplant-related mortality. The 3 yr PFS was 81.2% for the 21 patients who received TBC/ASCT after 2011 compared to only 54.5% for 22 historical control patients who received TBC/ASCT as part of upfront therapy for PCNSL prior to 2011 in Alberta, with respective 3 yr OS rates of 87.1% and 54.5%.

The Anocef-Goelams PRECIS prospective randomized phase II trial evaluated high dose chemotherapy and ASCT consolidation using TBC conditioning (n=38) vs WBRT (n=38) after induction therapy (R-MBVPx2 then R-AraC x2) for PCNSL pts 18-60yo in 23 French centres, and reported 2 yr PFS rates of 86.8% vs 63.2% in favor of ASCT²⁹⁴. Based on these data, we recommend TBC/ASCT consolidation therapy for all eligible PCNSL patients.^{295,296}

The role of Rituximab in treating PCNSL was evaluated in the International Extranodal Lymphoma Study Group (IELSG) 32 study²⁹⁷, which randomized patients with histologically-proven primary CNS lymphoma to receive a maximum of four 3-week cycles of methotrexate at 3.5 g/m² on day 1 and cytarabine at 2 g/m² twice daily on days 2 and 3, either alone (arm A; n = 75), in combination with 375 mg/m² of rituximab on day -5 and 0 (arm B; n = 69), or combined with rituximab at the same dose plus 30 mg/m² of thiotepa on day 4 (MATRIX arm; n = 75). The study was conducted at 52 locations across five countries. The median patient age was 58 years (range, 18-70) and all patients were HIV-negative. Overall, patients had an ECOG PS ≤3, with patients aged 66 to 70 years having an ECOG PS ≤2. Patient characteristics were well balanced among the study arms. Autologous stem cells were successfully collected after the second treatment course in 152 patients (94%). In the MATRIX arm C, the overall response rate was 87% (95% CI, 80-94) compared with 74% (95% CI, 64-84), and 53% (95% CI, 42-64) in arms B and A, respectively (P = .00001 for A vs C)²⁹⁷. As reported by Dr. Andrés Ferreri at the ASH 2016 conference (abstr 511), at a median follow-up of 40 months, the PFS rate was approximately 55% in the MATRIX arm C, 39% in arm B, and 29% in arm A, with OS rates of 63%, 46%, and 31%, respectively. Of the 219 enrolled patients, 118 (54%) patients without progressive disease (n=52) or excessive toxicity/poor mobilization/refusal (n=49) underwent a second randomization comparing consolidation with whole-brain irradiation (n=59) or ASCT (n=59). The CR

rate similarly improved from 54% after induction up to 94% after either consolidation therapy, suggesting a very important role for consolidation therapy. There were no statistically significant differences in PFS after the two consolidation treatments (3yr PFS approximately 60-70%), however, neurotoxicity rates were higher in the WBRT arm.

The potential benefit of rituximab with induction chemotherapy was not confirmed in different phase III trial by HOVON 105/ALLG NHL 24²⁹⁸, in which 119 patients in Netherlands, Australia and New Zealand were randomized to 2 cycles of induction (MTX, BCNU, teniposide, prednisone) with or without rituximab, then followed by consolidation with cytarabine and WBRT 30Gy (+10Gy boost) if <60yrs of age. This study reported non-significantly different 1 year EFS rates of 49% and 52% for rituximab vs no rituximab (ORR 87% and CR 67%).

The Alberta Lymphoma Group established a provincial PCNSL Treatment Protocol in November 2011. The rationale behind the 2011 protocol included:

1) Induction chemotherapy:

- a. First 2 cycles: HDMTX 3.5g/m² d1,15 with procarbazine 100mg/m² po d1-7. This treatment had been shown to induce response and is tolerable for patients who may be debilitated at the time of initial diagnosis of PCNSL. Cytarabine was not added to first cycle HDMTX because patients may not tolerate intensive therapy well until performance status improves.
- b. Stem Cell Mobilization and Apheresis: to be done with first dose of Cytarabine because stem cells may not mobilize well after multiple cycles Cytarabine/G-CSF. Rituximab will be used in addition to Cytarabine due to reports that lymphoma cells can circulate in blood and marrow in patients with PCNSL²⁹⁹, and Rituximab may decrease risk of collecting contaminated autograft as has been shown for other B-cell lymphomas.
- c. Final 2 Cycles will combine Cytarabine with HDMTX as done in a prior IELSG study to improve response rates and decrease frequency of primary progressive disease²⁷⁷.
- d. Rituximab was added in 2016 for a total of 6 doses during induction to improve response

2) High Dose Chemotherapy (patients <70 yo with no significant co-morbidities, KPS>60% after induction therapy, and PCNSL not secondary to immune suppression):

- a. Thiotepa 300mg/m² x2d and Busulfan 3.2mg/kg x3d without cyclophosphamide. Because cyclophosphamide does not penetrate the blood brain barrier particularly well, its omission may decrease treatment-related mortality without decreasing cure rates compared to the previous TBC regimen.

3) Ifosfamide consolidation (transplant refusal or ineligible patients):

- a. Ifosfamide crosses BBB approximately 30%, and gives some exposure of PCNSL to alkylating agent therapy^{300,301}.

Recommendations: PCNSL Transplant-Eligible (Usually <70 years old)

The above evidence suggests that transplant-eligible patients are best treated with HDMTX/AraC-based induction followed by TBU/ASCT consolidation. There also is a potentially important role for the addition of rituximab to induction chemotherapy when ASCT consolidation is used. However, the optimal number of induction chemotherapy cycles is unknown, and perhaps as soon as a patient achieves a response and is physically well, they should proceed directly to ASCT before the disease starts to progress, or cumulative toxicity from further induction therapy prevents ASCT consolidation. As such, the 2018 PCNSL guidelines have been modified to decrease the length of induction therapy prior to ASCT. We have not incorporated MATRIX induction, because the use of MATRIX may decrease the ability of patients to proceed to ASCT due to toxicity, increased likelihood of patient refusal due to treatment-fatigue, or due to poor stem cell mobilization. We believe the use of ASCT is more important than the use of MATRIX. Our real world outcomes using non-MATRIX induction and TBU/ASCT are numerically superior to those reported in the MATRIX study. We also increased the age limit for the transplant eligible protocol to 75 years, however, patients over age 70 years must be extremely healthy with no comorbidities and must also be highly motivated to receive TBU/ASCT. The increased age limit is supported by studies showing reasonable outcomes and tolerability of high dose therapy and ASCT for patients over age 65 years. For example, Schorb and colleagues reported TRM of only 3.8% and 2 year PFS of 80% for front-line and 54% for 2nd line thiotepa-based high dose therapy and ASCT in 52 PCNSL patients aged 65-77 years (median 68)²³³. MATRIX could, however, be used for transplant-eligible patients who refuse transplant.

Recommendations: PCNSL Transplant-Ineligible

There is no current standard of care for elderly PCNSL. We previously recommended high dose methotrexate in combination with high dose cytarabine with or without WBRT consolidation. In a recent review of our local data, of the 16 patients who were considered transplant-ineligible at diagnosis, their median age was 70 yrs (61-82), and only 8 were initiated on the transplant ineligible protocol of methotrexate and cytarabine (others received palliation only (n=4), WBRT alone (n=1), and single agent MTX alone (n=3). The 3 yr PFS rate for the 16 transplant ineligible patients was 0%. Based on these results and the poor quality of life associated with repeated hospitalisations for methotrexate, we propose an outpatient regimen of cytarabine, rituximab and thiotepa for patients who are unfit for transplant but motivated to attempt intensive therapy. This regimen should be considered for patients who are ECOG 0-2 and ambulatory. All other non-transplant eligible patients should be offered WBRT and or palliation alone.

- 1) Not chemotherapy candidates due to CIRS score>6 or ECOG≥3 after dexamethasone therapy:
 - a. palliative WBRT or
 - b. best supportive palliative care only
- 2) Chemotherapy candidates with CIRS score=0-6 and ECOG 0-2:
 - a. Cytarabine, Rituximab and Thiotepa x 2-4 cycles
 - b. MATRIX x 2-4 cycles.

c.

Restaging should be performed after 2 cycles of therapy. Patients who fail to achieve a radiological and/or clinical response after 2 cycles should be considered for palliation or referral for consolidation WBRT.

For a detailed description of recommended PCNSL treatment regimens, please refer to Appendix A, subheading VII, sections A and B.

For palliative therapy, doses of cranial radiotherapy should be 30Gy in 10-20 fractions.

Eye lymphoma

Orbital or peri-orbital lymphoma^{273,302}: Peri-orbital lymphoma of the bony orbit or the soft tissues in and around the orbit but outside of the globe and optic nerve should be managed as indicated in the earlier sections on aggressive lymphomas, marginal zone lymphomas or follicular lymphoma, as appropriate for the type and stage of the lymphoma. Approximately 40% of such patients have advanced disease discovered when carefully staged. In general, 25-30Gy/20 fractions radiotherapy to whole orbit/periorbital tissue is recommended for indolent peri-orbital lymphomas.

Conjunctival lymphoma^{273,302}: Lymphoma involving the conjunctiva but not the structures within the globe or the optic nerve is usually of low grade and should be treated with 25-30Gy/20 fractions of radiotherapy. Doses, fields, and shielding specifically modified for treatment of the eye are necessary to minimize long-term complications such as xerophthalmia or cataract formation.

Intra-ocular and optic nerve lymphoma^{273,303}:

- Lymphoma involving the vitreous, retina or other structures within the optic nerve or globe is usually of large cell type and is equivalent to PCNSL. Bilateral involvement is common. Evaluation and management should be the same as for PCNSL. Acceptable treatment involves induction chemotherapy with high dose methotrexate and high dose cytarabine as described for PCNSL in Appendix A.
- Lymphoma involving the uveal structures (choroid) is a rare presentation of lymphoma, and is usually of indolent type. This disease is best managed with treatment appropriate for stage and local extent of disease.

Aggressive T-Cell Lymphomas:

*NK/T-cell lymphoma, nasal type*³⁰⁴⁻³¹²

Natural killer (NK)/T-cell lymphoma, nasal type is a rare and aggressive extranodal neoplasm that almost exclusively affects Asian and South American adults in the fifth decade of life, with a male:female ratio of approximately 3:1. It typically arises in the nasal cavity or surrounding structures,

such as the sinuses, palate, nasopharynx, tonsils, hypopharynx, and larynx. While the pathogenesis of NK/T-cell lymphoma, nasal type is not well understood, the Epstein-Barr virus (EBV) is implicated in almost all cases. Approximately 25% of cases show a p53 mutation; in addition, p21 over-expression is also frequent in nasal NK/T-cell lymphoma, and seems to be independent of p53 gene status³⁰⁷.

Hematopathological evaluation of a biopsy specimen from the site of involvement is the basis for diagnosis of nasal NK/T-cell lymphoma. The recommended immunohistochemistry panel includes^{305,313}:

- B-cell: CD20
- T-lineage antigens: CD2, CD7, CD8, CD4, CD5, CD3
- NK lineage markers: CD56
- Cytotoxic granules (granzyme B and/or TIA-1)
- Ki-67
- *In situ* hybridization for EBV-encoded RNA (EBER)

For patients with early-stage nasal NK/T-cell lymphoma (ENKTCL), early or upfront radiotherapy (intensive regimens such as a total dose ≥ 50 Gy) plays an essential role in therapy, and has been associated with higher overall survival and complete response rates compared to chemotherapy alone³⁰⁸. However, radiotherapy alone is also associated with high relapse rates. Combined modality therapy is recommended with sequential and concurrent chemo-radiotherapy regimens having relatively equivalent outcomes. No standard of care therapy exists for ENKTCL and most novel regimens incorporate L-asparaginase into treatment due to high single agent activity.³¹⁴ Given the recent discontinuation of L-asparaginase, we favour the combination of peg-asparaginase with gemcitabine and oxaliplatin (P-GEMOX) for patients with limited stage disease. With this approach, treatment is initiated with 2 cycles of P-GEMOX, followed by radiotherapy (48-56 Gy) followed by 2 further cycles of P-GEMOX restarted 1 week after completion of radiotherapy. Radiotherapy may be introduced earlier in the therapy if feasible and early referral for radiotherapy is recommended for all patients with limited stage ENKTCL. With this approach, in 33 patients, the ORR was 94% and 2 year PFS and OS were 77% and 83% respectively. Notably, Grade 3-4 toxicities were rare.

For patients with stage III-IV disease, complete remission rates are less than 15%, and the median overall survival is approximately 4 months³¹². The recommended options for therapy include either enrollment in a clinical trial or treatment with an L-asparaginase-based combination chemotherapy regimen. The most well-studied regimen is the SMILE regimen with several small series of patients reported³¹⁵⁻³¹⁷. While the SMILE regimen was first reported to have excellent response rates (overall, and complete in 79% and 45%, respectively) in relapsed/refractory patients, an updated study of the use of the SMILE regimen as frontline therapy for advanced stage patients reported a short median OS (12.2 months; 1-year OS was 45%) with a high rate of TRM (5 of 87 patients died of sepsis)³¹⁵. While the GOLD regimen has less reported patients, the toxicity is significantly less (Grade 3-4 neutropenia of 16% compared to SMILE of 92%³¹⁶ with serious infections in 4% and 31-45%^{315,316} of

patients treated, respectively). For this reason, patients of advanced age or with comorbidities or a history of infections should be considered for therapy with GOLD for 2-4 cycles followed by SCT if possible while younger, fit patients can be treated with SMILE x 2 cycles with a goal of proceeding to SCT as consolidation. The role of allogeneic or autologous SCT is not yet well defined because of limited data; but it is suggested when possible for advanced stage or relapsed/refractory patients.

Early phase data suggests efficacy of the checkpoint inhibitor class (pembrolizumab) for relapsed/refractory ENKTCL. While this therapy is not funded in AB, it is the recommended approach for patients with relapsed/refractory ENKTCL who are fit enough to consider additional therapy, if drug access can be obtained^{318,319}.

Peripheral T-cell lymphomas (PTCL)³²⁰⁻³²⁸

With the exception of ALK-positive anaplastic large cell lymphoma, CHOP chemotherapy cures less than 30% of patients with PTCL. Options that may be associated with higher cure rates include CHOP x 4-6 cycles followed by HDCT/ASCT in responding patients or brentuximab-vedotin + CHP or intensification of CHOP with etoposide (CHOEP).³²⁹

The ECHELON-2 study was a Phase 3 trial including CD30+ ($\geq 10\%$ by immunohistochemistry) PTCL comparing CHOP with BV-CHP. PFS and OS were superior in the BV-CHP arm and important toxicities (including neuropathy and febrile neutropenia) were comparable between the arms. The benefit of BV appeared most pronounced in patients with ALCL who represented 70% of the trial population. Of note, patients with ALK+ ALCL were only included if their IPI was 2-5. BV-CHP is funded in Alberta for CD30+ ALCL, PTCL NOS, and AITL although the benefit is less clear in the latter two subgroups. Re-treatment with BV is funded for patients who remain progression-free for ≥ 6 months after BV-CHP with ORR rate 40-60% and CR rate 20-40% among patients with ALCL, PTCL NOS, and AITL who relapsed after BV-CHP³³⁰.

The German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) analyzed results of 343 PTCL patients treated within their trials³³¹. The majority belonged to the four major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), ALK-positive (n=78); ALCL, ALK-negative (n=113); peripheral T-cell lymphoma, unspecified (PTCLU; n=70); and angioimmunoblastic T-cell lymphoma (AITL; n=28). Treatment consisted of 6-8 courses of CHOP or CHOP plus etoposide (CHOEP). Three-year event-free and overall survival rates were 75.8% and 89.8% for the ALCL, ALK-positive patients, 50.0% and 67.5% for the AITL patients, 45.7% and 62.1% for the ALCL, ALK-negative patients, and 41.1% and 53.9% for the PTCLU patients. The International Prognostic Index (IPI) was effective in defining risk groups with significantly different outcomes. For patients, 60 years of age or younger with LDH levels $\leq$ upper normal value, etoposide was associated with an improvement in 3-year EFS (75.4% vs. 51.0%, $p=0003$)³²⁰. Aviles and colleagues recently reported the results of a phase III trial involving 217 patients with PTCL unspecified³²¹. Patients were treated with either CMED every 14 days x 6 cycles or standard CHOP. The 10-year PFS was 70% in the CMED group versus

43% in the CHOP group ($p<0.01$), and the 10-year OS was 60% in the CMED group versus 34% in the CHOP group ($p<0.01$)³²¹.

Retrospective and prospective phase II trials support the use of SCT as part of upfront therapy for PTCL. Sieniawski and colleagues reported 5-year PFS rates of 60% for 26 patients with enteropathy associated T-cell lymphoma treated with IVE-methotrexate induction therapy followed by autologous SCT, compared to only 22% for 54 patients treated with CHOP-like therapy alone³²¹. Two prospective trials have also been reported. In the first, Reimer and colleagues reported results of CHOP x 4-6 cycles followed by dexabeam or ESHAP followed by CyTBI/ASCT for 83 patients (including 32 with PTCL-not otherwise specified, and 27 with angioimmunoblastic T-cell lymphoma)³²³. Fifty-five of the 83 patients received transplantation. In an intent-to-treat analysis, with a median follow-up time of 33 months, the estimated 3-year OS, DFS, and PFS rate were 48%, 53%, and 36%, respectively³³². In the second prospective trial, Rodriguez and colleagues from the Spanish Lymphoma and Autologous Transplantation Cooperative Group reported the results of 74 patients transplanted in the first complete response (65% had 2-3 aalPI risk factors)³²⁴. With a median follow-up of 67 months from diagnosis, the 5-year OS and PFS rates were 68% and 63%, respectively.

PTCL patients who relapse following CHOP-type induction and respond to platinum-based chemotherapy should be considered for ASCT or allogeneic HCT, depending on the duration of initial remission, depth of response to salvage therapy, age and fitness, availability of a suitable donor, and underlying histology, with patients with AITL demonstrating particular susceptibility to the GVL effect of allogeneic HCT³³³.

Outcomes in r/r T cell lymphomas are very poor and early involvement of palliative care is recommended. Motivated patients could consider palliative therapies including: brentuximab vedotin, pralatrexate, hypomethylating agents or oral continuous chemotherapy. BV which is funded for patients with ALCL who have received at least 1 prior line of therapy³³⁴ and patients with CD30+ ALCL, AITL, or PTCL NOS who have remained progression-free for ≥ 6 months after BV-CHP (PMID: 34921960). The prospective PROPEL trial evaluated the effectiveness of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma. N=111 patients received pralatrexate after a median 3 prior therapies (range: 1-12). The overall response rate was 29% with 11% achieving complete response. The median duration of response was 10.1 months. Median PFS and OS were 3.5 months and 14.5 months, respectively. The most common grade ≥ 3 AEs were thrombocytopenia (32%), mucositis (22%), and anemia (18%).³³⁵ Romidepsin, previously funded in this space, has been withdrawn from the market and is no longer a treatment consideration. Hypomethylating agents may also have preferential activity for AITL and T follicular helper cell lymphomas and azacitidine is funded in Alberta without restriction (PMID: 38796193). ALK inhibitors are not funded in Alberta but have demonstrated promising activity in patients with r/r ALK+ ALCL³³⁶.

Summary of treatment recommendations for PTCL.

1. Anaplastic large cell lymphoma:
 - a. ALK positive: Consider CHO(E)P if IPI 0-1 otherwise BV-CHP x 6 cycles + consider HDCT/ASCT if high IPI
 - b. ALK negative: IPI 0-2: BV-CHP x 6 cycles
IPI 3-5: BV-CHP x 6 cycles + HDCT/ASCT if eligible
2. All other subtypes of PTCL:
 - <60 years of age with IPI=0-2: CHOEP x 6 cycles
 - <60-70 years of age with IPI=3-5: CHOP or BV-CHP x 4 cycles, then HDCT/ASCT
 - >70 years of age: CHOP, CEOP or BV-CHP x 6 cycles
3. NK/T-cell lymphoma, nasal type:
 - recommendation for stage I-II NK/T cell lymphoma: P-GEMOX x 2 cycles (then IFRT (48-56 Gy) then 1 week later, 2 further cycles P-GEMOX (total 4 cycles)³³⁷
 - SMILE for advanced stage ENKTCL patients fit to consider this intensive, inpatient regimen³³⁸

AIDS-related lymphomas:³³⁹⁻³⁴⁴

In general, the treatment of AIDS-related lymphoma should be the same as for non-AIDS related lymphoma if the AIDS does not otherwise compromise the patient's performance status and he/she is free of coincident serious opportunistic infection. HAART should be given with CHOP chemotherapy. Treatment should be planned in conjunction with the patient's HIV physician and an antiviral regimen without overlapping toxicity should be chosen. R-CHOP results in the highest rates of disease-free survival, but may also increase the risk of infectious complications and treatment-related mortality in patients with CD4 counts below 50.

Post-transplant lymphoproliferative disease (PTLD) after Solid Organ Transplant in Adults:

1. *Epidemiology.* Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous disease with clinical and pathologic manifestations ranging from benign lymphoid hyperplasia (ie. early lesions) to aggressive lymphoma (ie. monomorphic PTLD)^{345,346}. PTLD and its treatment cause a high rate of mortality and graft loss in patients with solid organ transplants (SOT)³⁴⁷. The incidence of PTLD is highest in multivisceral (>10%) and lowest in renal transplants (1-5%), attributed to intensity of immunosuppression and amount of lymphoid tissue in the allograft³⁴⁸⁻³⁵⁰. Epstein-Barr virus (EBV) infection drives the pathogenesis in PTLDs occurring early post-transplant; conversely, PTLDs occurring after prolonged immunosuppression tend to be monomorphic with no detectable EBV genome, calling an infectious etiology into question³⁵¹. An epidemiologic shift in PTLD has occurred in the most recent decade: the median latency time from transplant to PTLD has increased from 1 to 3 years^{352,353} and the proportion of EBV-positive vs. -negative PTLD has decreased³⁵⁴, attributed to EBV viral load monitoring in EBV seronegative (ie. high risk) patients.
2. *Diagnosis and staging.* Diagnostic tissue must be reviewed by expert pathologists and subtyped according to the WHO³⁵⁵. Several small case series have confirmed that PET-CT is an effective imaging modality for staging in PTLD³⁵⁶⁻³⁶¹. However, some subtypes of PTLD, such as early

lesions and T-cell lymphomas, may not be FDG-avid, necessitating CT as an alternate staging modality.

3. **Management.** Recommendations for the management of PTLD in SOT are based on few phase II clinical trials, retrospective case series, and expert opinion³⁶²⁻³⁶⁴. The mainstays of therapy for CD20-positive PTLD in SOT include reduction of immune suppression (RIS), rituximab, and chemotherapy; adoptive immunotherapy is promising but considered experimental and is unavailable in Alberta. All patients should undergo RIS to the lowest tolerated levels under the direction of the transplant physician as soon as the diagnosis of PTLD is confirmed³⁶². A recommended strategy is to discontinue antiproliferative agents and reduce the calcineurin inhibitor by 25-50% while maintaining the steroid³⁶². Published response rates vary widely (0-73%) and responses are seen within 2 to 4 weeks³⁶⁵⁻³⁶⁷.

3a. **Early lesions, polymorphic and CD20-positive monomorphic PTLD.** RIS may serve as definitive treatment of early lesions, but if response is incomplete further treatment with surgery or radiation is favored. In contrast, polymorphic and monomorphic PTLDs require definitive treatment along with RIS, discussed in further detail below³⁶²⁻³⁶⁴ (Figure 3).

Surgery and radiation. Patients with localized PTLD, such as isolated skin, GI or renal allograft lesions, can achieve prolonged remissions with surgery or localized radiation^{365,368}. Some experts consider surgical resection of isolated GI lesions prior to initiating systemic therapy to reduce early mortality from bowel perforation³⁶³. Radiation alone is generally not curative, with exception of plasmacytoma-like PTLD³⁶⁹, and should not be used as primary treatment³⁶². Radiation may be used for palliating obstructive or compressive symptoms where systemic therapy fails or is not possible³⁶².

Chemotherapy. SOT patients do not tolerate chemotherapy well, often developing severe infection or prolonged cytopenias. Estimates of efficacy of chemotherapy in treatment of PTLD in SOT are limited by the almost entirely retrospective nature of publications. Results of retrospective studies of anthracycline-based chemotherapy, mainly CHOP, show ORRs of 65-73% and 5-year OS of 25-78%; however, treatment-related mortality (TRM) is up to 31%³⁷⁰⁻³⁷⁴.

Rituximab. Several retrospective reviews and phase II clinical trials have confirmed the efficacy of rituximab monotherapy in CD20-positive PTLD post-SOT in patients that fail to respond to RIS. Phase II trials show overall response rates (ORR) of 44% to 71% and CR rates of 26% to 53% after 4 weekly doses with no reported TRM³⁷⁵⁻³⁷⁸. However, 57% of patients treated with rituximab monotherapy in 2 prospective trials had progressive disease within 12 months; risk factors for survival and need for further treatment included age > 60, ECOG ≥ 2, elevated LDH, and lack of CR after rituximab³⁷⁹. Therefore rituximab causes minimal toxicity but remissions achieved are durable in only a minority of patients.

Sequential therapy. Efficacy of a sequential treatment regimen (4 weekly doses of rituximab followed by 4 cycles of CHOP) was established in a phase II international multicentre trial in adult CD20-positive PTLD in SOT (n=70) in an attempt to improve upon the success of rituximab monotherapy and diminish the toxicity of chemotherapy³⁸⁰. The ORR was 60% after initial rituximab, increasing to 90% after sequential chemotherapy. EBV-positive and –negative PTLDs responded equally. OS was 61% at 3 years and time to progression was 69% at 3 years. There were no TRM events related to rituximab and 11% ascribed to CHOP. In a subsequent analysis, the authors concluded that patients who achieved CR and those in PR with a low-risk IPI score after rituximab monotherapy had a low risk of disease progression³⁸¹.

A subsequent phase II trial utilized risk-stratified sequential therapy, in which patients in CR (by CT) after 4 doses of rituximab received 4 further 3-weekly doses of rituximab, and those not in CR after initial rituximab proceeded to RCHOP (4 cycles supported with GCSF). With 152 patients treated, endpoints were superior to sequential therapy (3-year OS 70%, 3-year TTP 73%, TRM 7%), and response to initial rituximab was highly predictive of OS, TTP and PFS ($p<0.001$)^{382,383}. A strategy employing 6 cycles of RCHOP has not been investigated. Fit patients who have tolerated RCHOP x 4 cycles can be considered for a total of 6 cycles as per standard de novo DLBCL treatment.

In summary, rituximab monotherapy is effective first-line treatment in most CD20-positive PTLDs with minimal toxicity. Risk-stratified sequential therapy offers the highest survival rates published to date, and allows patients in CR after rituximab monotherapy to avoid chemotherapy. Close follow-up for disease progression is recommended for patients that received rituximab alone. For PTLD that behaves aggressively (ie. IPI 3-5) or progresses during initial treatment with rituximab, proceed directly to RCHOP before completing 4 doses of rituximab (Figure 3).

Patients with late onset and/or EBV-negative PTLD who are fit at time of DLBCL diagnosis can be considered for standard de novo DLBCL therapy (6 cycles of RCHOP).

3b. Primary CNS PTLD. In the largest reported retrospective series of primary CNS PTLD (n=84), patients treated with rituximab and/or cytarabine (most often given after MTX) survived longer, but significant variation in regimens precluded firm conclusions³⁸⁴. Patients with acceptable renal function and performance status should be offered high-dose methotrexate and rituximab, and others may benefit from palliative radiation^{363,384}.

3c. Burkitt Lymphoma PTLD. Several case series cite acceptable outcomes in this rare subtype of PTLD with chemotherapy regimens ranging in intensity³⁸⁵⁻³⁸⁷. However, no definite recommendations can be made and treatment should be considered individually.

3d. CD20-negative monomorphic PTLDs. Rare subtypes of PTLD that resemble non-transplant lymphomas, such as Hodgkin Lymphoma-like PTLD, T cell monomorphic PTLD, plasmablastic PTLD

and plasma cell dyscrasias, require specific chemotherapeutic treatment similar to their non-transplant counterparts (reviewed by^{362,363}).

4. Prognosis. The risk of death from NHL is significantly higher in SOT compared to non-transplant patients³⁸⁸, and PTLD increases the graft failure rate 5-fold³⁸⁹. Retrospective series of PTLD post-SOT report OS of 30-68% at 5 years, with excess mortality in the first year post-diagnosis^{348,353,390-392}. Adverse prognostic factors from retrospective studies include monomorphic subtype, monomorphic T-cell, bone marrow or CNS involvement, advanced stage, poor performance status, advanced age, elevated LDH, and hypoalbuminemia^{352,353,376,392-394}. Risk factors for worsened OS in the PTLD-1 prospective trial include IPI 3-5, thoracic organ transplant and lack of CR after rituximab monotherapy³⁸¹. A prognostic score developed from 500 PTLD cases in renal transplant patients is described in Table 8; the score was calculated with the exclusion of patients with monomorphic T-cell and CNS PTLD, both of which carried an adverse prognosis, but the score maintains its ability to discriminate risk groups in the whole population³⁸⁹.

Table 8. Post-Transplant Lymphoproliferative Disorders in Renal Transplant Prognostic Score (148). (One point is given for each of elevated LDH, disseminated PTLD (ie. higher than stage 1), monomorphic PTLD, and serum creatinine level >133 µmol/L; 2 points are given for creatinine >133 µmol/L if age > 55 at PTLD diagnosis.)

Risk Group (# Risk Factors)	% Alive at 1/5/10 years
Low (0)	100/92/85
Moderate (1)	89/83/80
High (2-3)	74/59/56
Very High (4-5)	52/35/0

References

1. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas. Version 1.2011.
2. Porcu P, Nichols CR. Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. *Curr Probl Cancer*. 1998;22(5):283-368. doi:S0147-0272(98)90003-4 [pii]
3. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. *N Engl J Med*. 1998;339(1):21-26. doi:10.1056/NEJM199807023390104 [doi]
4. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. *J Clin Oncol*. 2008;26(14):2258-2263. doi:10.1200/JCO.2007.13.6929 [doi]
5. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. *J Clin Oncol*. 2002;20(1):197-204. doi:10.1200/JCO.2002.20.1.197 [doi]
6. Sehn LH, Savage K, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. *Ann Oncol*. 2008;19(suppl 4):iv99-iv100.
7. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 2007;25(7):787-792. doi:JCO.2006.07.0722 [pii]
8. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med*. 1993;328(14):1002-1006. doi:10.1056/NEJM199304083281404 [doi]
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*. 2002;346(4):235-242. doi:10.1056/NEJMoa011795 [doi]
10. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. 2007;109(5):1857-1861. doi:blood-2006-08-038257 [pii]
11. Sehn LH, Chhanabhai M, Gill K, et al. Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level. *Blood*. 2006;108(11):2739.
12. Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *Ann Oncol*. 2008;19(3):545-552. doi:mdm514 [pii]
13. Pfreundschuh MG, Trümper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. *JCO*. 2004;22(14):6500. doi:10.1200/jco.2004.22.90140.6500; 28

14. Aviles A, Delgado S, Nambo MJ, Alatrisme S, Diaz-Maqueo JC. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. *Int J Radiat Oncol Biol Phys*. 1994;30(4):799-803. doi:0360-3016(94)90352-2 [pii]
15. Ferreri AJM, Dell'Oro S, Reni G, Ceresoli G, Cozzarini C, Ponzoni M. The role of consolidation radiotherapy in the management of stage III-IV diffuse large cell lymphoma. *Ann Oncol*. 1998;9(Suppl 4):Abstract 5180.
16. Yahalom J. Radiation therapy in the treatment of lymphoma. *Curr Opin Oncol*. 1999;11(5):370-374.
17. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. *N Engl J Med*. 1997;336(18):1290-1297. doi:10.1056/NEJM199705013361804 [doi]
18. Haion C, Lepage F, Gisselbrecht C. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LHN 87-2 protocol. A GELA study. *Blood*. 1999;ASH Annual Meeting Abstracts;94(Suppl 1):Abstract 2711.
19. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. *Cancer Treat Rev*. 2007;33(4):338-346. doi:S0305-7372(07)00030-8 [pii]
20. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med*. 1995;333(23):1540-1545. doi:10.1056/NEJM199512073332305 [doi]
21. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. *J Clin Oncol*. 2008;26(19):3166-3175. doi:10.1200/JCO.2007.14.4204 [doi]
22. Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. *Ann Hematol*. 2007;86(2):107-115. doi:10.1007/s00277-006-0210-5 [doi]
23. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. *The Lancet Oncology*. 2011;12(13):1258-1266. doi:10.1016/S1470-2045(11)70140-1 [doi]
24. Aukema SM, Siebert R, Schuurin E, et al. Double-hit B-cell lymphomas. *Blood*. 2011;117(8):2319-2331. doi:10.1182/blood-2010-09-297879 [doi]
25. Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. *Blood Cells Mol Dis*. 2010;45(4):317-323. doi:10.1016/j.bcmd.2010.08.002 [doi]
26. Wu D, Wood BL, Dorer R, Fromm JR. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. *Am J Clin Pathol*. 2010;134(2):258-265. doi:10.1309/AJCP7YLDTJPLCE5F [doi]
27. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. *The American Journal of Surgical Pathology*. 2010;34(3):327-340. doi:10.1097/PAS.0b013e3181cd3aeb [doi]
28. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. *J Clin Oncol*. 2003;21(16):3041-3050. doi:10.1200/JCO.2003.01.076 [doi]
29. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. *J Clin Oncol*. 2001;19(18):3874-3883. doi:10.1200/JCO.2001.19.18.3874 [doi]
30. Nieder C, Licht T, Andratschke N, Peschel C, Molls M. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. *Cancer Treat Rev*. 2003;29(1):11-19. doi:S0305737202000944 [pii]
31. Ng AK. Diffuse large B-cell lymphoma. *Semin Radiat Oncol*. 2007;17(3):169-175. doi:S1053-4296(07)00013-6 [pii]
32. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. *J Clin Oncol*. 2004;22(15):3032-3038. doi:10.1200/JCO.2004.06.088 [doi]
33. Aviles A, Fernandez R, Calva A, Neri N, Huerta-Guzman J, Nambo MJ. Radiotherapy versus combined therapy in early stages with bulky disease aggressive malignant lymphoma. *Hematology*. 2003;8(1):7-10. doi:10.1080/1024533021000059456 [doi]
34. Moser EC, Kluin-Nelemans HC, Carde P, et al. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys*. 2006;66(4):1168-1177. doi:S0360-3016(06)00811-X [pii]

35. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. *J Clin Oncol*. 2009;27(1):114-119. doi:10.1200/JCO.2008.16.8021 [doi]
36. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. *Blood*. 2008;111(9):4463-4470. doi:10.1182/blood-2007-08-105759 [doi]
37. Vellenga E, van Putten WL, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. *Blood*. 2008;111(2):537-543. doi:blood-2007-08-108415 [pii]
38. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *Ann Oncol*. 2007;18(1):149-157. doi:mdl327 [pii]
39. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. *J Clin Oncol*. 2006;24(19):3121-3127. doi:JCO.2005.05.1003 [pii]
40. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *The Lancet Oncology*. 2006;7(5):379-391. doi:S1470-2045(06)70664-7 [pii]
41. Schmitz N, Kloess M, Reiser M, et al. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. *Cancer*. 2006;106(1):136-145. doi:10.1002/cncr.21588 [doi]
42. Hashino S, Morioka M, Irie T, et al. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. *Int J Lab Hematol*. 2008;30(4):292-299. doi:10.1111/j.1751-553X.2007.00955.x [doi]
43. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 2005;23(18):4117-4126. doi:JCO.2005.09.131 [pii]
44. Zinzani PL, Martelli M, Poletti V, et al. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. *Haematologica*. 2008;93(9):1364-1371. doi:10.3324/haematol.12742 [doi]
45. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood*. 2004;104(3):634-641. doi:10.1182/blood-2003-06-2095 [doi]
46. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Viardot A. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the megaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood*. 2009;(ASH Annual Meeting Abstracts); 114 (22)(Abstract 404)
47. Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. *Ann Oncol*. 2012;23(1):147-153. doi:10.1093/annonc/mdr058 [doi]
48. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. *Cancer*. 2010;116(18):4283-4290. doi:10.1002/cncr.25278 [doi]
49. Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? *Curr Opin Oncol*. 2011;23(5):436-440. doi:10.1097/CCO.0b013e3283499c7c [doi]
50. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. *J Clin Oncol*. 2010;28(27):4170-4176. doi:10.1200/JCO.2009.27.3441 [doi]
51. Hong J, Kim AJ, Park JS, et al. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. *Korean J Hematol*. 2010;45(4):253-259. doi:10.5045/kjh.2010.45.4.253 [doi]
52. Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. *Blood*. 2018;131(2):174-181. doi:10.1182/blood-2017-07-793984 [doi]

53. Puckrin R, Ghosh S, Peters A, Stewart D. Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. *Leuk Lymphoma*. Mar 2022;63(3):583-590. doi:10.1080/10428194.2021.1992762
54. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Jan 27 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
55. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. *N Engl J Med*. Jul 30 1998;339(5):285-91. doi:10.1056/nejm199807303390501
56. Stephens DM, Li H, LeBlanc ML, et al. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. *J Clin Oncol*. Sep 1 2016;34(25):2997-3004. doi:10.1200/jco.2015.65.4582
57. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. *Lancet Oncol*. Oct 2011;12(11):1013-22. doi:10.1016/s1470-2045(11)70235-2
58. Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *Lancet*. Dec 21 2019;394(10216):2271-2281. doi:10.1016/s0140-6736(19)33008-9
59. Persky D, Li H, Stephens D, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 09/10/2020 2020;38(26)doi:10.1200/JCO.20.00999
60. Sehn LS, DW. Villa, D. Gerrie, AS. Freeman, CL. Parsons, CA. Pickles, T. Lo, A. Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC) | Blood | American Society of Hematology. *Blood*. 2019;134(Supplement_1):401. doi:10.1182/blood-2019-128722
61. Bologna SVB, T. Briere, J. Ribrag, V. Damaj, GL. Thieblemont, C. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE-ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B-CELL LYMPHOMA (AAPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09-1B TRIAL - Bologna - 2021 - Hematological Oncology - Wiley Online Library. *Hematological Oncology*. 2021;39(S2):26. doi:10.1002/hon.5_2879
62. Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. Feb 18 2021;137(7):929-938. doi:10.1182/blood.2020005846
63. Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. *Blood*. 2014;124(21):394.
64. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 09/10/2016 2016;34(26)doi:10.1200/JCO.2015.65.6520
65. Savage K. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. *Hematology American Society of Hematology Education Program*. 12/08/2017 2017;2017(1)doi:10.1182/asheducation-2017.1.578
66. Eyre T, Djebbari F, Kirkwood A, Collins G. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. *Haematologica*. 2020 Jul 2020;105(7)doi:10.3324/haematol.2019.229948
67. Puckrin R, El Darsa H, Ghosh S, Peters A, Owen C, Stewart D. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. *American journal of hematology*. 07/01/2021 2021;96(7)doi:10.1002/ajh.26181
68. Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood*. Jan 20 2022;139(3):413-423. doi:10.1182/blood.2021012888
69. Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. *Blood Adv*. Apr 27 2021;5(8):2142-2152. doi:10.1182/bloodadvances.2020003947
70. Conconi A, Chiappella A, Ferreri AJM, et al. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. *Blood Adv*. Mar 26 2024;8(6):1541-1549. doi:10.1182/bloodadvances.2023011251

71. Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. Apr 2020;21(4):593-602. doi:10.1016/s1470-2045(20)30059-0
72. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med*. Feb 17 2022;386(7):640-654. doi:10.1056/NEJMoa2116133
73. Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. *N Engl J Med*. Jul 13 2023;389(2):148-157. doi:10.1056/NEJMoa2301665
74. Vijay A, Duan Q, Henning JW, et al. High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. Dec 2013;54(12):2620-6. doi:10.3109/10428194.2013.783211
75. Stewart DA, Kuruvilla J, Lee D, et al. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma--outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP. *Br J Haematol*. May 27 2024;doi:10.1111/bjh.19555
76. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. *J Clin Oncol*. Apr 20 2023;41(12):2238-2247. doi:10.1200/jco.22.01725
77. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Dec 15 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913
78. Kasamon YL, Jones RJ, Piantadosi S, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. *Biol Blood Marrow Transplant*. 2005;11(2):93-100. doi:S1083879104005270 [pii]
79. Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. *Haematologica*. 2013;98(3):364-370. doi:10.3324/haematol.2012.077917 [doi]
80. Maziarz RT, Wang Z, Zhang MJ, et al. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *Br J Haematol*. 2013;162(5):648-656. doi:10.1111/bjh.12451 [doi]
81. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. *J Clin Oncol*. 1994;12(11):2415-2422. doi:10.1200/JCO.1994.12.11.2415 [doi]
82. Puckrin R, Chua N, Shafey M, Stewart DA. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. *Leuk Lymphoma*. Oct 2022;63(10):2444-2452. doi:10.1080/10428194.2022.2068005
83. Khwaja J, Kirkwood AA, Isbell LK, et al. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. *Haematologica*. Mar 1 2023;108(3):882-888. doi:10.3324/haematol.2022.281640
84. Alsouqi A, Ahmed G, Wang J, et al. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. *Am J Hematol*. Aug 2024;99(8):1624-1627. doi:10.1002/ajh.27354
85. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. *Blood*. 2014;124(15):2354-2361. doi:10.1182/blood-2014-05-578963 [doi]
86. Laude M, Lebras L, Sesques P, et al. First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. *American journal of hematology*. 03/01/2021 2021;96(3)doi:10.1002/ajh.26068
87. Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2017;35(20):2260-2267. doi:10.1200/JCO.2017.72.2157 [doi]
88. Wang Y, Link BK, Witzig TE, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. *Blood*. Oct 17 2019;134(16):1289-1297. doi:10.1182/blood.2019000858
89. Kansara R, Connors JM, Savage KJ, et al. Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. *Haematologica*. 2016:e411-e414. vol. 10.
90. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. *Br J Haematol*. Nov 2013;163(4):487-95. doi:10.1111/bjh.12570

91. Kuruvilla J, MacDonald DA, Kouroukis CT, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. *Blood*. Aug 6 2015;126(6):733-8. doi:10.1182/blood-2015-01-622084
92. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. *Critical reviews in oncology/hematology*. 2017;113:318-327. doi:S1040-8428(16)30244-X [pii]
93. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. *World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues*. International Agency for Research on Cancer (iARC); 2008.
94. Lazarovic iJ, Terroir M, Arfi-Rouche J, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. *European journal of nuclear medicine and molecular imaging*. 2017 Nov 2017;44(12)doi:10.1007/s00259-017-3758-5
95. Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. *British journal of haematology*. 2018;180(4):534-544. doi:10.1111/bjh.15051 [doi]
96. Hayden A, Tonseth P, Lee D, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. *Blood*. 12/10/2020 2020;136(24)doi:10.1182/blood.2019004296
97. Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. *Haematologica*. 2018 Aug 2018;103(8)doi:10.3324/haematol.2018.192492
98. Hawkes E. Can PET eradicate irradiation in PMBCL? *Blood*. 12/10/2020 2020;136(24)doi:10.1182/blood.2020007766
99. Barrington S, Mikhaeel N, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 09/20/2014 2014;32(27)doi:10.1200/JCO.2013.53.5229
100. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. *Hematol Oncol*. 2005;23(1):10-17. doi:10.1002/hon.743 [doi]
101. Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. *Semin Radiat Oncol*. 2007;17(3):198-205. doi:S1053-4296(07)00017-3 [pii]
102. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. *J Clin Oncol*. 1996;14(4):1282-1290. doi:10.1200/JCO.1996.14.4.1282 [doi]
103. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. *J Clin Oncol*. 2004;22(8):1454-1459. doi:10.1200/JCO.2004.10.086 [doi]
104. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. *J Clin Oncol*. 2003;21(1):5-15. doi:10.1200/jco.2003.05.128 [doi]
105. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 1997;15(3):1110-1117. doi:10.1200/JCO.1997.15.3.1110 [doi]
106. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. *J Clin Oncol*. 1998;16(7):2332-2338. doi:10.1200/JCO.1998.16.7.2332 [doi]
107. Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. *Ann Oncol*. 1999;10(10):1191-1197. doi:1008347425795 [doi]
108. Hagenbeek A, Eghbali H, Monfardini S. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective randomized phase III clinical trial in 381 patients. *Blood*. 1998;ASH Annual Meeting Abstracts); 92:Abstract 1294.
109. Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. *J Clin Oncol*. 1992;10(6):942-947. doi:10.1200/JCO.1992.10.6.942 [doi]
110. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. *J Clin Oncol*. 1994;12(6):1177-1184. doi:10.1200/JCO.1994.12.6.1177 [doi]

111. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. *J Clin Oncol.* 1997;15(2):445-450. doi:10.1200/JCO.1997.15.2.445 [doi]
112. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. *Blood.* 1998;92(5):1832-1836.
113. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol.* 1998;16(8):2825-2833. doi:10.1200/JCO.1998.16.8.2825 [doi]
114. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood.* 1997;90(6):2188-2195.
115. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol.* 2004;22(8):1469-1479. doi:10.1200/JCO.2004.06.055 [doi]
116. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol.* 2002;20(10):2453-2463. doi:10.1200/JCO.2002.11.076 [doi]
117. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. *J Clin Oncol.* 2003;21(21):3918-3927. doi:10.1200/JCO.2003.10.023 [doi]
118. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. *Ann Oncol.* 2000;11(12):1585-1590. doi:1008399623564 [doi]
119. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood.* 2005;105(4):1417-1423. doi:2004-08-3175 [pii]
120. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol.* 2008;26(28):4579-4586. doi:10.1200/JCO.2007.13.5376 [doi]
121. Hochster HS, Weller E, Gascoyne RD, Ryan TS, Habermann TM, Gordon LI. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. ASH Annual Meeting Abstracts. *Blood.* 2005;106(11):349.
122. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood.* 2006;108(10):3295-3301. doi:10.1182/blood-2006-05-021113 [pii]
123. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol.* 2010;28(17):2853-2858. doi:10.1200/JCO.2009.26.5827 [doi]
124. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2007;99(9):706-714. doi:10.1093/jnci/kj106 [pii]
125. Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR, Members of the Hematology DSGotCCOPiE-BC. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. *Cancer Treat Rev.* 2007;33(2):161-176. doi:S0305-7372(06)00207-6 [pii]
126. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. *Cancer.* 2007;109(9):1804-1810. doi:10.1002/cncr.22617 [doi]
127. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol.* 2008;26(32):5156-5164. doi:10.1200/JCO.2008.17.2015 [doi]
128. Brown JR, Feng Y, Gribben JG, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. *Biol Blood Marrow Transplant.* 2007;13(9):1057-1065. doi:S1083-8791(07)00307-2 [pii]
129. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. *J Clin Oncol.* 2008;26(21):3614-3620. doi:10.1200/JCO.2007.15.5358 [doi]

130. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. *Blood*. 2008;112(13):4824-4831. doi:10.1182/blood-2008-04-153189 [doi]
131. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. *J Clin Oncol*. 2009;27(10):1607-1614. doi:10.1200/JCO.2008.17.1561 [doi]
132. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. *Blood*. 2009;113(5):995-1001. doi:10.1182/blood-2008-05-160200 [doi]
133. Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. *Cancer*. 2006;107(5):1014-1022. doi:10.1002/cncr.22093 [doi]
134. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). *Blood*. 2006;108(8):2540-2544. doi:blood-2006-03-013193 [pii]
135. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood*. 2008;111(8):4004-4013. doi:10.1182/blood-2007-10-116749 [doi]
136. Nickenig C, Dreyling M, Hoster E, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. *Ann Oncol*. 2007;18(1):136-142. doi:mdl348 [pii]
137. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. *J Clin Oncol*. 2006;24(10):1590-1596. doi:24/10/1590 [pii]
138. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood*. 2005;106(12):3725-3732. doi:2005-01-0016 [pii]
139. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). *J Cancer Res Clin Oncol*. 2006;132(2):105-112. doi:10.1007/s00432-005-0023-2 [doi]
140. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. *J Clin Oncol*. 2007;25(18):2554-2559. doi:JCO.2006.09.8327 [pii]
141. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7 [doi]
142. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. *J Hematol Oncol*. 2009;2:14-14. doi:10.1186/1756-8722-2-14 [doi]
143. Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. *Biol Blood Marrow Transplant*. 2010;16(4):443-468. doi:10.1016/j.bbmt.2010.01.008 [doi]
144. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2 [doi]
145. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). *Blood*. 2010;116(21):856.

146. Davies G, Ghosh S, Oh D, et al. Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011. *Blood*. 2017;130:4041.
147. Northend MW, W. Clifton-Hadley, L. Rana, Z. Martin, TL, Young, M. Miall, F. Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy | *Blood* | American Society of Hematology. *Blood*. 2022;140(Supplement 1):1456-1458. doi:10.1182/blood-2022-156790
148. Marcus RE, Davies AJ, Ando K, et al. Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. *Blood*. 2016;128(22):6.
149. Oh DH, Li H, Duan Q, et al. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. *Biol Blood Marrow Transplant*. 2016;22(5):941-948. doi:10.1016/j.bbmt.2016.01.015 [doi]
150. Puckrin R, Chua N, Chin K, et al. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma. *Br J Haematol*. Apr 2023;201(2):319-325. doi:10.1111/bjh.18640
151. Leonard J, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 05/10/2019 2019;37(14)doi:10.1200/JCO.19.00010
152. Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). *Blood*. Feb 8 2024;143(6):496-506. doi:10.1182/blood.2023021243
153. Dreyling M, Fowler NH, Dickinson M, et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. *Blood*. Apr 25 2024;143(17):1713-1725. doi:10.1182/blood.2023021567
154. Gopal A, Kahl B, de Vos S, et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *The New England journal of medicine*. 03/13/2014 2014;370(11)doi:10.1056/NEJMoa1314583
155. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. *Semin Oncol*. 1998;25(4):483-491.
156. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. *Blood*. 1994;83(6):1452-1459.
157. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. *J Clin Oncol*. 1994;12(12):2694-2698. doi:10.1200/JCO.1994.12.12.2694 [doi]
158. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. *J Clin Oncol*. 1999;17(2):546-553. doi:10.1200/JCO.1999.17.2.546 [doi]
159. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. *Blood*. 1998;92(4):1165-1171.
160. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). *Leukemia*. 2009;23(1):153-161. doi:10.1038/leu.2008.261 [doi]
161. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. *Blood*. 2007;109(12):5096-5103. doi:blood-2006-11-055012 [pii]
162. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. *J Clin Oncol*. 2005;23(7):1564-1577. doi:23/7/1564 [pii]
163. Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG, Haemato-Oncology Task Force of the British Committee for Standards in H. Guidelines on the management of Waldenstrom macroglobulinaemia. *Br J Haematol*. 2006;132(6):683-697. doi:BJH5948 [pii]
164. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. *Leukemia*. 2008;22(3):487-495. doi:2405068 [pii]
165. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. *Leuk Lymphoma*. 2014;55(11):2640-2642. doi:10.3109/10428194.2014.897703 [doi]
166. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med*. 2002;347(2):89-94. doi:10.1056/NEJMoa013376 [doi]
167. Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. *Blood*. 2011;117(9):2585-2595. doi:10.1182/blood-2010-09-271437 [doi]

168. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. *Br J Haematol.* 1991;78(2):206-209.
169. Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. *Semin Hematol.* 2010;47(2):143-147. doi:10.1053/j.seminhematol.2010.01.004 [doi]
170. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. *Cancer.* 2006;107(1):125-135. doi:10.1002/cncr.21931 [doi]
171. Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. *Am J Hematol.* 2012;87(11):119. doi:10.1002/ajh.23314 [doi]
172. Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. *Br J Haematol.* 2015;169(4):520-527. doi:10.1111/bjh.13320 [doi]
173. Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. *Br J Haematol.* 2011;155(3):308-317. doi:10.1111/j.1365-2141.2011.08843.x [doi]
174. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. *The oncologist.* 2013;18(2):190-197. doi:10.1634/theoncologist.2012-0251 [doi]
175. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. *Ann Oncol.* May 1994;5(5):397-400. doi:10.1093/oxfordjournals.annonc.a058869
176. Ruskoné-Fourmestreaux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. *Gut.* Jun 2003;52(6):912-3. doi:10.1136/gut.52.6.912
177. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 01 2020;31(1):17-29. doi:10.1016/j.annonc.2019.10.010
178. Services AH. *Helicobacter Pylori (H. pylori) Primary Care Pathway.* Accessed July 28, 2022.
179. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of *Helicobacter pylori*: a multicentre cohort follow-up study of 420 patients in Japan. *Gut.* Apr 2012;61(4):507-13. doi:10.1136/gutjnl-2011-300495
180. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following *Helicobacter pylori* eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. *Ann Oncol.* Jun 2009;20(6):1086-93. doi:10.1093/annonc/mdn760
181. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after *Helicobacter pylori* eradication. *J Clin Oncol.* Nov 01 2005;23(31):8018-24. doi:10.1200/JCO.2005.02.3903
182. Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-*Helicobacter* therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. *Br J Haematol.* Feb 2009;144(3):367-75. doi:10.1111/j.1365-2141.2008.07486.x
183. Liu H, Ye H, Ruskoné-Fourmestreaux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to *H. pylori* eradication. *Gastroenterology.* May 2002;122(5):1286-94. doi:10.1053/gast.2002.33047
184. Ruskoné-Fourmestreaux A, Matysiak-Budnik T, Fabiani B, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up. *Radiother Oncol.* Oct 2015;117(1):178-82. doi:10.1016/j.radonc.2015.08.029
185. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. *Cancer.* Aug 15 2010;116(16):3815-24. doi:10.1002/cncr.25226
186. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys.* May 01 2015;92(1):11-31. doi:10.1016/j.ijrobp.2015.01.009
187. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. *Radiother Oncol.* Jul 2011;100(1):86-92. doi:10.1016/j.radonc.2011.05.013
188. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-*Helicobacter pylori* therapy. *J Clin Oncol.* Mar 20 2005;23(9):1979-83. doi:10.1200/JCO.2005.08.128
189. Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a

- multicentre, single-arm, phase 2 trial. *Lancet Haematol*. Dec 2014;1(3):e104-11. doi:10.1016/S2352-3026(14)00021-0
190. Zucca E, Conconi A, Martinelli G, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. *J Clin Oncol*. Jun 10 2017;35(17):1905-1912. doi:10.1200/JCO.2016.70.6994
 191. Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). *Blood*. Aug 01 2005;106(3):1037-41. doi:10.1182/blood-2005-01-0004
 192. Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. *Blood*. Apr 01 2003;101(7):2547-50. doi:10.1182/blood-2002-10-3167
 193. Xie YL, He CY, Wei SQ, Guan WJ, Jiang Z. Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis. *Chin Med J (Engl)*. Jun 05 2020;133(11):1337-1346. doi:10.1097/CM9.0000000000000813
 194. Takigawa H, Yuge R, Masaki S, et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy. *Gastric Cancer*. 07 2021;24(4):937-945. doi:10.1007/s10120-021-01172-x
 195. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. *J Clin Oncol*. Nov 15 2003;21(22):4157-64. doi:10.1200/JCO.2003.06.085
 196. Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. *Ann Oncol*. May 2013;24(5):1344-51. doi:10.1093/annonc/mds623
 197. Fang P, Gunther JR, Pinnix CC, et al. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. *Int J Radiat Oncol Biol Phys*. 04 01 2021;109(5):1414-1420. doi:10.1016/j.ijrobp.2020.11.070
 198. Yahalom J, Xu AJ, Noy A, et al. Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. *Blood Adv*. 04 13 2021;5(7):1830-1836. doi:10.1182/bloodadvances.2020003992
 199. Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. *J Clin Oncol*. May 10 2023;41(14):2607-2616. doi:10.1200/jco.22.01805
 200. Tam C, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. *Blood*. 10/29/2020 2020;136(18)doi:10.1182/blood.2020006844
 201. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *The Lancet Oncology*. 2017;18(2):241-250. doi:S1470-2045(16)30632-5 [pii]
 202. Treon S, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 02/20/2021 2021;39(6)doi:10.1200/JCO.20.00555
 203. Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. *J Clin Oncol*. Nov 20 2023;41(33):5099-5106. doi:10.1200/jco.22.02830
 204. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*. Jul 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2
 205. Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. *Am J Hematol*. 2017;92(12):1382-1390. doi:10.1002/ajh.24936 [doi]
 206. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. *Blood*. 1998;92(6):1918-1926.
 207. von Rohr A, Schmitz SF, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. *Ann Oncol*. 2002;13(10):1641-1649. doi:10.1093/annonc/mdf272 [doi]

208. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. *J Clin Oncol*. May 10 2020;38(14):1527-1538. doi:10.1200/jco.19.02250
209. Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. *Blood*. 2011;118(14):3818-3823. doi:10.1182/blood-2011-04-351502 [doi]
210. Dietrich S, Pircher A, Endris V, et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. *Blood*. 2016;127(23):2847-2855. doi:10.1182/blood-2015-11-680074 [doi]
211. Tiacchi E, De Carolis L, Simonetti E, et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. *N Engl J Med*. May 13 2021;384(19):1810-1823. doi:10.1056/NEJMoa2031298
212. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. *Blood*. 2017;129(5):553-560. doi:10.1182/blood-2016-01-689422 [doi]
213. p Codr Expert Review Committee. Treanda for indolent Non-Hodgkin Lymphoma. 2012.
214. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. *J Clin Oncol*. 1995;13(11):2819-2826. doi:10.1200/JCO.1995.13.11.2819 [doi]
215. Fisher RI, Dahlborg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. *Blood*. 1995;85(4):1075-1082.
216. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. *J Clin Oncol*. 1998;16(5):1922-1930. doi:10.1200/JCO.1998.16.5.1922 [doi]
217. Kroger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. *Bone Marrow Transplant*. 1998;21(1):55-57. doi:10.1038/sj.bmt.1701033 [doi]
218. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. *J Clin Oncol*. 1998;16(1):13-18. doi:10.1200/JCO.1998.16.1.13 [doi]
219. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. *J Clin Oncol*. 2003;21(23):4407-4412. doi:10.1200/JCO.2003.05.501 [doi]
220. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. *J Clin Oncol*. 2002;20(5):1288-1294. doi:10.1200/JCO.2002.20.5.1288 [doi]
221. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol*. 2005;23(9):1984-1992. doi:JCO.2005.08.133 [pii]
222. Kasamon YL, Jones RJ, Diehl LF, et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. *Biol Blood Marrow Transplant*. 2005;11(1):39-46. doi:S1083879104005099 [pii]
223. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO. Hematopoietic stem cell transplantation in mantle cell lymphoma. *Ann Oncol*. 2005;16(4):618-624. doi:md1107 [pii]
224. Witzig TE. Current treatment approaches for mantle-cell lymphoma. *J Clin Oncol*. 2005;23(26):6409-6414. doi:23/26/6409 [pii]
225. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. *Blood*. 2005;105(7):2677-2684. doi:2004-10-3883 [pii]
226. Delarue R, Haioun C, Ribrag V, et al. RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA. *Blood*. 2008;112(11):581.
227. Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). *Blood*. 2010;116(21):110.

228. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. *J Clin Oncol*. 2005;23(28):7013-7023. doi:JCO.2005.01.1825 [pii]
229. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. *J Clin Oncol*. 2009;27(8):1209-1213. doi:10.1200/JCO.2008.19.6121 [doi]
230. Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. *J Clin Oncol*. 2009;27(32):e189-90; author reply e191. doi:10.1200/JCO.2009.23.9731 [doi]
231. Fernandez V, Salameró O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. *Cancer Res*. 2010;70(4):1408-1418. doi:10.1158/0008-5472.CAN-09-3419 [doi]
232. Dreyling M. ASCT for Mantle Cell Lymphoma in First Remission. *ASH*. 2008:a769.
233. Zoellner A, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. *The Lancet Haematology*. 2021 Sep 2021;8(9):doi:10.1016/S2352-3026(21)00195-2
234. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. *Lancet*. May 25 2024;403(10441):2293-2306. doi:10.1016/s0140-6736(24)00184-3
235. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. *Blood*. 2008;112(7):2687-2693. doi:10.1182/blood-2008-03-147025 [doi]
236. Hermine O, Jiang L, Walewski J, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 01/20/2023 2023;41(3):doi:10.1200/JCO.22.01780
237. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. *Blood*. 2017;130(17):1903-1910. doi:10.1182/blood-2017-04-779736 [doi]
238. Lew T, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. *The Lancet Haematology*. 2023 Feb 2023;10(2):doi:10.1016/S2352-3026(22)00355-6
239. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis. *Haematologica*. 2018;haematol.2018.205229. doi:10.3324/haematol.2018.205229
240. Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 01/20/2023 2023;41(3):doi:10.1200/JCO.21.02370
241. Wang Y, Jain P, Locke F, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 05/10/2023 2023;41(14):doi:10.1200/JCO.22.01797
242. Lew T, Cliff E, Dickinson M, et al. T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. *Bone marrow transplantation*. 2021 Nov 2021;56(11):doi:10.1038/s41409-021-01418-3
243. O'Reilly M, Sanderson R, Wilson W, et al. Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. *British journal of haematology*. 2022 Oct 2022;199(1):doi:10.1111/bjh.18378
244. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. *N Engl J Med*. 2012;367(6):520-531. doi:10.1056/NEJMoa1200920 [doi]
245. Dietrich S, Weidle J, Rieger M, et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. *Leukemia*. 2014;28(3):708-709. doi:10.1038/leu.2013.332 [doi]
246. Wang M, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. *The New England journal of medicine*. 06/30/2022 2022;386(26):doi:10.1056/NEJMoa2201817

247. Rummel M, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). meeting-report. https://doi.org/10.1200/JCO20163415_suppl7503. 2016-05-20 2016;doi:7503
248. Hill B. Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant | Blood | American Society of Hematology. 2021;doi:10.1182/blood-2019-129404
249. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl_4):iv62-iv71. doi:10.1093/annonc/mdx223 [doi]
250. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. *Lancet*. 2016;387(10020):770-778. doi:10.1016/S0140-6736(15)00667-4 [doi]
251. Wang M, Rule S, Zinzani P, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. *Lancet (London, England)*. 02/17/2018 2018;391(10121)doi:10.1016/S0140-6736(17)33108-2
252. Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. *Blood Adv*. Jun 22 2021;5(12):2577-2585. doi:10.1182/bloodadvances.2020004074
253. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. *The Lancet Oncology*. 2016;17(1):57-66. doi:10.1016/S1470-2045(15)00447-7 [doi]
254. Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. *The Lancet Haematology*. 2017;4(1):e15-e23. doi:S2352-3026(16)30185-5 [pii]
255. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. *N Engl J Med*. 2015;372(10):944-953. doi:10.1056/NEJMoa1412096 [doi]
256. Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. *Blood*. 2017;130(17):1881-1888. doi:10.1182/blood-2017-05-737510 [doi]
257. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). *Blood*. 2006;108(13):4003-4008. doi:blood-2006-04-016725 [pii]
258. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. *The Lancet Oncology*. 2012;13(7):716-723. doi:10.1016/S1470-2045(12)70200-0 [doi]
259. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. *J Clin Oncol*. Aug 20 2023;41(24):3988-3997. doi:10.1200/jco.23.00562
260. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. Apr 2 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347
261. Picozzi VJ, Jr., Coleman CN. Lymphoblastic lymphoma. *Semin Oncol*. 1990;17(1):96-103. doi:0093-7754(90)90153-T [pii]
262. Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. *J Clin Oncol*. 1992;10(7):1078-1085. doi:10.1200/JCO.1992.10.7.1078 [doi]
263. Santini G, Sweetenham JW, Simnett S. Autologous stem cell transplantation in first remission improves outcome in adult patients with lymphoblastic lymphoma: results from a randomized trial of the European group for blood and marrow transplantation (EBMT) and the UK lymphoma group (UKLG). *Bone Marrow Transplant*. 1998;21(European Group for Blood and Bone Marrow Transplantation Meeting Abstracts):Abstract 624.
264. Milpied N, Attal M, Gisselbrecht C. Lymphoblastic lymphoma: What is the best time for transplantation (BMT). A study from SFGM. . *Bone Marrow Transplant*. 1998;21(European Group for Blood and Bone Marrow Transplantation Meeting Abstracts):Abstract 597.
265. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. *J Clin Oncol*. 2001;19(11):2927-2936. doi:10.1200/JCO.2001.19.11.2927 [doi]

266. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. *Blood*. 1998;92(5):1556-1564.
267. Hoelzer D, Gokbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. *Blood*. 2002;99(12):4379-4385. doi:10.1182/blood-2002-01-0110 [doi]
268. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. *J Clin Oncol*. 1996;14(3):925-934. doi:10.1200/JCO.1996.14.3.925 [doi]
269. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. *J Clin Oncol*. 1991;9(6):941-946. doi:10.1200/JCO.1991.9.6.941 [doi]
270. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. *Blood*. 1995;85(3):664-674.
271. Dunleavy K, Fanale M, Abramson J, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. *The Lancet Haematology*. 2018 Dec 2018;5(12):doi:10.1016/S2352-3026(18)30177-7
272. Roschewski M, Dunleavy K, Abramson J, et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 08/01/2020 2020;38(22):doi:10.1200/JCO.20.00303
273. Connors JM. Problems in lymphoma management: special sites of presentation. *Oncology (Williston Park)*. 1998;12(2):185-5. doi:172170 [pii]
274. Shahab N, Doll DC. Testicular lymphoma. *Semin Oncol*. 1999;26(3):259-269.
275. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. *J Clin Oncol*. 2003;21(1):20-27. doi:10.1200/JCO.2003.11.141 [doi]
276. Zouhair A, Weber D, Belkacemi Y, et al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. *Int J Radiat Oncol Biol Phys*. 2002;52(3):652-656. doi:S0360301601026475 [pii]
277. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. *Lancet*. 2009;374(9700):1512-1520. doi:10.1016/S0140-6736(09)61416-1 [doi]
278. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. *J Clin Oncol*. 2005;23(22):5034-5043. doi:JCO.2005.13.524 [pii]
279. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. *J Clin Oncol*. 1998;16(9):3000-3006. doi:10.1200/JCO.1998.16.9.3000 [doi]
280. Boiardi A, Silvani A, Pozzi A, Fariselli L, Broggi G, Salmaggi A. Chemotherapy is effective as early treatment for primary central nervous system lymphoma. *J Neurol*. 1999;246(1):31-37.
281. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. *J Clin Oncol*. 1998;16(3):859-863. doi:10.1200/JCO.1998.16.3.859 [doi]
282. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *J Clin Oncol*. 2003;21(14):2726-2731. doi:10.1200/JCO.2003.11.036 [doi]
283. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. *J Clin Oncol*. 2003;21(2):266-272. doi:10.1200/JCO.2003.09.139 [doi]
284. Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. *J Clin Oncol*. 2003;21(12):2407-2414. doi:10.1200/JCO.2003.01.135 [doi]
285. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. *J Clin Oncol*. 2000;18(17):3144-3150. doi:10.1200/JCO.2000.18.17.3144 [doi]
286. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. *J Clin Oncol*. 2007;25(30):4730-4735. doi:25/30/4730 [pii]
287. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. *J Clin Oncol*. 2001;19(3):742-749. doi:10.1200/JCO.2001.19.3.742 [doi]

288. Curry RC, Correa D, Raizer JJ, et al. Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. *JCO*. 2012;30(15):2006. doi:10.1200/jco.2012.30.15_suppl.2006; 28
289. Thiel E, Korfel A, Martus P, et al. Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. *JCO*. 2010;28(15):8008. doi:10.1200/jco.2010.28.15_suppl.8008; 28
290. Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. *Bone Marrow Transplant*. 2003;31(8):679-685. doi:10.1038/sj.bmt.1703917 [doi]
291. Campen CJ, Tombleson RL, Green MR. High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. *J Neurooncol*. 2011;101(3):345-355. doi:10.1007/s11060-010-0279-5 [doi]
292. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. *J Clin Oncol*. 2006;24(24):3865-3870. doi:JCO.2006.06.2117 [pii]
293. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. *Haematologica*. 2008;93(1):147-148. doi:10.3324/haematol.11771 [doi]
294. Houillier C, Taillandier L, Lamy T, et al. Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Hematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). *Blood*. 2016;128(22):782.
295. Alimohamed N, Daly A, Owen C, Duggan P, Stewart DA. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. *Leuk Lymphoma*. 2012;53(5):862-867. doi:10.3109/10428194.2011.633250 [doi]
296. Sanders S, Chua N, Larouche J, Owen C, Shafey M, Stewart D. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2019 Aug 2019;25(8)doi:10.1016/j.bbmt.2019.04.004
297. Ferreri AJ, Cwynarski K, Pulczynski E. Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary CNS lymphoma: The first randomization of the IELSG32 trial abstract]. 2015;33:103-104.
298. Bromberg J, Issa S, Bukanina K, et al. Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study. *Blood*. 2017;130:582.
299. McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH. Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. *Blood*. 2009;113(19):4677-4680. doi:10.1182/blood-2008-09-179366 [doi]
300. Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. *Clin Pharmacokinet*. 2006;45(9):871-903. doi:4592 [pii]
301. Wiebe VJ, Smith BR, DeGregorio MW, Rapoport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. *Crit Rev Oncol Hematol*. 1992;13(3):241-270. doi:1040-8428(92)90092-5 [pii]
302. Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. *Blood*. 2006;108(5):1451-1460. doi:blood-2006-02-005017 [pii]
303. Soussain C, Merle-Beral H, Reux I, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. *Leuk Lymphoma*. 1996;23(3-4):339-345. doi:10.3109/10428199609054837 [doi]
304. Hasserjian RP, Harris NL. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. *Am J Clin Pathol*. 2007;127(6):860-868. doi:0458U56002771413 [pii]
305. Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. *Expert Rev Hematol*. 2010;3(5):593-602. doi:10.1586/ehm.10.51 [doi]
306. Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. *The Lancet Oncology*. 2009;10(11):1093-1101. doi:10.1016/S1470-2045(09)70265-7 [doi]
307. Quintanilla-Martinez L, Kremer M, Keller G, et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. *Am J Pathol*. 2001;159(6):2095-2105. doi:S0002-9440(10)63061-1 [pii]

308. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. *J Clin Oncol*. 2006;24(1):181-189. doi:24/1/181 [pii]
309. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. *J Clin Oncol*. 2009;27(35):6027-6032. doi:10.1200/JCO.2009.23.8592 [doi]
310. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. *J Clin Oncol*. 2009;27(33):5594-5600. doi:10.1200/JCO.2009.23.8295 [doi]
311. Kim SJ, Eom H-S, Kim JS, et al. Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy In Stage I/II Extranodal NK/T-Cell Lymphoma of Nasal Cavity/Nasopharynx. *Blood*. 2010;116(21):1765-1765. doi:10.1182/blood.V116.21.1765.1765
312. Au WY, Weisenburger DD, Intratumorinchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. *Blood*. 2009;113(17):3931-3937. doi:10.1182/blood-2008-10-185256 [doi]
313. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. *Blood*. 2008;112(10):3989-3994. doi:10.1182/blood-2008-06-155820 [doi]
314. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. *International journal of hematology*. 2003 Aug 2003;78(2)doi:10.1007/BF02983387
315. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. *Blood*. 2012;120(15):2973-2980. doi:10.1182/blood-2012-05-431460 [doi]
316. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol*. 2011;29(33):4410-4416. doi:10.1200/JCO.2011.35.6287 [doi]
317. Kim SJ, Park S, Kang ES, et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. *Ann Hematol*. 2015;94(1):71-78. doi:10.1007/s00277-014-2171-4 [doi]
318. Kwong Y, Chan T, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. *Blood*. 04/27/2017 2017;129(17)doi:10.1182/blood-2016-12-756841
319. Cheng J, Liu B, Farjat A, Routh J. National Characteristics of Lymphatic Malformations in Children: Inpatient Estimates and Trends in the United States, 2000 to 2009. *Journal of pediatric hematology/oncology*. 2018 Apr 2018;40(3)doi:10.1097/MPH.0000000000001078
320. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood*. 2010;116(18):3418-3425. doi:10.1182/blood-2010-02-270785 [doi]
321. Aviles A, Castaneda C, Neri N, et al. Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. *Med Oncol*. 2008;25(3):360-364. doi:10.1007/s12032-008-9046-2 [doi]
322. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. *Blood*. 2010;115(18):3664-3670. doi:10.1182/blood-2009-07-231324 [doi]
323. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. *J Clin Oncol*. 2009;27(1):106-113. doi:10.1200/JCO.2008.17.4870 [doi]
324. Rodriguez J, Conde E, Gutierrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. *Ann Oncol*. 2007;18(4):652-657. doi:mdl466 [pii]
325. Rodriguez J, Conde E, Gutierrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. *Eur J Haematol*. 2007;78(4):290-296. doi:EJH815 [pii]
326. Sohn BS, Park I, Kim EK, et al. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. *Bone Marrow Transplant*. 2009;44(5):287-293. doi:10.1038/bmt.2009.29 [doi]
327. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. *Bone Marrow Transplant*. 2007;40(5):443-450. doi:1705752 [pii]

328. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). *Br J Haematol*. 2011;153(4):451-485. doi:10.1111/j.1365-2141.2011.08651.x [doi]
329. Horwitz S, O'Connor O, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet (London, England)*. 01/19/2019 2019;393(10168):doi:10.1016/S0140-6736(18)32984-2
330. Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. *Ann Oncol*. Mar 2022;33(3):288-298. doi:10.1016/j.annonc.2021.12.002
331. Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. *J Neurooncol*. 2006;80(1):97-100. doi:10.1007/s11060-006-9162-9 [doi]
332. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. *Neurology*. 2008;71(9):665-669. doi:10.1212/01.wnl.0000324624.52935.46 [doi]
333. Hamadani M, Ngoya M, Sureda A, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. *Blood Adv*. Feb 8 2022;6(3):920-930. doi:10.1182/bloodadvances.2021005899
334. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol*. 2012;30(18):2190-2196. doi:10.1200/JCO.2011.38.0402 [doi]
335. O'Connor O, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 03/20/2011 2011;29(9):doi:10.1200/JCO.2010.29.9024
336. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. *Cancer Sci*. Dec 2020;111(12):4540-4547. doi:10.1111/cas.14671
337. Wei W, Wu P, Li L, Zhang Z. Effectiveness of pegasparge, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. *Hematology (Amsterdam, Netherlands)*. 2017 Jul 2017;22(6):doi:10.1080/10245332.2016.1264163
338. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol*. Nov 20 2011;29(33):4410-6. doi:10.1200/jco.2011.35.6287
339. DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. *Semin Oncol*. 1998;25(4):492-502.
340. Kaplan LD. Clinical management of human immunodeficiency virus-associated non-Hodgkin's lymphoma. *Journal of the National Cancer Institute Monographs*. 1998;(23):101-5. doi(23):101-105. doi:10.1093/oxfordjournals.jncimonographs.a024165 [doi]
341. Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. *Hematol Oncol Clin North Am*. 1996;10(5):1111-1124. doi:S0889-8588(05)70387-7 [pii]
342. Straus DJ. HIV-associated lymphomas. *Curr Opin Oncol*. 1997;9(5):450-454.
343. Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. *Hematol Oncol Clin North Am*. 1996;10(5):1125-1134. doi:S0889-8588(05)70388-9 [pii]
344. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood*. 2005;106(5):1538-1543. doi:2005-04-1437 [pii]
345. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008;
346. Allen UD, Preiksaitis JK, Practice ASTIDCo. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. *Am J Transplant*. 2013;13 Suppl 4:107-120. doi:10.1111/ajt.12104 [doi]
347. Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. *Nat Rev Dis Primers*. Jan 28 2016;2:15088. doi:10.1038/nrdp.2015.88
348. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. *Am J Transplant*. 2004;4(2):222-230.
349. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., et al. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA*. 2011;306(17):1891-1901. doi:10.1001/jama.2011.1592 [doi]

350. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. *Am J Transplant*. 2013;13(1):174-183. doi:10.1111/j.1600-6143.2012.04302.x [doi]
351. Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? *Clin Dev Immunol*. 2013;2013:150835. doi:10.1155/2013/150835 [doi]
352. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. *J Clin Oncol*. 2005;23(30):7574-7582. doi:JCO.2005.01.0934 [pii]
353. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. *J Clin Oncol*. 2010;28(6):1038-1046. doi:10.1200/JCO.2009.25.4961 [doi]
354. Luskin MR, Heil DS, Tan KS, et al. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. *Am J Transplant*. 2015;15(10):2665-2673. doi:10.1111/ajt.13324 [doi]
355. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569 [doi]
356. Blaes AH, Cioc AM, Froelich JW, Peterson BA, Dunitz JM. Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders. *Clin Transplant*. 2009;23(6):794-799. doi:10.1111/j.1399-0012.2008.00938.x [doi]
357. Takehana CS, Twist CJ, Mosci C, Quon A, Mittra E, Iagaru A. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. *Nucl Med Commun*. 2014;35(3):276-281. doi:10.1097/MNM.0000000000000050 [doi]
358. McCormack L, Hany TI, Hubner M, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? *Am J Transplant*. 2006;6(7):1731-1736. doi:AJT1358 [pii]
359. Panagiotidis E, Quigley AM, Pencharz D, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. *Leuk Lymphoma*. 2014;55(3):515-519. doi:10.3109/10428194.2013.813501 [doi]
360. von Falck C, Maecker B, Schirg E, et al. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. *Eur J Radiol*. 2007;63(3):427-435. doi:S0720-048X(07)00029-0 [pii]
361. Dierickx D, Tousseyn T, Requilé A, et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. *Haematologica*. May 2013;98(5):771-5.
362. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. *Br J Haematol*. 2010;149(5):693-705. doi:10.1111/j.1365-2141.2010.08160.x [doi]
363. Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? *Hematology*. 2013;2013:95-102. doi:10.1182/asheducation-2013.1.95 [doi]
364. Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. *Blood*. 2015;126(20):2274-2283. doi:10.1182/blood-2015-05-615872 [doi]
365. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(bigstar). *Am J Transplant*. 2011;11(2):336-347. doi:10.1111/j.1600-6143.2010.03387.x [doi]
366. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. *Transplantation*. 2008;86(2):215-222. doi:10.1097/TP.0b013e3181761659 [doi]
367. Rabot N, Buchler M, Foucher Y, et al. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. *Transpl Int*. 2014;27(9):956-965. doi:10.1111/tri.12375 [doi]
368. Seckin D, Barete S, Euvrard S, et al. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. *Am J Transplant*. 2013;13(8):2146-2153. doi:10.1111/ajt.12281 [doi]
369. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. *Haematologica*. 2011;96(7):1067-1071. doi:10.3324/haematol.2010.039214 [doi]

370. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. *Haematologica*. 2007;92(2):273-274. doi:10.3324/haematol.10595 [doi]
371. Fohrer C, Caillard S, Koumariou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. *Br J Haematol*. 2006;134(6):602-612. doi:BJH6228 [pii]
372. Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. *Transplantation*. 2006;82(3):375-381. doi:10.1097/01.tp.0000228906.31675.fb [doi]
373. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. *Transplant Proc*. 2005;37(2):956-957. doi:S0041-1345(04)01569-6 [pii]
374. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. *Am J Transplant*. 2006;6(3):569-576. doi:AJT1211 [pii]
375. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). *Am J Transplant*. Dec 2005;5(12):2901-6. doi:10.1111/j.1600-6143.2005.01098.x
376. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. *Blood*. 2006;107(8):3053-3057. doi:2005-01-0377 [pii]
377. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. *Haematologica*. 2007;92(11):1489-1494. doi:92/11/1489 [pii]
378. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. *Cancer*. 2005;104(8):1661-1667. doi:10.1002/cncr.21391 [doi]
379. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. *Ann Hematol*. 2007;86(8):599-607. doi:10.1007/s00277-007-0298-2 [doi]
380. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. *The Lancet Oncology*. 2012;13(2):196-206. doi:10.1016/S1470-2045(11)70300-X [doi]
381. Trappe RU, Choquet S, Dierickx D, et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. *Am J Transplant*. 2015;15(4):1091-1100. doi:10.1111/ajt.13086 [doi]
382. Trappe RU, Dierickx D, Reinke P, et al. Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST). *J Clin Oncol*. 2012;30(15_suppl):8030-8030. doi:10.1200/jco.2012.30.15_suppl.8030
383. Trappe RU, Dierickx D, Zimmermann H, et al. Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. *Blood*. 2015;126(23):816-816. doi:10.1182/blood.V126.23.816.816
384. Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. *Am J Transplant*. 2013;13(6):1512-1522. doi:10.1111/ajt.12211 [doi]
385. Zimmermann H, Reinke P, Neuhaus R, et al. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. *Cancer*. 2012;118(19):4715-4724. doi:10.1002/cncr.27482 [doi]
386. Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. *Am J Transplant*. 2012;12(11):3069-3075. doi:10.1111/j.1600-6143.2012.04206.x [doi]
387. Xicoy B, Ribera JM, Esteve J, et al. Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial). *Leuk Lymphoma*. 2003;44(9):1541-1543. doi:10.3109/10428190309178777 [doi]
388. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. *Am J Transplant*. 2013;13(5):1296-1304. doi:10.1111/ajt.12192 [doi]

389. Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. *Am J Kidney Dis*. 2011;58(6):971-980. doi:10.1053/j.ajkd.2011.07.015 [doi]
390. Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. *J Clin Oncol*. 2013;31(10):1302-1309. doi:10.1200/JCO.2012.43.2344 [doi]
391. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. *Am J Transplant*. 2006;6(5 Pt 1):1017-1024. doi:AJT1294 [pii]
392. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. *J Clin Oncol*. 2007;25(31):4902-4908. doi:25/31/4902 [pii]
393. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. *Curr Oncol Rep*. 2010;12(6):383-394. doi:10.1007/s11912-010-0132-1 [doi]
394. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. *J Clin Oncol*. 2009;27(20):3354-3362. doi:10.1200/JCO.2008.20.0857 [doi]

IV. Cutaneous Lymphomas¹⁻²⁵

Table 1. Classification criteria of primary cutaneous lymphomas (WHO 2016)

Disease entity	Subtype	Minimum diagnostic workup	Other useful diagnostic tests
Primary Cutaneous T-Cell Lymphomas			
Mycosis fungoides (MF)	• Classic MF* • Folliculotropic MF • Pagetoid reticulosis • Granulomatous slack skin disease	Clinico-pathological correlation supported by immunohistochemistry (CD3, CD4, CD8, CD30) and clonality by TCRr Large cell transformation (>25%) to be noted if present	• IHC: CD2, CD5, CD7, PD1 • DUSP22-IRF4 translocations (tumor stage)¹
Sezary's syndrome (SS)		Clinico-pathological correlation supported by: • skin biopsy (IHC and TCRr) • blood: CD4/CD8 ratio (FC), clonality by TCRr or TCRVbeta chain Abs	PD-1 (IHC and FC) Blood: CD5, CD7, CD26, CCR4, CD158k, Sezary cell absolute count in blood smear
Primary cutaneous CD30+ lymphoproliferative disease	• lymphomatoid papulosis (LyP, types A,B,C,D,E) • pcALCL (anaplastic large cell lymphoma)	Typical skin lesions and histopathology • IHC: CD3, CD4, CD8, CD30, ALK, EMA	• IHC: CD2,3,5,CD7,CD15, TIA-1, granzymeB, CD56, betaF1, MUM-1 • FISH: 6p25 rearrangement (DUSP22-IRF4) • TCRr
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)		Typical skin lesions and histopathology • IHC: CD3, CD8,CD4,TIA-1, CD56, CD30, EBER • TCRr	• IHC: granzyme B, TCR-gamma.(-)1 βF1,
EBV-associated T-cell especially extranodal NK/T cell lymphoma	nasal type angioimmunoblastic hydroa vacciniforme-like lymphoproliferative disorder	• EBER by ISH • CD3,CD56,CD4,CD8, CD2,CD5,CD7 • EBV antibody profile and DNA load • TCR and IgH clonality status	IHC: TIA-1, granzymeB, CD56, CD21,PD-1, CXCL13, CD10, bcl-6, CD20
Primary cutaneous acral CD8+ lymphoma		Typical skin lesions and histopathology • IHC: CD4,CD8,CD3, CD2,CD7 7 • TCRr	IHC: TIA-1 granzymeB,perforin, KI67, βF1
pc CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma		Typical skin lesions and histopathology • IHC: CD2, 3, 4, 5, 7, 8, 15, 30, 45RA, TIA-1, CD56, betaF1, EBER by FISH • TCRr	• IHC: TCR-gamma, granzymeB, perforin
pc gamma-delta T-cell lymphoma		• IHC: CD2, 3, 4, 5, 7, 8, 30, 45RA, TIA-1, CD56, betaF1, EBER by ISH • TCRr	• IHC: TCR-gamma, granzymeB,perforin

*not included in formal WHO classification of pc lymphomas

¹ DUSP22-IRF4 translocation FISH assay is not routinely available in Alberta

pc CD4+ small/medium cell T-cell lymphoproliferative disorder		- Clinical picture,sudden - CD4, CD8,CD3, PD-1, CD30,CD7, CD56,TIA-1, CD20	IHC: CXCL13,BCL6
pcPTL NOS		IHC: CD2, 3, 4, 5, 7, 8, 30,, TIA-1, CD56, betaF1, EBER by FISH TCRr	IHC: TCR-gamma, granzymeB, CXCL13, CD10, bcl-6, CD20
Primary Cutaneous B-Cell Lymphomas			
pc follicle center lymphoma (pc FCL)		- Typical skin lesions and histopathology—R/O EBV+ mucocutaneous ulcer - IHC: CD3, CD5, CD20, CD10, bcl-2, bcl-6, MUM-1, kappa/lambda - Ig rearrangement	-CD30, CD138, FOX-P1, EBER by ISH (in DLBL), Ki-67, Cyclin D1,CD79a,CD21, CD23 -MYD88L265P mutation in DLBLLT
pc diffuse large B-cell lymphoma, leg type			
Other Lymphomas Presenting In The Skin (Not Included In Who2016 Classification)			
Intravascular B-cell lymphoma	- Intravascular B-cell lymphoma* - Intravascular NK/T cell lymphoma* - CD30+ lymphoma	Variable clinical presentation; diagnosis based on histopathology and IHC - IHC: CD2, CD3, CD5, CD20, CD79a, CD10, bcl-2, bcl-6, MUM-1, kappa/lambda, CD56, CD30, betaF1, EBER1, TIA-1, granzymeB, ALK-1 - Ig rearrangement - TCRr	
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	This is not a mature lymphoid neoplasm as per the 2016 WHO classification, but may present with prominent skin disease	Variable but often skin-based clinical presentation; diagnosis based on histopathology and IHC - IHC: CD2, CD3, CD7,CD5, CD4, D8, CD20, CD79a, CD56, CD123, TIA-1, TdT, CD34,TIA-1, perforin, CD117, myeloperoxidase,lysozyme - Ig rearrangement - TCRr - EBER and LMP1	granzymeB, TCL-1, CD303 TCR-gamma, βF1
Adult T-cell leukemia lymphoma	Smoldering and chronic forms are skin-presenting illnesses with mild systemic signs	- CD4,CD25,CD8,CD3,CD7,CD2,CD5, CD52,CD30 - HTLV1 serology /integration status	FOXP3 by IHC
T _{FH} lymphoma		IHC: CD2, 3, 4, 5, 7, 8, 10, 30, PD-1 TCRr	IHC: ICOS, bcl-6, CXCL13, bcl
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue		- Typical skin lesions and histopatholgy - IHC: CD3, CD5, CD20, CD10, bcl-2, bcl-6, MUM-1, kappa/lambda(IHC or FISH) - Ig rearrangement	CD138, Ki-67, Cyclin D1,CD79a,CD21, CD23,CD4,CD8,PD1

Abbreviations: Pc = primary cutaneous, IHC = immunohistochemistry, TCRr = TCR rearrangement, FC = flow cytometry.

Table 2. Mycosis Fungoides and Sezary's Syndrome Staging (2007 ISCL/EORTC)

Classification	Description	Comments
T (skin)		
T0	No clinically and/or histopathologically suspicious lesions	Patch indicates any size skin lesion without significant elevation or induration whereas a plaque is elevated or indurated. Presence/absence of hypo- or hyperpigmentation, scale, crusting, poikiloderma or ulceration should be noted. Tumor indicates at least one 1-cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note total number and volume of lesions, largest size lesion, and region of body involved.
T1 T1a patch only T1b plaque +/- patch	Limited patches, papules, and/or plaques covering <10% of the skin surface.	
T2 T2a patch only T2b plaque +/- patch	Patches, papules or plaques covering => 10% of the skin surface.	
T3	One or more tumors (=>1-cm diameter)	
T4	Confluence of erythema covering =>80% body surface area	
N (lymph nodes)		
N0	No clinically abnormal peripheral lymph nodes	Abnormal peripheral lymph node indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which are not generally amenable to pathologic assessment, are not currently considered in the nodal classification unless used to establish N3 histopathologically.
N1 N1a – clone negative N1b – clone positive	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.	
N2 N2a – clone negative N2b – clone positive	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3	
N3	Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative	
Nx	Clinically abnormal peripheral lymph nodes; no histologic confirmation	
B (peripheral blood)		
B0 B0a – clone negative B0b – clone positive	Absence of significant blood involvement: =<5% of peripheral blood lymphocytes are atypical (Sézary) cells	For blood, Sézary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. Alternatives to Sezary cell count: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26
B1 B1a – clone negative B1b – clone positive	Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2	
B2	High blood tumor burden: _=>1000/uL Sezary cells with positive clone	
M (visceral organs)		
M0	No visceral organ involvement	For viscera, spleen and liver may be diagnosed by imaging criteria
M1	Visceral involvement (must have pathology confirmation and organ involved should be specified)	

Table 3. Staging of mycosis fungoides and Sezary's syndrome²⁶⁻²⁹

Clinical Stages and 5-year Disease Specific Survival (%)					
	T	N	M	B	5-year DSS (%)
IA	1	0	0	0,1	98
IB	2	0	0	0,1	89
IIA	1-2	1,2	0	0,1	89
IIB	3	0-2	0	0,1	56
IIIA	4	0-2	0	0	54
IIIB	4	0-2	0	1	48
IVA ₁	1-4	0-2	0	2	41
IVA ₂	1-4	3	0	0-2	23
IVB	1-4	0-3	1	0-2	18

Staging procedures for Mycosis Fungoides/Sezary Syndrome

- **Complete physical examination:** Describe type size of skin lesions, estimate percentage of body surface area involved, presence of palpable lymph nodes, and organomegaly
- **Skin biopsy:** At least one biopsy required, several concurrent biopsies may be indicated
- **Blood tests:** CBC with differential, liver function tests, creatinine, LDH. Peripheral blood flow cytometry and molecular studies for TCR gene rearrangement in cases of suspected Sezary Syndrome
- **Imaging:** For MF stage IA no additional imaging techniques are necessary. For patients with MF stage II or higher imaging including CT scan of chest, abdomen, and pelvis and/or FDG-PET scan are recommended. Full body imaging for MF stage IB (T2N0M0) is discretionary, and simple CXR and select U/S imaging may be adequate
- **Lymph node biopsy:** Biopsy of enlarged (>1.5cm) or abnormal lymph node. Preference given for nodes with abnormal uptake on FDG-PET. Excisional biopsy is preferred in cases of MF in order to reliably discriminate dermatopathic lymphadenopathy from that involved with lymphoma
- **Bone marrow biopsy:** Bone marrow biopsy and aspiration is not a routinely recommended procedure in MF unless a patient has stage IV disease (B2)

Treatment of mycosis fungoides/sezary syndrome

Overview

MF at early stages (I-IIA) should preferentially be treated with skin-directed therapies (SDT) including phototherapy, topical steroids, nitrogen mustard. Treatment can be combined with biological

response modifiers (IFN- α , retinoids) in cases of resistant or progressive skin disease. Local radiotherapy plays a key role in palliation and treating sanctuary sites. Total skin electron beam therapy is highly effective in T2 or T3 disease however its widespread use is limited by the availability of this technique. Predictably, chemotherapy leads to short remission durations and therefore should be reserved after other therapies have been tried. Its use should be limited to tumour (T3) or more advanced stages. It may be considered frontline in cases with histologic large-cell transformation and high risk features (see discussion below). Monotherapy (low-dose methotrexate, gemcitabine) is generally preferred over combination chemotherapy (e.g. CHOP) unless the patient has extensive burden of disease (nodal and extra-cutaneous and is fit to tolerate. Targeted therapies have demonstrated activity in MF/SS, and are currently reserved for the relapsed/refractory setting or in clinical trials. The optimal conditions for allogenic bone marrow transplant have not been elucidated, but may play a role in highly selected cases (see discussion below). Extracorporeal photopheresis is a unique treatment modality indicated for the treatment of erythrodermic MF/SS. Consensus recommendations for the treatment of MF/SS have recently been updated and are outlined elsewhere³⁰. The following table intends to summarize a management approach.

Table 4. Treatment of mycosis fungoides^{1, 2, 7-9, 12, 14, 24, 30-33}

Therapy	Mycosis Fungoides		SS/E-MF	Dose and potential toxicities
	Early stage disease	Advanced stage disease		
Expectant policy	++			Suitable for stage I in conjunction with symptomatic treatment if required. Patient with single lesion can be considered for RT for “curative therapy”
Topical Corticosteroids	++++	++	+++	Potent steroids such as Clobetasol/betamethasone, long term use can cause side effects such as skin atrophy
PUVA	+++	+	+++	For patch/plaque disease. 2-3 X week. Limited availability, available only in Edmonton/Calgary. Risk of skin cancer with cumulative dosing
UVB	++++	+	++	For thin patch only, as skin penetration not as deep, 2-3 x week. Risk of skin cancer with cumulative dosing
Topical Carmustine	++			Has to be compounded. Erythema ,mostly mild but can be severe
Oral Bexarotene	++	+++	++++	200 to 300mg/M2, orally

				daily. Responses can be durable. Most common side effects are hypertriglyceridemia and hypothyroidism usually requiring treatment and have to be monitored regularly. Not available in Canada, requires SAP.
Interferon alpha	++	++++	++++	3-5 MU/d or 3 x week. Difficult tolerating the drug, cytopenias, thyroid disturbance, mood changes. It can be combined with PUVA, ECP, and Retinoid.
HDACi: Vorinostat, romidepsin	+	+++	++++	Vorinostat, 400 mg po daily, S/E diarrhea, nausea, QT prolongation, cytopenias. Not on the Formulary, only through private insurance. Romidepsin-14mg/M2 iv day1,8,15 of a 28 day cycle, QT prolongation, metabolized by CYP3A4. Limited data in combination, can be used with ECP
Oral Methotrexate	+	+++	+++	20-30mg/week can be given up to 60-70 mg/week. Watch for cytopenias, liver dysfunction. Can be used in combination with ECP, PUVA, and IFN.
Localized radiotherapy	+++	+++		Localized plaques, tumors or nodules
TSEB	+	+++	+	For widespread disease. Can be repeated but high cumulative doses associated with skin toxicity. Patient to travel to Ontario.
ECP		++	++++	Available only in Calgary, needs IV access, which can be problematic
Alemtuzumab		+	++++	Available through Clinigen on compassionate basis. Low dose 10mg three times a week, may be effective decreasing the risk of infections
Brentuximab		+++		Shown to be effective with all levels of CD30

				expression but responses significantly lower if CD30 expression less than 30 %.Peripheral neuropathy, limiting side effect.1.8mg/kg IV q every 3 weeks for up to 16 cycles
Single agent chemotherapy, Gemcitabine, liposomal Doxorubicin		+	++	Beyond third line
Combination chemotherapy such as CHOP			+	Refractory Disease
Allogenic Bone marrow transplant		+	++	Very selected cases
Clinical trials				Use if available.

Staging and treatment of non-MF cutaneous lymphomas^{19, 23, 25, 34}

Table 5. Diagnostic workup and staging

Classification		Description
T	T1	Solitary skin lesion
		• T1a: a solitary lesion with diameter <5cm
		• T1b: a solitary lesion with diameter >5cm
	T2	Regional skin involvement (multiple lesions limited to 1 body region or 2 contiguous body regions)
		• T2a: skin lesions present in a <15-cm diameter circular area
		• T2b: skin lesions present in a >15-cm and <30-cm diameter circular area
		• T2c: skin lesions present in a >30-cm diameter circular area
N	T3	Generalized skin involvement
		• T3a: multiple lesions involving 2 noncontiguous body regions
		• T3b: multiple lesions involving 3 or more body regions
	N0	No clinical or pathologic lymph node involvement
	N1	Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement
M	N2	Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region that does not drain an area of current or prior skin involvement
	N3	Involvement of central lymph nodes
	M0	No evidence of organ disease
	M1	Extracutaneous organ disease

Staging of other types of non-MF cutaneous lymphomas

Table 6. Diagnostic workup

Disease entity	Laboratory and radiologic workup
Lymphomatoid papulosis	• Screening for concurrent cancer may be warranted in elderly patients or presence of risk factors
pcALCL	• CBC with diff, blood chemistries and LDH • PET/CT or CT • Lymph node biopsy (if clinically or radiologically abnormal) • Bone marrow biopsy in patients with evidence of extracutaneous disease or multiple tumors
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)	• CBC with diff, blood chemistries and LDH, • PET/CT or CT • Lymph node biopsy (if clinically or radiologically abnormal) • Bone marrow biopsy in patients with evidence of extracutaneous disease, multiple tumors or hematocytopenic syndrome
CD4+ small/medium cell primary cutaneous T-cell lymphoproliferative disorder	• None
Aggressive pcCTCL: Extranodal NK/T-cell lymphoma, CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma; gamma-delta T-cell lymphoma, Blastic plasmacytoid dendritic cell neoplasm	• As other aggressive lymphomas
Extranodal MZL with cutaneous presentation	• CBC with diff, blood chemistries and LDH • Borrelia serology
pcFCL	• CBC with diff, blood chemistries and LDH • PET/CT or CT • Lymph node biopsy (if clinically or radiologically abnormal) • Bone marrow biopsy
pc diffuse large B-cell lymphoma,	• CBC with diff, blood chemistries and LDH • PET/CT • Lymph node biopsy (if clinically or radiologically abnormal)
Primary cutaneous acral CD8+ lymphoma	None

Treatment of other types of non-MF cutaneous lymphomas^{3, 4, 6, 10, 11, 13, 17, 18, 20-22, 35-39}

Table 7. Treatment of other types of cutaneous lymphomas

CTCL Subtype	First line treatment	Second or third line treatment
Lymphomatoid papulosis • Solitary lesion • Large/stigmatizing lesion • Multifocal	Observation Topical high potency corticosteroids Surgical excision Local radiotherapy Narrow band UVB Psoralen UVA light therapy Low dose MTX(5-25mg/wk)	Topical carmustine 0.2-0.4%* Interferon alpha Isotretinoin or Alitretinoin
Primary Cutaneous ALCL • Solitary lesion • Multifocal or frequently recurrent • Extracutaneous involvement	Surgical excision Local radiotherapy (15Gy) Low dose MTX (5-25mg/week) maintenance CHOP or CEOP	Isotretinoin or Alitretinoin Interferon Single agent chemotherapy (gemcitabine, etoposide) Brentuximab vedotin*
Subcutaneous panniculitis-like T-cell lymphoma • Associated hemophagocytic syndrome	Systemic corticosteroids, alone, or in combination with methotrexate CHOP or CEOP x 6 +/- HDT-ASCT in eligible patients	Cyclosporine ^s Vorinostat ^{fl} Local radiotherapy Oral Bexarotene ¹
Primary cutaneous acral CD8+ T-cell lymphoma <i>Provisional entity</i>	Intralesional corticosteroids Local radiotherapy	
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder • If tumour rapidly growing or > 5cm, High Ki67	Observation Topical corticosteroids Intralesional corticosteroids Local radiotherapy	Local radiotherapy
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma or Primary cutaneous $\gamma\delta$ T-Cell lymphoma	Multiagent chemotherapy (CHOP or CEOP) plus IFRT 30Gy/10 or 45Gy/25	Vorinostat ^{fl} HDT/ASCT or Allogeneic stem cell transplantation in eligible candidates
Blastic plasmacytoid dendritic cell neoplasm (CD4+/CD56+ hematodermic neoplasm)	Multiagent chemotherapy (CHOP or CEOP)	Single agent chemotherapy (Gemcitabine)

	Acute lymphoblastic leukemia type protocol if concurrent bone marrow involvement Allogeneic stem cell transplantation in first remission for eligible patients	Local radiotherapy
Primary cutaneous extranodal NK/T cell lymphoma, nasal type	Combined Modality (CHOP or CEOP plus IFRT) for localized presentation SMILE or equivalent for advanced stage	HDT-ASCT in eligible patients with relapsed/refractory
Primary Cutaneous Marginal Zone Lymphoma or Primary Cutaneous Follicle Center Lymphoma • Solitary lesion • Multifocal lesions • <i>B. burgdorferi</i> associated pcMZL	Surgical excision Local radiotherapy (15-35Gy) Observation Chlorambucil Rituximab monotherapy* Antibiotics (cephalosporin or doxycycline)	Intralesional corticosteroids Intralesional rituximab (5-20mg per lesion q4week x 3-6 cycles)* Treat as systemic (R-Bendamustine x 6)
Primary cutaneous large B cell lymphoma, leg type	R-CHOP x 6 +/- IFRT IFRT +/- rituximab monotherapy* if frail	

• Short term director's privilege (STDP) required

§ Short term exceptional drug therapy (STEDT) approval required

⌘ Health Canada Special Access Program required

¶ Not covered by AHS Cancer Control Drug Benefit list. Manufacturer's reimbursement assistance program available. Dispensed through retail pharmacy

★ Manufacturer application required for access. Drug not funded.

Special topics in CTCL

The role of transplantation in cutaneous lymphoma^{8, 9, 14, 40-49}.

Existing studies of allogeneic stem cell transplantation in mycosis fungoides or sezary syndrome are limited to small, retrospective reports or case series. Autologous stem cell transplantation has not been associated with durable remissions and therefore has been largely abandoned for MF/SS. The following recommendations are based on best available outcome data and established consensus guidelines:

- Patients with MF/SS should be risk-stratified using the CTCL International Consortium prognosis score. Patients with high-risk disease (3 or 4 of age>60, elevated LDH, stage IV or LCT) should be considered for allogeneic transplantation as part of second line of therapy.
- Patients with advanced stage 3 or stage 4 MF/SS who progress after more than two lines of systemic therapy should be considered for allogeneic transplantation.
- Selected patients with stage 2 MF/SS or with large cell transformation may be considered for allogeneic BMT..
- Patients must meet other eligibility criteria for transplant prior to being considered. Issues such as chemosensitivity (CR or PR to last line of therapy), adequate performance status (ECOG 0-2) and preserved organ function apply.
- TSEB before transplant may be considered prior to transplantation for improved skin control.
- Transplantation in other rare and aggressive CTCL such as CD8+ epidermotropic aggressive T cell lymphoma or primary cutaneous gamma-delta T cell lymphoma is at this time a largely experimental approach
- Relapses still occur after allogeneic transplants and may be treated adjustment of immunosuppression, DLI infusion, or further skin-directed treatments. Distinguishing CTCL from transplant associated GVHD requires multidisciplinary expertise.

Large Cell Transformation in Mycosis Fungoides:

The pathologic definition of large cell transformation in mycosis fungoides (LCT-MF) is the presence of large cells (≥ 4 times the size of a small lymphocyte) in 25% of more of the dermal infiltrate *or* forming microscopic nodules. The cells are often CD30+ by IHC however CD30- variants are also described. It is difficult to discriminate from other subtypes of cutaneous lymphoma, including cutaneous anaplastic large cell lymphoma (cALCL) or lymphomatoid papulosis (LyP), which may also coexist with mycosis fungoides.

The prognosis of LyP and cALCL is considerably more favourable than LCT-MF. Historical estimates for long-term survival with LCT-MF is less than 20%, and most series report a median survival of 2-36

months. However, a subset of patients with limited LCT-MF may follow a more indolent course. One large EORTC cohort analysis reported a median survival of 8.3 years for patients with LCT, and the authors concluded LCT is significant for disease progression but not survival outcome²⁶.

Currently, there is a lack of prospective research to guide a standardized approach for management of LCT-MF. Most patients are treated with combination chemotherapy however it remains unclear which patients benefit from this approach.

Several clinical and pathological characteristics in LCT-MF have been associated with poor prognosis^{28, 31}, including advanced age (> 60 years), elevated LDH at transformation, advanced stage (III/IV), extra-cutaneous transformation, the presence of follicular mucinosis, folliculotropism, and CD30-negativity. Additional pathologic variables have been described but may not be routinely analyzable so have been omitted from these recommendations.

We recommend to consider intensive chemotherapeutic strategies (monotherapy or combination in suitable fit candidates) in patients with any of the following clinical or pathologic variables associated with high risk LCT-MF. In the absence of these, we recommend treatment as per MF guidelines (see Table I).

Clinical variables for high risk LCT-MF:

- *advanced age (> 60 years)*
- *elevated LDH at transformation*
- *generalized tumours (versus solitary or regional)*
- *advanced stage (III/IV)*
- *extra-cutaneous transformation*

Adverse Pathologic variables in LCT

- *absent papillary dermal involvement (assessment may be limited by provided tissues)*
- *folliculotropism*
- *follicular mucinosis*
- *absence of fibrosis*
- *CD30 expression in less than 50% of neoplastic cells*

Brentuximab vedotin has activity in LCT-MF. A phase 2 study of brentuximab in a heavily pre-treated CD30+ MF/SS population, the majority of whom had LCT (30/32, 90%) showed a significant response rate of 70%.³⁵ A subsequent prospective, randomized controlled trial of brentuximab vedotin versus physician's choice (MTX or bexarotene) in CD30+ CTCL demonstrated a significant improvement in objective global response lasting at least 4 months with brentuximab (56.3% versus 12.5%)³⁹. The study included both previously treatment CD30+ MF and CD30+ ALCL. Although the histologic characteristics of the CD30+ MF patients were unreported, a proportion may have had transformed MF, as this was not an exclusion criteria. Brentuximab vedotin is indicated for previously treated

CD30+ MF, and could be tried for high risk LCT-MF patients as defined above, who are either unsuitable for chemotherapy or refractory/relapsed following chemotherapy.

References

1. Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, et al. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. *Ann Oncol*. 2012;23(10):2703-2707.
2. Alencar AJ, Bustinza E, Barker J, Byrne GE, Lossos IS. Hematodermic tumor presenting with generalized skin involvement. *J Clin Oncol*. 2009;27(18):3059-3061.
3. Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. *Br J Haematol*. 2017;177(2):287-310.
4. Ally MS, Robson A. A review of the solitary cutaneous T-cell lymphomas. *J Cutan Pathol*. 2014;41(9):703-714.
5. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. *Blood*. 2008;112(8):3082-3087.
6. Besner Morin C, Roberge D, Turchin I, Petrogiannis-Haliotis T, Popradi G, Pehr K. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma. *J Cutan Med Surg*. 2016;20(3):244-248.
7. Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. *Haematologica*. 2007;92(6):784-794.
8. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. *Bone Marrow Transplant*. 2008;41(7):597-604.
9. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. *J Clin Oncol*. 2014;32(29):3347-3348.
10. Garcia-Herrera A, Colomo L, Camos M, Carreras J, Balague O, Martinez A, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. *J Clin Oncol*. 2008;26(20):3364-3371.
11. Hoefnagel JJ, Vermeer MH, Jansen PM, Heule F, van Voorst Vader PC, Sanders CJ, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. *Arch Dermatol*. 2005;141(9):1139-1145.
12. Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. *Blood*. 2015;125(1):71-81.
13. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. *Blood*. 2011;118(15):4024-4035.
14. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. *Bone Marrow Transplant*. 2014;49(11):1360-1365.
15. Marcus RE, Davies AJ, Ando K, Klapper W, Opat S, Owen CJ, et al. Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. *Blood*. 2016;128(22):6.
16. Nguyen CV, Bohjanen KA. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. *Dermatol Clin*. 2015;33(4):683-696.
17. Penate Y, Hernandez-Machin B, Perez-Mendez LI, Santiago F, Rosales B, Servitje O, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. *Br J Dermatol*. 2012;167(1):174-179.
18. Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? *Bone Marrow Transplant*. 2003;32(7):637-646.
19. Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. *Br J Haematol*. 2017;176(1):16-36.

20. Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. *The Cochrane database of systematic reviews*. 2013;(8):CD008908. doi(8):CD008908.
21. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood*. 2008;112(5):1600-1609.
22. Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT, International Lymphoma Radiation Oncology G. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys*. 2015;92(1):32-39.
23. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
24. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. *Blood*. 2016;127(25):3142-3153.
25. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood*. 2008;111(2):838-845.
26. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. *J Clin Oncol*. 2010;28(31):4730-4739.
27. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*. 2007;110(6):1713-1722.
28. Pulitzer M, Myskowski PL, Horwitz SM, Querfeld C, Connolly B, Li J, et al. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. *Pathology*. 2014;46(7):610-616.
29. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. *J Clin Oncol*. 2015;33(32):3766-3773.
30. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. *Eur J Cancer*. 2017;77:57-74.
31. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. *Blood*. 2012;119(7):1643-1649.
32. Kadin ME, Hughey LC, Wood GS. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. *J Am Acad Dermatol*. 2014;70(2):374-376.
33. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. *J Clin Oncol*. 2011;29(18):2598-2607.
34. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*. 2007;110(2):479-484.
35. Kim YH, Tavallaei M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. *J Clin Oncol*. 2015;33(32):3750-3758.
36. Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. *J Am Acad Dermatol*. 2012;67(4):748-759.
37. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. *Dermatol Ther*. 2003;16(4):311-321.
38. Pellegrini C, Stefoni V, Casadei B, Maglie R, Argnani L, Zinzani PL. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. *Ann Hematol*. 2014;93(11):1853-1857.
39. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet*. 2017;390(10094):555-566.

40. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood*. 2005;105(10):3768-3785.
41. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. *J Clin Oncol*. 2005;23(25):6163-6171.
42. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. *Biol Blood Marrow Transplant*. 2009;15(8):982-990.
43. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. *J Clin Oncol*. 2010;28(14):2365-2372.
44. Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. *Bone Marrow Transplant*. 2012;47(7):940-945.
45. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sezary Syndrome. *Clin Lymphoma Myeloma Leuk*. 2015;15(5):83.
46. de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. *Haematologica*. 2014;99(3):527-534.
47. Alpdogan O, Grosso D, Flomenberg N. Recent advances in haploidentical stem cell transplantation. *Discov Med*. 2013;16(88):159-165.
48. Shiratori S, Fujimoto K, Nishimura M, Hatanaka KC, Kosugi-Kanaya M, Okada K, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. *Hematol Oncol*. 2016;34(1):9-16.
49. Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. *Dermatol Clin*. Oct 2015;33(4):807-18.

V. Hodgkin Lymphoma

Pathologic Classification

The histological sub-classification of Hodgkin lymphoma is based on the light microscopic H&E interpretation. If problems with differential diagnosis arise, staining for CD15, CD30, T-cell and B-cell panels and EMA may be helpful. For lymphocyte predominant B-Cell Hodgkin lymphoma, CD20, CD45, +/- CD57 are recommended.

Table 1. WHO classification of histologic subtypes of Hodgkin lymphoma¹

Classical
- Nodular Sclerosis
- Mixed Cellularity
- Lymphocyte Rich
- Lymphocyte Depleted
Nodular Lymphocyte Predominant B-Cell Lymphoma

Staging

Mandatory staging procedures include²⁻⁸:

- Pathology review whenever possible (essential for core needle biopsies)
- Complete history and physical examination (B symptoms, Etoh intolerance, pruritis, fatigue, ECOG performance score, examination of nodes, Waldeyer's ring, spleen, liver, skin)
- CBC & differential, creatinine, electrolytes, Alk P, ALT, LDH, bilirubin, total protein, albumin, calcium
- ESR (required for limited stage patients)
- If a PET/CT is not done, then perform a bone marrow aspiration and biopsy (2cm core preferable) for patients with stage IIB-IV or cytopenias (note: flow cytometry on the marrow aspirate does not add useful information and should not be done)
- Chest x-ray (PA and lateral)
- CT scan of the neck, chest, abdomen, and pelvis
- A PET scan is preferred as initial staging and after 2 cycles of ABVD⁹⁻¹⁴.
- Pregnancy test, if at risk (consider fertility and/or psychosocial counseling)
- Semen cryopreservation if chemotherapy or pelvic radiotherapy is contemplated
- HIV: if HIV risk factors or unusual disease presentations

Primary Treatment of Classical Hodgkin Lymphoma¹⁵⁻¹⁹

General principles: For treatment planning, supradiaphragmatic clinical stage (CS) I or II without bulk (mass >10cm or >1/3 maximal transthoracic diameter (MTD) on CXR) or significant B symptoms is considered limited stage. Initial treatment options for classical Hodgkin Lymphoma involve the

chemotherapy regimens ABVD, BV-AVD, or escalated BEACOPP or escalated BPDac as well as involved field radiotherapy (IFRT). Multiple phase III studies conducted by the German Hodgkin Study Group (GHSG) and other cooperative study groups have demonstrated that optimal cure rates are achieved with: 1) ABVD x2 cycles followed by 20Gy IFRT for favorable risk limited stage disease (5yr PFS >90%); 2) ABVD x4 cycles followed by 30Gy IFRT for unfavorable risk limited stage (≥ 3 nodal sites, ESR > 50 or >30 with B symptoms, or extranodal disease) (5yr PFS >85%); 3) escalated BEACOPP x 4-6 cycles for young healthy patients with advanced stage disease 4) BV-AVD x 6 cycles for advanced stage disease. Advanced stage patients also receive IFRT following chemotherapy to localized PET+ residual disease >2.5cm, and is considered for sites of prior bulk after ABVD.

Data supporting escalated BEACOPP for advanced stage disease: The GHSG HD9 trial conducted in the 1990s demonstrated that 8 cycles of an escalated-dose BEACOPP regimen were superior to 8 cycles of a COPP/ABVD regimen or 8 cycles of a baseline-dose BEACOPP regimen in terms of freedom from treatment failure and overall survival rates in patients with advanced-stage Hodgkin lymphoma²⁰. At the 10-year analysis, freedom from treatment failure was 64% for the COPP/ABVD group, 70% for the baseline BEACOPP group, and 82% for the escalated BEACOPP group ($p<0.001$); overall survival rates were 75%, 80%, and 86%, respectively ($p<0.001$)²¹. There were higher rates of hematologic toxicities, grades 3-4 infections and higher rate of AML/MDS in the escBEACOPP group, but not an increase in all second malignancies. A meta-analysis of 4 subsequent phase III trials confirmed superior PFS and long term OS with escBEACOPP compared to ABVD^{22,23}.

The German Hodgkin Study Group recently published the results of their HD15 prospective randomized clinical trial²⁴. 2182 patients with newly diagnosed Hodgkin lymphoma aged 18-60 years with stage IIB (large mediastinal mass or extranodal lesions), or stage III-IV disease were randomly assigned to receive either 8 cycles of escBEACOPP (8B_{esc}), 6 cycles of escBEACOPP (6B_{esc}), or 8 cycles of BEACOPP₁₄ (8B₁₄). After a median follow-up of 48 months, there were 53 deaths (7.5%) in the 8B_{esc} group, 33 (4.6%) in the 6B_{esc} group and 37 (5.2%) in the 8B₁₄ group. The higher number of deaths in the 8B_{esc} group mainly resulted from acute toxicity of chemotherapy and secondary neoplasms. There were 72 secondary cancers including 29 secondary acute myeloid leukemias and myelodysplastic syndromes: 19 (2.7%) in the 8B_{esc} group, 2 (0.3%) in the 6B_{esc} group and 8 (1.1%) in the 8B₁₄ group. Five year OS rates were 91.9% in the 8B_{esc} group, 95.3% in the 6B_{esc} group, and 94.5% in the 8B₁₄ group. PET scans performed after chemotherapy for 822 patients revealed that 739 were in PR with residual mass ≥ 2.5 cm. 548 patients were PET-negative (74.2%) and 191 were PET-positive (25.8%). PFS was comparable between patients in CR or those in PET-negative PR after chemotherapy with 4-year PFS rates of 92.6% and 92.1%, respectively. Only 11% of all patients in the HD15 trial received additional radiotherapy as compared to 71% in the prior HD9 study²⁴.

In an attempt to reduce severe toxicities associated with escBEACOPP, an open-label, randomized, parallel-group, phase 3 trial (HD18) investigated the utility of PET after 2 cycles of standard

escBEACOPP to allow for adaptation of treatment intensity²⁵. The trial included 18-60 year olds with newly diagnosed advanced-stage Hodgkin's lymphoma (N=1945), and assigned patients (1:1) to two parallel treatment groups on the basis of their PET results after cycle 2 of escBEACOPP (PET-2). Patients with positive PET-2 were randomised to receive six additional cycles of either standard escBEACOPP (8 × escBEACOPP in total) or escBEACOPP with rituximab (8 × R-eBEACOPP) (rituximab abandoned mid-trial due to lack of efficacy). Patients with negative PET-2 were randomised between standard treatment with 4-6 additional cycles of escBEACOPP (6-8 × escBEACOPP... the trial switched from total 8 to total 6 escBEACOPP in the standard arm after the results of HD15) or experimental treatment with 2 additional cycles only (total = 4 × escBEACOPP). Patients with negative PET-2 randomly assigned to either 6-8 × escBEACOPP (n=504) or 4 × escBEACOPP (n=501) had 5-year progression-free survival of 90·8% (95% CI 87·9-93·7) and 92·2% (89·4-95·0), respectively (difference 1·4%, 95% CI -2·7 to 5·4). 4 × escBEACOPP was associated with fewer severe infections (8% vs 15%) and organ toxicities (8% vs 18%) as compared to patients receiving 6-8 × escBEACOPP. The trial supports reducing therapy to total 4 escBEACOPP in patients who achieve PET- negative disease after 2 cycles of escBEACOPP.

Data Supporting Replacement of Procarbazine with Dacarbazine in escBEACOPP

Procarbazine and dacarbazine are both guanine methylation agents with similar mechanisms of action. Dacarbazine is thought to be less gonadotoxic and less hematotoxic than procarbazine. The pediatric EuroNet-PHL-C1 study²⁶ was an open-label, non-inferiority, randomized controlled trial of children and adolescents with intermediate and advanced stage Hodgkin's lymphoma. 937 patients were randomized 1:1 to receive COPP or COPDAC (COPDAC is identical to COPP, except that procarbazine is replaced with dacarbazine). In the per-protocol analysis, event-free survival at 5 years was 89.9% for COPDD vs. 86.1% for COPDAC (difference -3.7%, 95% CI -8.0% to +0.6%). Overall survival rates at 5 years were similar (98.1% for COPP vs. 98.9% for COPDAC). Fertility outcomes were much improved in the COPDAC group, with 19 (83%) of 23 analyzed males in the COPP group having azoospermia at a median of 40 months follow-up, vs 0 of 22 males in the COPDAC group (p<0.0001). Rates of premature ovarian failure were also lower in the female patients who received COPDAC.

On the basis of interim results from the EuroNet-PHL-C1 study, it has become increasingly common practice in Europe to use escBPDac, (e.g. escBEACOPP, but with procarbazine replaced with dacarbazine), for adult patients. Retrospective data published by Santasieri et al (N=225)²⁷ showed that, compared to 58 matched escBEACOPP controls, patients treated with escBPDac required fewer non-elective days of inpatient care (mean 3.35 vs. 5.84 days, p=0.022), fewer pRBC transfusions (mean 1.79 vs. 4.16 units; p<0.001), and had earlier return of menstruation (mean 4.64 vs. 9.12 months; p=0.0026). Efficacy was also similar to historical controls from the HD18 and RATHL trials, with 77% of patients achieving a Deauville score of 3 or less on their interim PET2, and with a 22-month PFS rate of 94.9%. Santasieri et al.²⁸ also published whole genome sequencing data from

patients exposed to either escBPDac or escBEACOPP, which strongly suggested that patients treated with escBPDac have a much lower rate of potentially oncogenic mutations in their hematopoietic stem cells (mean 291 excess mutations in escBPDac patients, compared to 1153 excess mutations in escBEACOPP patients).

Based on the above data, we recommend modifying escBEACOPP to escBPDac, by replacing procarbazine with dacarbazine.

Due to concerns of toxicity, escBEACOPP/escBPDac in Alberta should only be considered for the following patients^{2,21,22,29-33}:

- Age < 60 years
- KPS score $\geq$ 70 (ECOG 0-2)
- HIV negative, no other major co-morbidities
- Patients must be made aware of infertility implications, particularly if using escBEACOPP, and consent to proceed.

Data Supporting Replacement of escBEACOPP with BrECADD

BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) has been compared to escBEACOPP among 1500 patients 18-60 years old with high-risk stage II or advanced stage HL in the HD21 trial. BrECADD resulted in a similar rate of iPET2-negativity (64% versus 64%) and superior 4-year PFS (94% vs 91%, $p=0.035$) with similar 4-year OS (99% vs 98%) compared to escBEACOPP. In addition, BrECADD was associated with less grade 4 hematologic toxicity, less febrile neutropenia, lower transfusion requirements, less neuropathy, and improved gonadal recovery and higher birth rates compared to escBEACOPP³⁴.

Of note, patients receiving escBEACOPP or BrECADD should have once-twice weekly CBCs to assess for severe cytopenias requiring dose reduction. A dose level reduction is recommended for patients who develop 1 or more toxic events in a given cycle: WBC <1 for >4 days, thrombocytopenia <25, grade 4 infection or other toxicities, or treatment delay >2 weeks due to inadequate recovery of blood counts:

5.4.2.11 Dose levels for BrECADD

Full dose, dose level 4

Cyclophosphamide	1250 mg/m ²	i.v.	Day 2
Doxorubicin	40 mg/m ²	i.v.	Day 2
Etoposide	150 mg/m ²	i.v.	Day 2-4

Dose level 3

Cyclophosphamide	1100 mg/m ²	i.v.	Day 2
Doxorubicin	40 mg/m ²	i.v.	Day 2
Etoposide	125 mg/m ²	i.v.	Day 2-4

Dose level 2

Cyclophosphamide	950 mg/m ²	i.v.	Day 2
Doxorubicin	40 mg/m ²	i.v.	Day 2
Etoposide	100 mg/m ²	i.v.	Day 2-4

Dose level 1

Cyclophosphamide	800 mg/m ²	i.v.	Day 2
Doxorubicin	40 mg/m ²	i.v.	Day 2
Etoposide	100 mg/m ²	i.v.	Day 2-4

Data Supporting Brentuximab vedotin for Primary Therapy of Hodgkin Lymphoma ³⁶

An open-label, multicenter phase 3 trial of 1334 patients with previously untreated stage III/IV Hodgkin lymphoma, randomized (1:1) patients to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV+AVD) or ABVD. PFS outcomes favored BV-AVD over ABVD. At a median follow-up of 72.6 months, the 6-year progression-free survival estimates were 82.3% with BV-AVD and 74.5% with ABVD (hazard ratio for disease progression or death, 0.68; 95% CI, 0.53 to 0.86)³⁵.

Neutropenia was higher in the BV+AVD group (58% vs 45%), febrile neutropenia occurred in 83 patients (rate: 11% in those receiving prophylactic GCSF and 21% in those without GCSF). Peripheral neuropathy was also higher in the BV+AVD group (67% vs. 43%), with resolution at last follow-up in 2/3 of patients. Pulmonary toxicity ≥grade 3 occurred in 1% of BV+AVD patients vs. 3% in ABVD. Updated 6-year OS data favour BV-AVD over ABVD with estimated OS rates of 93.9% (95% CI, 91.6 to 95.5) vs 89.4% (95% CI, 86.6 to 91.7), respectively.

Originally, Health Canada restricted approval to patients with Stage 4 disease but longer follow-up survival data led to approval in both Stage III and IV. With the favourable OS data, BV+AVD should be considered in patients with advanced stage HL. There are no direct comparisons of BV+AVD vs escBEACOPP/BPDac or BrECADD. For stage III-IV HL, both BV+AVD and BrECADD are considered

highly curative treatment options. Patient factors, such as age, comorbidities, toxicity concerns (specifically neuropathy with BV+AVD or myelosuppression with BrECADD), and length of treatment should factor into clinical decision making.

Data Supporting Nivolumab for Primary Therapy of Hodgkin Lymphoma³⁶

An open-label, multicenter phase 3 trial of 994 patients aged 12 and older with previously untreated stage III/IV Hodgkin lymphoma, randomized (1:1) patients to receive nivolumab, doxorubicin, vinblastine, and dacarbazine (Nivo+AVD), or BV+AVD. PFS outcomes favored Nivo+AVD over BV+AVD. At a median follow-up of 2.1 years, the 2-year progression-free survival estimates were 92% with Nivo+AVD and 83% with BV+AVD (hazard ratio for disease progression or death, 0.45; 95% CI, 0.30 to 0.65).³⁶ The PFS advantage observed with Nivo+AVD was consistent across disease stage and age subgroups.

BV+AVD patients received mandatory G-CSF prophylaxis, whereas this was at the investigator's discretion in the Nivo+AVD arm. Despite this, rates of infection and febrile neutropenia were similar in the two groups. Peripheral sensory neuropathy of any grade occurred in 29% of Nivo+AVD patients, as compared with 56% of BV+AVD patients. Rates of grade 2 or higher peripheral sensory neuropathy were 3% and 32%, respectively. Occurrences of pneumonitis, gastritis, rash, and colitis were similar in the two groups. Hypothyroidism and hyperthyroidism occurred more frequently in the Nivo+AVD group (7% and 3%, respectively) as compared to the BV+AVD group (<1% and 0%, respectively).

As of July 2025, Nivo+AVD is not publicly funded in Alberta, but given its clear PFS advantage and favourable toxicity profile compared to BV+AVD, we would recommend Nivo+AVD over BV+AVD in most stage III or IV HL patients, with the possible exception of patients with pre-existing autoimmune conditions. Alternative funding options for Nivo+AVD could be explored while we await approval for public funding.

Nivo+AVD has not been directly compared to BrECADD, which demonstrated a 4-year PFS of 94.3% in the HD21 trial.³⁴ Patients in the HD21 trial were restricted to ages 18-60, and HD21 also included some high-risk stage IIB patients. Both BrECADD and Nivo+AVD would be reasonable options for upfront treatment of stage III or IV HL patients as funding allows, with BrECADD perhaps being preferred in younger patients who prioritize higher remission rates and a shorter duration of therapy at the cost of higher toxicity.

Data Supporting a PET-Guided Treatment Approach³⁷⁻⁴⁰:

Limited Stage:

In the *UK Rapid trial*, patients with stage I-IIA non-bulky HL received ABVD x3 cycles then underwent a PET scan. If the PET was positive (uptake more than blood pool, Deauville score 3-5) the patients received one more cycle of ABVD then IFRT, whereas if the PET was negative patients were randomized to observation or IFRT. The 3yr PFS was 85.9% in the 145 PET+ patients, 94.6% in the PET- patients who received IFRT and 90.8% in PET- patients who were observed. The difference in PFS was -3.8% (95%CI: -8.8%, 1.3%) exceeding the -7% non-inferiority margin. Of interest, the per-protocol PFS was 97% vs 90.8% because 26 pts did not get their allocated IFRT. The respective 3 year overall survival rates were 97.1% vs 99.0%. In the *EORTC/LYSA/FIL H10 trial*, stage I-II HL patients were randomized between control arm therapy with ABVD x3 +INRT (favorable risk) or ABVD x4 +INRT (unfavorable risk), with all patients undergoing PET after cycle 2 ABVD. In the experimental arm of the study, patients received ABVD x2 then a PET scan, followed by ABVD x 2 (favorable) or 4 (unfavorable) if PET-, or escBEACOPP x2 cycles +INRT if PET+. Comparing control (INRT) and experimental (no INRT) arms for patients with negative PET after 2 cycles ABVD, the difference in PFS was -11.9% (95%CI -16.9%, -8.2%) for favorable risk (not meeting non-inferiority endpoint) and -2.5% (95%CI -6.6%, 0.5%) for unfavorable risk (not meeting non-inferiority endpoint). There was no difference in overall survival. For patients with PET+ disease after ABVD, the 5y PFS 77% vs 91% (p=0.002) and 5yr OS 89% vs 96% (p=0.06) favouring escBEACOPP compared to ABVD + INRT.

As neither the RAPID nor H10 trials confirmed non-inferiority of the PET-directed radiotherapy omission approach, this would support the use of radiotherapy despite a negative interim PET. However, given the lack of difference in OS and small differences in PFS, a PET-directed approach to omit RT may be recommended depending on the age of the patient and sites of disease, accepting the risk of reduced local control with potential need for salvage chemotherapy and transplantation at relapse, reconciled by an expected late gain in OS due to avoidance of the long term sequelae of radiotherapy such as secondary malignancy and cardiovascular disease.

Advanced Stage:

The *UK RATHL trial* treated patients with 2 cycles ABVD then performed a PET scan. 172 patients with PET+ disease (uptake > liver, Deauville 4-5) had therapy intensified to escBEACOPP whereas PET- patients were randomized to ABVD x4 (n=470) or AVD x4 (n=465). For PET- patients, 3yr PFS was 85.7% vs 84.4% for ABVD vs AVD (95%CI crossed 5% difference non-inferiority limit), the respective 3yr OS rates were 97.2% vs 97.6%, and the rate of grade 3-4 pneumonitis was 1% vs 0.2%, respectively. Recently reported long follow up of this trial, showed that at a median follow up is 87.2 months (IQR 63.0 - 104.0), the overall PFS at 7 years is 78.2% (95% CI 75.6 - 80.5) and overall

survival (OS) 91.6% (95% CI 89.7 - 93.2). PFS at 7 years for ABVD was 81% (95% CI 76.9 - 84.4), and for AVD 79.2% (95% CI 75.1 - 82.8), HR: 1.10 (95%CI 0.82 - 1.47)⁴¹.

- Results reliably exclude a 5% inferior 3 year PFS following de-escalation (omission of bleomycin for cycles 3-6) after a negative interim PET-CT, with no evidence of a later divergence.
- For those with a positive PET2, intensified therapy with escBEACOPP is effective and safe, with no evidence of an increase in second malignancies by comparison with the group who received ABVD/AVD.

The aforementioned HD18 study by German Hodgkin Study Group confirmed that 4 escBEACOPP was as effective as 6-8 escBEACOPP but less toxic in patients who achieved PET-negative status after 2 cycles of escBEACOPP. 3 yr PFS in this group (PET-2 negative after escBEACOPP) was 95.3% and 3 yr OS was 98.8%. As mentioned, the HD21 trial confirmed that PET-directed BrECADD is more effective and better tolerated than escBEACOPP.

Figure 1. Treatment algorithm for Limited Stage classic Hodgkin lymphoma using PET-Guided therapy (Preferred Approach)





Figure 2: Treatment Algorithm for bulky stage II, stage IIB, or stage III Hodgkin lymphoma using PET-guided therapy



PET+ patients are those who achieve a partial remission to therapy but maintain FDG-avidity of Deauville 4. Patients with stable or progressive disease on interim PET scan have refractory Hodgkin lymphoma and should be followed as per “Management of Recurrent Lymphoma”.

Table 2: Treatment options for advanced stage Hodgkin lymphoma

	Nivo+AVD <i>Not yet publicly funded as of May 2025</i>	BV-AVD	BrECADD
Treatment schedule	Fixed course treatment Every 2 weeks x 24 weeks No interim PET	Fixed course treatment Every 2 weeks x 24 weeks No interim PET	Interim PET2 directed IV chemo days 1-3 every 3 weeks x 12 weeks if iPET2-neg (64%) x 18 weeks if iPET2-pos (36%)
Cumulative dose of BV	None	14.4 mg/kg	7.2 mg/kg (4 cycles) 10.8 mg/kg (6 cycles)
Efficacy	2-year PFS 92%	6-year PFS 82%	4-year PFS 94%
Notable toxicities	Neuropathy 32% Febrile neutropenia 6% Second cancers no data at 2y Hypothyroidism 7% Hyperthyroidism 3%	Neuropathy 67% Febrile neutropenia 19% (11% with G-CSF) Second cancer 4% at 6y	Neuropathy 43% Febrile neutropenia 21% (G-CSF required) Second cancer 3% at 4y Patients >60 yo excluded from HD21

Management of Recurrent Hodgkin Lymphoma^{2,42-57}:

Similar to the initial workup, recurrent disease should involve re-staging tests.

Initial relapse.

- Re-induction chemotherapy with GDP or DICEP then high dose therapy and autologous SCT ± IFRT 20-30Gy to prior bulk site at relapse, or PET-positive residual disease post-ASCT
- Brentuximab vedotin consolidation post-ASCT for patients with primary refractory HL, relapse within 12 months or extranodal disease at relapse
- Pembrolizumab iv q3-6 weeks for older/unfit patients who are deemed ineligible for ASCT

Second or subsequent relapse.

- IFRT if localized relapse in previously non-irradiated site
- A PD1-inhibitor (eg. Nivolumab or Pembrolizumab) after prior failure of chemotherapy (and autologous SCT in transplant eligible patients) [data suggests longer remissions with PD1-inhibitor compared to Brentuximab vedotin making PD1i then BV the preferred sequencing]
- Brentuximab vedotin IV q21d for up to 16 doses if prior failure of initial chemotherapy (ABVD or BEACOPP) and prior autologous SCT (excluding patients who progress on BV consolidation post-ASCT)
- Palliative chemotherapy for symptomatic patients (GDP, COPP, ChIVPP, CEPP, vinblastine)

- Allogeneic SCT is a curative option for fit patients who have exhausted other therapies, resulting in a 2-year PFS 69% in the immune checkpoint inhibitor era (PMID: 33658659). Given that the outcomes of allogeneic SCT are highly dependent on disease status at the time of transplant, eligible patients should be referred for discussion of allogeneic HCT when starting their second novel agent (i.e. checkpoint inhibitor or BV). For patients with highly refractory disease or short duration of remissions, consider using the second novel agent to achieve a response as a bridge to allogeneic HCT. Other patients who achieve a complete response to the second novel agent may reasonably defer allotransplant to the next relapse provided that effective bridging therapy is expected to be available

Brentuximab vedotin (BV) monotherapy ⁵⁸⁻⁶⁰:

A phase II study of N=102 patients treated with BV (1.8mg/kg, outpatient IV, 30min, every 3 weeks for up to 16 cycles) for relapsed/refractory Hodgkin lymphoma after failed hematopoietic autologous stem cell transplantation reported outcomes after approximately 3-years of follow-up. Median OS and PFS were estimated at 40.5 months and 9.3 months, respectively. The estimated 3-year OS and PFS rates were 73% (95%CI: 57-88%) and 58% (95%CI: 41-76%), respectively. Younger age, good performance status, and lower disease burden at baseline were favorable prognostic factors for OS. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. Chen et al. reported 5-year end-of-study data. For the entire cohort, OS was 41% (95% CI: 31-51) and PFS was 22% (95% CI: 13-31). Complete response (evaluated via Revised Response Criteria for Malignant Lymphoma): was observed in 34 patients. For those who achieved CR, OS and PFS rates were 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively (median OS and PFS not yet reached). At the time of study close, 13 CR patients remained in remission (4 received consolidative hematopoietic allogeneic stem cell transplant; 9 received no further anticancer treatment). Of those patients who experienced BV associated peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms.

Consolidation with Brentuximab Vedotin after ASCT

The AETHERA clinical trial evaluated a strategy of consolidation with brentuximab vedotin after autologous stem cell transplantation in high risk relapsed Hodgkin lymphoma patients. Patients were eligible for BV if they were either: refractory to frontline treatment, relapsed < 12months after frontline therapy, or relapsed ≥ 12 months with extranodal involvement. Patients were randomized to receive either BV (1.8mg/kg every 3 weeks for up to 16 cycles) or placebo. 5 year PFS was 59% for BV versus 41% for placebo. PFS benefit was most pronounced for patients who were PET+ before ASCT or those with >1 risk factor. Grade 3-4 peripheral motor and sensory neuropathy was observed in 6 and 10% of patients receiving BV consolidation, however, improves or resolves in the majority of patients.^{61,62}

Patients were excluded from the AETHERA trial if they had previously received brentuximab vedotin, and most AETHERA patients received ABVD or BEACOPP as their initial therapy. It is therefore unclear whether patients who received a BV-containing regimen such as BrECADD or BV-AVD as

initial therapy still benefit from BV consolidation after ASCT. Several retrospective European studies suggested that the benefit of BV consolidation was maintained in patients with prior BV exposure.⁶³⁻⁶⁵ However, most BV-exposed patients included in these studies received ABVD as their initial therapy, and were subsequently salvaged with a BV-containing regimen, suggesting that these patients may be less refractory to BV than patients treated up front with BrECADD or BV-AVD. In contrast, a US retrospective cohort study of 921 relapsed/refractory Hodgkin's patients undergoing ASCT, BV consolidation was associated with a significant PFS benefit among patients who received no novel agents before ASCT (HR 0.27 [0.12-0.65], $p < 0.001$), but not for patients treated with BV (HR 0.56 [0.28-1.10], $p = 0.091$).⁶⁶ We therefore recommend against offering BV consolidation after ASCT to most Hodgkin's patients who received BrECADD or BV-AVD as their initial therapy. An exception could be made for patients who met the AETHERA criteria of relapse ≥ 12 months with extranodal involvement.

The same US study cited above⁶⁶ also found that patients previously treated with PD-L1 blockade before ASCT did not benefit from BV consolidation (HR 1.10 [0.22-5.56], $p = 0.91$). We therefore tentatively recommend against offering BV consolidation after ASCT to patients who received Nivo-AVD as their initial therapy. This recommendation may be revised if further evidence becomes available in the future.

PD1-inhibitor Monotherapy⁶⁷:

The open-label phase III Keynote-204 study compared pembrolizumab ($n = 151$) versus brentuximab in relapsed or refractory classic Hodgkin lymphoma, with the dual primary end points of PFS and OS. The interim analysis did not include OS data, however, with a median follow-up after randomization of 25.7 months, median PFS was 13.2 months (95%CI: 10.9-19.4) for pembrolizumab versus 8.3 months (95%CI: 5.7-8.8) for brentuximab vedotin (HR: 0.65; 95%CI: 0.48-0.88; $p = 0.003$). Serious treatment-related AEs occurred in 16% of pembrolizumab patients and 11% of brentuximab vedotin patients. Grade 3-5 treatment-related adverse events were: pneumonitis 4% in the pembrolizumab group vs 1% in the brentuximab vedotin group, neutropenia 2% vs 7%, decreased neutrophil count 1% vs 5%, and peripheral neuropathy 1% vs 3%, respectively. The study included patients who had relapsed after ASCT and patients who were ASCT-ineligible making PD1 inhibition the preferred secondline therapy for non-transplant eligible patients and the preferred third line therapy for patients who relapse post-ASCT.

CheckMate 205, a single-arm, multicenter, phase 2 study enrolled patients with relapsed/refractory Hodgkin lymphoma who failed autologous hematopoietic cell transplantation to receive nivolumab (3 mg/kg every 2 weeks until disease progression/unacceptable toxicity). After a median follow-up of 18 months, 40% of patients were still on treatment. Objective response rates were 65-73% dependent on cohort, (overall 69%). The median duration of response was 16.6 months (95%CI: 13.2-20.3m), and median PFS was 14.7 months (95%CI: 11.3-18.5m). Most common grade 3-4 AEs included lipase increases (5%), neutropenia (3%), and ALT increases (3%).

Nodular Lymphocyte Predominant B-Cell Lymphoma⁶⁸

This rare subtype of B cell lymphoma typically has a very indolent course with excellent survival. This entity was formerly called “Nodular Lymphocyte Predominant Hodgkin Lymphoma” (NLPHL), but recently, major biological and clinical differences with classic Hodgkin lymphoma have led to this name change in the 2022 ICC classification⁶⁹. The 5th edition of the WHO classification continues to use the term “Nodular Lymphocyte Predominant Hodgkin Lymphoma”, but considers the new nomenclature acceptable in preparation for future definitive adoption⁷⁰.

Patients most commonly present with early stage disease, the clinical course is indolent and the prognosis is very favourable. Similar to other indolent CD20+ lymphoma, late relapses as well as transformation to DLBCL or to T-cell/histiocyte-rich large B-cell lymphoma (3–5% of cases) can occur. Even after relapse, patients may survive for many years, and therefore minimizing risk of treatment-related mortality is important.

The diagnosis of nodular lymphocyte predominant B-cell lymphoma may sometimes require excisional lymph node biopsy that may remove all gross disease, in which case observation alone can be considered after staging with PET-CT. In terms of treatment recommendations, patients with residual but localized nodular lymphocyte predominant B-cell lymphoma (stage 1-2A with ≤ 2 contiguous sites of disease) should be offered involved-site radiotherapy (ISRT)⁷¹. Patients with Stage 1B or more advanced stage 2A/B disease, or those with stage 3-4 disease, should be treated in a similar fashion as those with other forms of indolent CD20+ lymphoma including watchful waiting if asymptomatic or chemoimmunotherapy (eg. BR or RCVp) as appropriate. Consider the possibility of high-grade transformation in patients with rapidly progressive disease, marked B symptoms, focal abnormalities in the spleen, extranodal disease, high LDH, variant histology, or prior bone marrow involvement. R-CHOP is appropriate for patients with transformed disease, with consideration for HDCT/ASCT, especially in those who have relapsed < 2 years after prior chemoimmunotherapy. Consider rituximab monotherapy in patients with advanced stage nodular lymphocyte predominant B-cell lymphoma who have serious co-morbidities that would preclude the use of combination chemotherapy.

References

1. Swerdlow SH, Campo E, Harris NL. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed. Lyon: International Agency for REsearch on Cancer. 2008;
2. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Hodgkin Lymphoma. Version 3. 2011.
3. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. *J Clin Oncol*. 1987;5(7):1041-1049. doi:10.1200/JCO.1987.5.7.1041 [doi]
4. Mauch P, Larson D, Osteen R, et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. *J Clin Oncol*. 1990;8(2):257-265. doi:10.1200/JCO.1990.8.2.257 [doi]
5. Leisenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. *J Clin Oncol*. 1989;7(1):81-91. doi:10.1200/JCO.1989.7.1.81 [doi]
6. Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. *Blood*. 1996;87(9):3625-3632.
7. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. *Cancer J Sci Am*. 1995;1(1):33-42.
8. Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. *Br J Haematol*. 2002;119(2):408-411. doi:3842 [pii]
9. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood*. 2005;106(5):1538-1543. doi:2005-04-1437 [pii]
10. Dobert N, Menzel C, Berner U, et al. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. *Cancer Biother Radiopharm*. 2003;18(4):565-571. doi:10.1089/108497803322287646 [doi]
11. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. *Br J Cancer*. 2004;90(3):620-625. doi:10.1038/sj.bjc.6601561 [doi]
12. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. *J Nucl Med*. 2003;44(8):1225-1231.
13. Swinnen LJ. Treatment of organ transplant-related lymphoma. *Hematol Oncol Clin North Am*. 1997;11(5):963-973. doi:S0889-8588(05)70473-1 [pii]
14. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. *Transplantation*. 1999;68(10):1517-1525. doi:10.1097/00007890-199911270-00015 [doi]
15. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol*. 2010;28(27):4199-4206. doi:10.1200/JCO.2010.29.8018 [doi]
16. Brockelmann PJ, Gorgen H, Plutschow A, et al. Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma (hl): Updated analyses of the german hodgkin study group hd7, hd8, hd10 and hd11 trials. *J Clin Oncol*. 2017:S106.
17. Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. *J Natl Cancer Inst*. 2015;107(4):10.1093/jnci/djv018. Print 2015 Apr. doi:10.1093/jnci/djv018 [doi]
18. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. *N Engl J Med*. 2015;373(26):2499-2511. doi:10.1056/NEJMoa1505949 [doi]
19. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. *J Clin Oncol*. 2011;29(31):4096-4104. doi:10.1200/JCO.2011.34.8268 [doi]
20. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. *Ann Oncol*. 2008;19(10):1727-1733. doi:10.1093/annonc/mdn351 [doi]
21. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol*. 2009;27(27):4548-4554. doi:10.1200/JCO.2008.19.8820 [doi]

22. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. *J Clin Oncol*. 2009;27(5):805-811. doi:10.1200/JCO.2008.17.0910 [doi]
23. Jiang Y, Chen Y, Huang R, Chen G. Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis. *International journal of hematology*. 2016;104(4):413-419. doi:10.1007/s12185-016-2080-5 [doi]
24. Engert A, Haverkamp H, Kobe C, Marcova J, Renner C, Ho AD. Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: the GHSG HD15 final results. *Blood*. 2011;ASH Annual Meeting Abstracts; 118(21)(Abstract 589)
25. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet*. 2018;390(10114):2790-2802. doi:S0140-6736(17)32134-7 [pii]
26. Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. *The Lancet Oncology*. 2022 Jan 2022;23(1)doi:10.1016/S1470-2045(21)00470-8
27. Santarsieri AS, K. Brice, P. Menne, TF. Osborne, W. Creasey, T. Ardeschna, KM. Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp. *Blood*. 2021;138(Supplement 1):877.
28. Santarsieri AM, E. Sturgess, K. Brice, P. Menne, TF. Osborne, W. Creasey, T. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy | Blood | American Society of Hematology. *Blood*. 2023;140(Supplement 1):1761-1764. doi:10.1182/blood-2022-166543
29. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N Engl J Med*. 2003;348(24):2386-2395. doi:10.1056/NEJMoa022473 [doi]
30. Diehl V, Haverkamp H, Mueller R, Mueller-Hermelink H, Cerny T, Markova J. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). *J Clin Oncol*. 2009;(ASCO Meeting Abstracts); 27(Abstract 8544)
31. Borchmann P, Engert A, Pluetschow A, Fuchs M, Markova J, Lohri A. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. *Blood*. 2008;(ASH Annual Meeting Abstracts); 112(Abstract 367)
32. Ng AK, van Leeuwen FE. Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance. *Semin Hematol*. 2016;53(3):209-215. doi:10.1053/j.seminhematol.2016.05.008 [doi]
33. Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood*. 2016;127(18):2189-2192. doi:10.1182/blood-2015-11-681064 [doi]
34. Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. *Lancet*. Jul 27 2024;404(10450):341-352. doi:10.1016/s0140-6736(24)01315-1
35. Ansell S, Radford J, Connors J, et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. *The New England journal of medicine*. 07/28/2022 2022;387(4)doi:10.1056/NEJMoa2206125
36. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. *N Engl J Med*. Oct 17 2024;391(15):1379-1389. doi:10.1056/NEJMoa2405888
37. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med*. 2015;372(17):1598-1607. doi:10.1056/NEJMoa1408648 [doi]
38. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. *N Engl J Med*. 2016;374(25):2419-2429. doi:10.1056/NEJMoa1510093 [doi]
39. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. *Ann Oncol*. 2003;14(1):91-96. doi:10.1093/annonc/mdg020 [doi]

40. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet*. 2015;385(9976):1418-1427. doi:10.1016/S0140-6736(14)61469-0 [doi]
41. Luminari SF, A. Trotman, J. Molin, D. d'Amore, FA. Enblad, G. Berkahn, L. Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy | Blood | American Society of Hematology. *Blood*. 2022;140(Supplement 1):766-767. doi:10.1182/blood-2022-162780
42. Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood*. 2009;114(22):404.
43. Roach M, 3rd, Brophy N, Cox R, Varghese A, Hoppe RT. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. *J Clin Oncol*. 1990;8(4):623-629. doi:10.1200/JCO.1990.8.4.623 [doi]
44. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. *J Clin Oncol*. 1992;10(2):210-218. doi:10.1200/JCO.1992.10.2.210 [doi]
45. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet*. 1993;341(8852):1051-1054. doi:0140-6736(93)92411-L [pii]
46. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. *Blood*. 1997;89(3):814-822.
47. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 1998;21(1):1-7. doi:10.1038/sj.bmt.1701089 [doi]
48. Stahel RA, Jost LM, Pichert G, Widmer L. High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas. *Cancer Treat Rev*. 1995;21(1):3-32. doi:0305-7372(95)90009-8 [pii]
49. Marshall NA, DeVita VT, Jr. Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. *Semin Oncol*. 1999;26(1):67-73.
50. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. *Ann Oncol*. 1993;4(9):767-773. doi:10.1093/oxfordjournals.annonc.a058662 [doi]
51. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. *Blood*. 1993;81(5):1137-1145.
52. Stewart DA, Guo D, Sutherland JA, et al. Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy. *Ann Oncol*. 1997;8(12):1277-1279. doi:1008268027332 [doi]
53. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. *Bone Marrow Transplant*. 1997;20(1):21-26. doi:10.1038/sj.bmt.1700838 [doi]
54. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. *Ann Oncol*. 2003;14(12):1762-1767. doi:10.1093/annonc/mdg496 [doi]
55. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. *Bone Marrow Transplant*. 2003;31(8):667-678. doi:10.1038/sj.bmt.1703891 [doi]
56. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. *Ann Oncol*. 2002;13(9):1370-1377.
57. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*. 2012;30(18):2183-2189. doi:10.1200/JCO.2011.38.0410 [doi]

58. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. *Blood*. 2015;125(8):1236-1243. doi:10.1182/blood-2014-08-595801 [doi]
59. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood*. 2016;128(12):1562-1566. doi:10.1182/blood-2016-02-699850 [doi]
60. Brockelmann PJ, Zagadailov EA, Corman SL, et al. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. *Eur J Haematol*. 2017;99(6):553-558. doi:10.1111/ejh.12973 [doi]
61. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. May 9 2015;385(9980):1853-62. doi:10.1016/s0140-6736(15)60165-9
62. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*. Dec 20 2018;132(25):2639-2642. doi:10.1182/blood-2018-07-861641
63. Marouf A, Cottreau AS, Kanoun S, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. *Haematologica*. Jul 1 2022;107(7):1681-1686. doi:10.3324/haematol.2021.279564
64. Martínez C, de Haro ME, Romero S, et al. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. *Ann Hematol*. Feb 2023;102(2):429-437. doi:10.1007/s00277-022-05011-6
65. Martínez C, Khvedelidze I, Fekom M, et al. Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group. *Bone Marrow Transplant*. Jun 2025;60(6):879-887. doi:10.1038/s41409-025-02568-4
66. Falade A, Redd R, Shah H, et al. 624.HODGKIN LYMPHOMAS AND T/NK CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL. presented at: The 65th ASH Annual Meeting Abstracts; 2023;
67. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. *J Clin Oncol*. 2018;36(14):1428-1439. doi:10.1200/JCO.2017.76.0793 [doi]
68. McKay P, Fielding P, Gallop-Evans E, et al. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. *Br J Haematol*. 2016;172(1):32-43. doi:10.1111/bjh.13842 [doi]
69. Campo E, Jaffe E, Cook J, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood*. 09/15/2022 2022;140(11)doi:10.1182/blood.2022015851
70. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*. 2022 Jul 2022;36(7)doi:10.1038/s41375-022-01620-2
71. Binkley M, Rauf M, Milgrom S, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. *Blood*. 06/25/2020 2020;135(26)doi:10.1182/blood.2019003877

VI. Hematopoietic Cell Transplantation and Cell Therapy for Lymphoma

Eligibility for hematopoietic cell transplantation (HCT) for lymphoma

- Patients are generally considered eligible for autologous stem cell transplant (ASCT) or allogeneic HCT if they are less than approximately 75 years old and have controlled disease status (e.g. complete or partial response), a good performance status (e.g. ECOG 0 or 2), no serious uncontrolled infections, and adequate organ function. Note that these are general recommendations rather than absolute contraindications and that eligibility for HCT must be determined on an individual basis.
- To ensure engraftment, recipients of ASCT should have $>2 \times 10^6$ CD34+ cells/kg collected and recipients of allogeneic HCT should have $>3 \times 10^6$ CD34+ cells/kg collected

Eligibility for chimeric antigen receptor (CAR)-T cell therapy for lymphoma

- Axicabtagene autoleucel is approved as second-line therapy for diffuse large B-cell lymphoma (DLBCL) which is refractory or has relapsed within 12 months of completion of first-line therapy [Funding anticipated in 2024]
- Axicabtagene autoleucel, tisagenlecleucel, and soon lisocabtagene maraleucel are approved for relapsed or refractory DLBCL after 2 or more lines of systemic therapy
 - This includes most subtypes of DLBCL, including transformed indolent lymphoma and follicular large B-cell lymphoma (previously known as follicular lymphoma grade 3B)
 - Patients with Richter transformation arising from previously-treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are not currently eligible
 - Patients with rare subtypes of DLBCL which typically lack B-cell antigens should have demonstration of CD19 expression to be eligible for CD19-directed CAR-T
- Brexucabtagene autoleucel is approved for relapsed or refractory mantle cell lymphoma after 2 or more lines of systemic therapy including a BTK inhibitor
- Patient must also meet the following criteria:
 - Clinically stable and expected to remain so until the planned CAR-T cell infusion date with adequate organ function and performance status (ECOG 0-2)
 - No prior treatment with a CAR-T cell product targeting the same antigen
 - Patients with previous or active secondary CNS involvement are eligible for CAR-T but patients with active primary CNS lymphoma are not currently eligible

Allogeneic HCT conditioning for lymphoma

- Reduced intensity conditioning is recommended for older or less fit patients and for most patients who have heavily-pretreated lymphoma (e.g. relapse after ASCT or multiply-relapsed disease), intrinsically chemoresistant lymphomas (e.g. TP53-mutated mantle cell lymphoma or

cutaneous T-cell lymphomas), or indolent lymphomas with high susceptibility to the graft-versus-lymphoma effect (e.g. CLL/SLL or follicular lymphoma)

- Myeloablative conditioning may be considered for younger fit patients undergoing first-line allogeneic HCT consolidation for high-risk chemosensitive lymphoma (e.g. certain peripheral T-cell lymphomas)

ASCT conditioning for lymphoma

Aggressive NHL (DLBCL, PTCL)	(R) + Bu(13500uM.min) + Mel(140mg/m ²)
Indolent NHL (FL, MZL, LPL)	(R) + Mel(180mg/m ²) + TBI(5Gy x1)
Mantle cell lymphoma	(R) + Mel(180mg/m ²) + TBI(5Gy x1)
Hodgkin lymphoma	Gemcitabine 1500 mg/m ² + Melphalan 200 mg/m ²
Primary CNS lymphoma	(R) + Thiotepa(600mg/m ²) + Bu(13500 uM.min)
Secondary CNS lymphoma	(R) + Thiotepa(500mg/m ²) + Bu(13500uM.min) + Mel (100mg/m ²)

Diffuse large B-cell lymphoma

- Consolidative ASCT may be considered for high-risk patients with DLBCL responding to first-line therapy, such as those with (1) high IPI score 4-5 and partial metabolic response on interim PET or (2) high-grade B-cell lymphoma with MYC and BCL2 rearrangements with IPI score 2-5¹⁻⁵. This practice will require re-evaluation once second-line CAR-T cell therapy and novel first-line therapies are available.
- Once funded, second-line CAR-T cell therapy is recommended for eligible patients with DLBCL refractory to or relapsing within 12 months of completion of first-line chemoimmunotherapy⁶⁻⁹
- ASCT is recommended for eligible patients with chemosensitive relapse of DLBCL occurring >12 months after completion of first-line chemoimmunotherapy¹⁰. Examples of appropriate salvage regimens before ASCT include R-DICEP, R-GDP, R-DHAP, or R-ICE¹¹⁻¹⁵.
- Third-line CAR-T cell therapy is recommended for patients with relapsed/refractory DLBCL after >2 lines of therapy who have not previously received CAR-T cell therapy¹⁶⁻¹⁹.
- Allogeneic HCT is rarely performed for DLBCL but may be considered for fit, motivated patients who relapse after CAR-T cell therapy and achieve an adequate response to pre-transplant therapy^{20, 21}.

Central nervous system (CNS) lymphoma

- Thiotepa/busulfan-based ASCT is recommended for eligible patients with primary CNS lymphoma responding to HD-MTX and HDAC based induction (see Lymphoma guideline)²²⁻²⁷
- Thiotepa/busulfan/melphalan-based ASCT is recommended for eligible patients with chemosensitive secondary CNS lymphoma (SCNSL), with favorable outcomes observed among those with SCNSL at diagnosis or isolated CNS relapse (see Lymphoma guideline)^{28,}

29

- The prognosis of patients with early concurrent CNS and systemic relapse is poor and the optimal treatment is unclear, so these patients should be considered for ASCT or second-line CAR-T cell therapy once funded on a case-by-case basis ²⁸⁻³⁰. Patients with SCNSL undergoing CAR-T cell therapy should receive appropriate CNS-directed bridging therapy before infusion since outcomes appear poor if there is active CNS disease at the time of infusion ³⁰.
- Allogeneic HCT is not well established for CNS lymphoma ³¹.

Transformed lymphoma

- ASCT is recommended for patients with chemosensitive transformed DLBCL if they have previously received chemotherapy for indolent B-cell lymphoma ^{32, 33}
- Patients who develop transformed DLBCL within 12 months of receiving R-CHOP or R-CEOP for indolent lymphoma may be considered for second-line CAR-T cell therapy once funded ⁶⁻⁹. Otherwise, CAR-T cell therapy is recommended for patients with relapsed/refractory transformed lymphoma after >2 lines of therapy (e.g. 1 for indolent lymphoma and 1 for DLBCL) ^{16, 18, 19}
- Allogeneic HCT is rarely performed for transformed lymphoma but may be considered for fit, motivated patients who relapse after CAR-T cell therapy and achieve an adequate response to pre-transplant therapy ^{20, 21, 33}.

Burkitt lymphoma

- Relapsed Burkitt lymphoma has a poor prognosis but ASCT or rarely allogeneic HCT may be considered for patients with chemosensitive relapses ³⁴

Mantle cell lymphoma

- Consolidative ASCT is recommended for eligible patients responding to first-line cytarabine-containing chemotherapy ³⁵⁻⁴⁰
- Maintenance rituximab is recommended every 2 months for 3 years after ASCT ^{41, 42}
- CAR-T cell therapy is recommended for eligible patients with relapsed MCL after >2 lines of therapy including a BTK inhibitor ^{43, 44}
- Allogeneic HCT may be considered for fit, motivated patients who relapse after CAR-T cell therapy and achieve an adequate response to pre-transplant therapy ⁴⁵
- Patients with TP53-mutated mantle cell lymphoma have poor outcomes with chemotherapy and do not benefit from ASCT ⁴⁶. These patients should be prioritized for first-line allogeneic HCT or third-line CAR-T cell therapy on a case-by-case basis.

Follicular lymphoma

- Given the poor prognosis with standard chemotherapy, ASCT is recommended for eligible patients with chemosensitive relapse of follicular lymphoma occurring within 24 months of first-line treatment (POD24) ⁴⁷

- ASCT achieves durable remissions and is also a reasonable option for fit patients with first or second relapse of follicular lymphoma arising >24 months after first-line treatment ⁴⁸⁻⁵⁰
- Once funded, CAR-T cell therapy is recommended for eligible patients with relapsed/refractory follicular lymphoma after >2 lines of systemic therapy ^{51, 52}
- Allogeneic HCT is rarely performed for follicular lymphoma but may be considered for fit, motivated patients who have relapsed after, or are unable to receive, ASCT and/or CAR-T cell therapy and who achieve an adequate response to pre-transplant therapy ⁵³.

Other indolent B-cell lymphomas

- ASCT may be considered for selected patients with first or second chemosensitive relapse of MZL, LPL, or NLPBL, particularly for those with early relapses, aggressive clinical behavior, and in patients who prioritize the possibility of long-term disease control or who lack other treatment options ⁵⁴⁻⁵⁶
- Allogeneic HCT is seldomly performed for rare indolent B-cell lymphomas but may be considered for fit, motivated patients who lack other therapeutic options and have relapsed after, or are unable to receive, ASCT and achieve an adequate response to pre-transplant therapy ⁵⁷

Hodgkin lymphoma (HL)

- ASCT is recommended for eligible patients with relapsed/refractory HL who respond to second-line chemotherapy or immune checkpoint inhibitors (ICI) ⁵⁸⁻⁶²
- Maintenance brentuximab vedotin (BV) every 3 weeks for 16 cycles starting 4-6 weeks after ASCT is funded for patients with primary refractory HL, relapsed HL <12 months from the end of frontline therapy, or extranodal disease at relapse. The risks and benefits must be weighed given the lack of survival benefit and the risks of toxicity and potential overtreatment of patients already cured by ASCT. The benefit of maintenance BV may be more pronounced in patients with 2-3 risk factors or with a positive PET before ASCT ^{63, 64}.
- Allogeneic HCT is recommended for fit, motivated patients with HL who have exhausted other treatment options ⁶⁵. Eligible patients should be referred for discussion of allogeneic HCT when starting their second novel agent (i.e. ICI or BV). For patients with highly refractory disease or short duration of remissions, consider using the second novel agent to achieve a response as a bridge to allogeneic HCT. Other patients who achieve a complete response to the second novel agent may reasonably defer allotransplant to the next relapse provided that effective bridging therapy is expected to be available. A washout period of the ICI for 6-12 weeks before allogeneic HCT is recommended to reduce the risk of GVHD ^{65, 66}.

Peripheral T-cell lymphomas (PTCL) and natural killer-cell (NK) lymphomas

- Given the poor prognosis with standard chemotherapy, consolidative ASCT is recommended for eligible patients responding to first-line therapy with advanced stage or high IPI score PTCL NOS, angioimmunoblastic T-cell lymphoma, ALK-negative anaplastic large cell lymphoma

(ALCL), advanced-stage NK/T-cell lymphoma, or enteropathy-associated T-cell lymphoma⁶⁷⁻⁷³. Although ALK-positive ALCL usually has a favorable prognosis with BV-CHP, consolidative ASCT may be considered for selected cases with a high IPI score given their poorer outcomes with standard chemotherapy and the uncertain benefit of brentuximab vedotin in this high-risk subgroup⁷²⁻⁷⁵.

- First-line allogeneic HCT is recommended for eligible patients with certain poor prognosis lymphomas responding to first-line therapy, such as hepatosplenic T-cell lymphoma, acute or lymphoma-type adult T-cell leukemia/lymphoma, aggressive NK cell leukemia, and selected cases of advanced-stage NK/T-cell lymphoma^{71, 73}
- ASCT is recommended for patients with relapsed PTCL who have not previously received ASCT and who demonstrate a good response to second-line chemotherapy (e.g. DICEP or GDP)^{76, 77}
- Allogeneic HCT is also recommended for patients with PTCL who relapse after ASCT or who are unable to receive ASCT due to chemorefractory disease, provided that an adequate response to pre-transplant therapy is achieved⁷⁸

Cutaneous T-cell lymphomas (CTCL)

- ASCT is not routinely recommended for patients with mycoses fungoides or Sezary syndrome (MF/SS) but allogeneic HCT may be considered for selected high-risk cases^{79, 80}

References

1. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. *N Engl J Med*. Oct 2013;369(18):1681-90.
2. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. *J Clin Oncol*. Jul 10 2017;35(20):2260-2267.
3. Puckrin R, Sterrett R, Chua N, Owen C, Duggan P, Shafey M, et al. Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell Lymphoma. *Transplant Cell Ther*. Dec 2023;29(12):763.e1-763.e5.
4. Puckrin R, Sterrett R, Shafey M, Chua N, Stewart D. Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma. *Transplant Cell Ther*. Nov 2022;28(11):762.e1-762.e4.
5. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. *Blood*. Jun 15 2006;107(12):4623-7.
6. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med*. Dec 11 2021;
7. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. *N Engl J Med*. Jun 05 2023;
8. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*. 06 18 2022;399(10343):2294-2308.
9. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. *Blood*. Apr 06 2023;141(14):1675-1684.
10. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med*. Dec 07 1995;333(23):1540-5.

11. Stewart D, Shepherd L, Dudebout J, Larouche J, Chua N, Baetz T, et al. Canadian Cancer Trials Group (CCTG) LY. 17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL)-Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP. . *Blood*. 2022;140(Supplement 1)::3734-6.
12. Vijay A, Duan Q, Henning JW, Duggan P, Daly A, Shafey M, et al. High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. Dec 2013;54(12):2620-6.
13. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol*. Nov 01 2014;32(31):3490-6.
14. van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeschna KM, Kuliczowski K, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. *J Clin Oncol*. Feb 10 2017;35(5):544-551.
15. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. Sep 20 2010;28(27):4184-90.
16. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 12 28 2017;377(26):2531-2544.
17. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood*. May 11 2023;141(19):2307-2315.
18. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 01 03 2019;380(1):45-56.
19. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*. 09 19 2020;396(10254):839-852.
20. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. *Haematologica*. Jan 01 2023;108(1):98-109.
21. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, et al. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. *Blood Adv*. Jan 25 2022;6(2):486-494.
22. Illerhaus G, Ferreri AJ, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, et al. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma-Results of an International Randomized Phase III Trial (MATRix/IELSG43). *Blood*. 2022;140 (Supplement 2), pp.LBA-3.
23. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*. Nov 2017;4(11):e510-e523.
24. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotoxicity of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. *Leukemia*. Jul 2022;36(7):1870-1878.
25. Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. *J Clin Oncol*. 04 01 2019;37(10):823-833.
26. Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. *J Clin Oncol*. Nov 10 2022;40(32):3692-3698.
27. Sanders S, Chua N, Larouche JF, Owen C, Shafey M, Stewart DA. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. *Biol Blood Marrow Transplant*. 08 2019;25(8):1505-1510.
28. Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. *Lancet Haematol*. Feb 2021;8(2):e110-e121.

29. Puckrin R, Chua N, Shafey M, Stewart DA. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. *Leuk Lymphoma*. Oct 2022;63(10):2444-2452.
30. Ahmed G, Alsouqi A, Szabo A, Rojek AE, Riedell PA, Awan FT, et al. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis. *Blood*. 2023;142:3088.
31. Sterling CH, Tsai HL, Holdhoff M, Bolaños-Meade J, Luznik L, Fuchs EJ, et al. Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. *Transplant Cell Ther*. 10 2021;27(10):863.e1-863.e5.
32. Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. *Blood*. Aug 06 2015;126(6):733-8.
33. Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. *J Clin Oncol*. Mar 20 2013;31(9):1164-71.
34. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. Feb 2013;19(2):173-9.
35. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. *Blood*. Apr 01 2005;105(7):2677-84.
36. Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. *Lancet Haematol*. Sep 2021;8(9):e648-e657.
37. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet*. Aug 06 2016;388(10044):565-75.
38. Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. *J Clin Oncol*. Jan 20 2023;41(3):479-484.
39. Merryman RW, Edwin N, Redd R, Bsai J, Chase M, LaCasce A, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. *Blood Adv*. Mar 10 2020;4(5):858-867.
40. Stewart C, Owen C, Chua N, Peters A, Shafey M, Stewart DA, et al. Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. *Blood*. 2023;142:3599.
41. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. *N Engl J Med*. Sep 28 2017;377(13):1250-1260.
42. Sarkozy C, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Damaj G, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. *J Clin Oncol*. Mar 01 2024;42(7):769-773.
43. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. Apr 02 2020;382(14):1331-1342.
44. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. *J Clin Oncol*. Jun 04 2022;JCO2102370.
45. Robinson SP, Boumendi A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. *Bone Marrow Transplant*. May 2018;53(5):617-624.
46. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. *Blood*. Oct 26 2017;130(17):1903-1910.

47. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*. 06 2018;24(6):1163-1171.
48. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. *J Clin Oncol*. Nov 01 2003;21(21):3918-27.
49. Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, et al. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. *Biol Blood Marrow Transplant*. May 2016;22(5):941-8.
50. Puckrin R, Chua N, Chin K, Peters A, Duggan P, Shafey M, et al. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma. *Br J Haematol*. Apr 2023;201(2):319-325.
51. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*. 01 2022;23(1):91-103.
52. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*. 02 2022;28(2):325-332.
53. Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†. *Ann Oncol*. Jun 01 2016;27(6):1088-1094.
54. Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, et al. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. *Br J Haematol*. Sep 2018;182(6):807-815.
55. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. May 01 2010;28(13):2227-32.
56. Akhtar S, Montoto S, Boumendil A, Finel H, Masszi T, Jindra P, et al. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. *Am J Hematol*. Jan 2018;93(1):40-46.
57. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, et al. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. *Biol Blood Marrow Transplant*. Jan 2017;23(1):60-66.
58. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet*. Apr 24 1993;341(8852):1051-4.
59. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*. Jun 15 2002;359(9323):2065-71.
60. Shafey M, Duan Q, Russell J, Duggan P, Balogh A, Stewart DA. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. *Leuk Lymphoma*. Apr 2012;53(4):596-602.
61. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. *Blood Adv*. Mar 23 2021;5(6):1648-1659.
62. Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood*. Jun 23 2022;139(25):3605-3616.
63. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. May 09 2015;385(9980):1853-62.
64. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*. Dec 20 2018;132(25):2639-2642.

65. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. *Leukemia*. Sep 2021;35(9):2672-2683.
66. Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. *Blood*. Jul 05 2018;132(1):9-16.
67. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. *J Clin Oncol*. Sep 01 2012;30(25):3093-9.
68. Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. *Blood Adv*. Oct 11 2022;6(19):5550-5555.
69. Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. *Blood*. May 13 2021;137(19):2646-2656.
70. Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. *Blood*. Sep 01 2022;140(9):1009-1019.
71. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Nov 2017;23(11):1826-1838.
72. Vose J, Armitage J, Weisenburger D, Project IT-CL. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol*. Sep 01 2008;26(25):4124-30.
73. Fox CP, Ahearne MJ, Pettengell R, Dearden C, El-Sharkawi D, Kassam S, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. *Br J Haematol*. Feb 2022;196(3):507-522.
74. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet*. Jan 19 2019;393(10168):229-240.
75. Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. *Ann Oncol*. Mar 2022;33(3):288-298.
76. Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. *Leuk Lymphoma*. Oct 2017;58(10):2319-2327.
77. Ngu HS, Parkin S, Scott DW, Villa D, Gerrie AS, Toze CL, et al. Outcome of relapsed and refractory peripheral T-cell lymphoma (PTCL) with intention for curative therapy incorporating high dose chemotherapy and hematopoietic stem cell transplant (HDC/SCT). *Blood*. 2021;138(624)
78. Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. *Blood Adv*. Feb 08 2022;6(3):920-930.
79. de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. *Lancet*. Jun 10 2023;401(10392):1941-1950.
80. Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. Jun 2021;56(6):1391-1401.

VII. Prevention and Management of Toxicities of Bispecific Antibodies in Lymphoma

Overview

Epcoritamab and glofitamab are bispecific antibodies targeting CD20xCD3 which are currently approved for patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) after ≥ 2 lines of therapy who have already received or are unable to receive CAR-T cell therapy. Bispecific antibodies produce complete responses in approximately 40% of patients with median time to response of 6 weeks^{1,2,1}. Response assessment is therefore recommended 6-8 weeks after C1D1 of epcoritamab or glofitamab. Although some delayed responses have been observed as late as 8-10 months after treatment initiation, these are unlikely to occur in patients with progressive disease at the time of first response assessment.

Bispecific antibodies result in cytokine release syndrome (CRS) in 50-60% of patients with LBCL. Severity of CRS should be determined using the ASTCT grading criteria (Tables 1 and 2)³. Most cases of CRS are grade 1 but 12-17% of patients develop grade 2 CRS and 3-4% develop grade ≥ 3 CRS. The highest risk period for CRS is after the C1D15 dose of epcoritamab or the C1D8 dose of glofitamab (Figure 1). Median time to CRS onset is 2 days after the most recent dose of epcoritamab or 20 hours after the first full dose of epcoritamab, and 13.5 hours after the C1D8 dose of glofitamab. CRS resolves within a median of 30-48 hours, although 20-30% of patients require treatment with tocilizumab and/or corticosteroids. In contrast to CRS, immune-effector cell-associated neurotoxicity syndrome (ICANS) is relatively rare with bispecific antibodies, occurring in 6-8% of patients. Neurotoxicity is usually low-grade and often consists of headaches or dizziness. Onset of ICANS is at median 16 days and median time to resolution is 5 days after epcoritamab. Prevention and treatment of CRS, ICANS, and other toxicities are summarized in tables 3-5⁴.

Risk factors for CRS include high tumor burden (e.g. increased metabolic tumor volume, elevated LDH, advanced stage), peripheral blood or bone marrow involvement, older age, and comorbidities. Patients with early-onset CRS and those with CRS during the first ramp-up doses may be at increased risk of subsequent CRS or more severe CRS. All patients are required to remain within proximity of the treatment facility (where a supply of tocilizumab and ICU access must be available) for CRS and ICANS monitoring for 24 hours after the C1D15 dose of epcoritamab and for 10 hours following the 4-hour infusion of glofitamab on C1D8.

Patients should have a caregiver present and be aware to seek medical attention immediately if they develop features of CRS or ICANS. Patients should have a thermometer at home to monitor temperature 3 times per day for 48 hours after each step-up dose. Home blood pressure and oxygen monitoring equipment is not mandated but may be useful if available. Alternatively, hospitalization for 1-2 days after the highest risk doses may be considered for patients at increased risk of CRS or those who are unable to reliably self-monitor as an outpatient. All patients should have a supply of acetaminophen and dexamethasone tablets on hand in case of delays to treatment of CRS as an outpatient.

Table 1: ASTCT cytokine release syndrome grading criteria

	Grade 1	Grade 2	Grade 3	Grade 4
Fever*	Yes, $\geq 38^{\circ}$	Yes, $\geq 38^{\circ}$	Yes, $\geq 38^{\circ}$	Yes, $\geq 38^{\circ}$
		with		
Hypotension	None	Not requiring vasopressors	Requiring a vasopressor with or without vasopressin	Requiring multiple vasopressors (excluding vasopressin)
		with		
Hypoxia**	None	Requiring low-flow nasal cannula (≤ 6 LPM) or blow-by	Requiring high-flow nasal cannula (> 6 LPM), facemask, non-rebreather, or Venturi mask	Requiring positive pressure (CPAP, BiPAP, intubation and mechanical ventilation)

* Fever is defined as temperature ≥ 38 degrees not attributable to other cause. In patients who have CRS then receive antipyretic or anticytokine therapy, fever is no longer required to grade CRS. In this case CRS grading is driven by hypotension and/or hypoxia.

** Hypoxia should not be explained by other causes i.e. rigors or sedation in order to meet the definition of hypoxia in CRS

Table 2: ASTCT Immune Effector Cell-Associated Encephalopathy (ICE) tool and ICANS grading criteria

Symptom or sign	Grade 1	Grade 2	Grade 3	Grade 4
ICE score	7-9 (mild)	3-6 (moderate)	0-2 (severe)	Unable to perform
Level of Consciousness	Awakens spontaneously	Awakens to voice	Awakens to touch	Unarousable or requires vigorous or repeated stimuli to arouse. Stupor or coma
Seizure	NA	NA	Any clinical seizure focal or generalized that resolves rapidly or non-convulsive seizure that resolves with intervention	Life-threatening or prolonged seizure (> 5 minutes) or repetitive clinical or electrical seizures without return to baseline between
Motor Findings	NA	NA	NA	Deep focal motor weakness such as hemiparesis or paraparesis
Elevated ICP/Cerebral edema	NA	NA	Focal/local edema on neuroimaging	Diffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or CN VI palsy; or papilledema or Cushing's

ICE tool:

- Orientation to
 - Year – 1 point
 - Month – 1 point
 - City – 1 point
 - Hospital – 1 point
- Naming 3 objects – up to 3 points
- Following Commands (eg, Show me two fingers) – 1 point
- Writing a short sentence – 1 point
- Attention: Count backwards from 100 by ten – 1 point

Figure 1: Onset of CRS with epcoritamab (left) and glofitamab (right) in LBCL




Table 3: Prevention and treatment of cytokine release syndrome

Grade	Recommendations for cytokine release syndrome
Prophylaxis	- Follow recommendations in product monograph - Ensure sufficient oral or IV hydration - Epcoritamab: - Dexamethasone 16mg for 4 consecutive days starting on C1D1, C1D8, C1D15, and C1D22 - Patients who develop grade ≥ 2 CRS should continue to receive dexamethasone prophylaxis into cycle 2 and beyond until epcoritamab is given without grade ≥ 2 CRS - Acetaminophen/antihistamine before first 4 doses - Glofitamab - Obinutuzumab 1,000mg on C1D1 - Dexamethasone 20mg on C1D8, C1D15, C2D1, C3D1 - Patients who develop CRS should continue to receive dexamethasone prophylaxis with subsequent cycles until they tolerate treatment without CRS - Acetaminophen/antihistamine before all doses - Ensure outpatients have supply of acetaminophen and dexamethasone tablets on hand in case of delays to treatment of CRS - Consider holding antihypertensives for 24 hours before high-risk doses - Patients who miss treatment doses should undergo re-priming according to the product monograph
Supportive care	- Treat CRS with anti-pyretics, supplemental oxygen, IV fluids as needed - Evaluate for and treat suspected infections with broad-spectrum antibiotics - Early use of vasopressors recommended if hypotension persists after $>2L$ of IV fluids

Grade	Recommendations for cytokine release syndrome
Grade 1	▪ Supportive care and anti-pyretics (e.g. acetaminophen) are usually sufficient ▪ Hold treatment until symptoms resolve ▪ Outpatients with grade 1 CRS should be directed to clinic or ER for evaluation on case-by-case basis ▪ Consider dexamethasone 8mg PO for outpatients, particularly if fever persists 6-8 hours after antipyretic ▪ Consider tocilizumab 8mg/kg (max 800mg) IV and/or dexamethasone 10mg IV if fever lasts >48-72 hours, especially if early onset CRS, comorbidities, or high risk for severe CRS
Grade 2	▪ Hold treatment until symptoms resolve ▪ Most patients will require inpatient evaluation and management ▪ Anti-pyretics, supplemental oxygen, IV fluids as needed ▪ Administer dexamethasone 10mg IV q6-12h ▪ Recommend tocilizumab 8mg/kg IV (max 800mg) especially if high risk for severe CRS, persistent CRS for 4-6 hours after dexamethasone, or if CRS develops during steroid prophylaxis → repeat q8h as needed up to 2 times per CRS event or 3 times in a 6-week period ▪ Consider alternative cytokine therapy (e.g. anakinra) for persistent CRS despite tocilizumab and dexamethasone
Grade 3-4 CRS	▪ Hold treatment until symptoms resolve ▪ Consider permanently discontinuing treatment for grade 4 CRS ▪ Transfer patient to ER or ICU for vasopressors and respiratory support ▪ Tocilizumab 8mg/kg (max 800mg) IV q8h as needed up to 2 times per CRS event or 3 times in a 6-week period ▪ Dexamethasone 10-20mg IV q6h → methylprednisolone 1g daily if refractory ▪ Consider alternative cytokine therapy (e.g. anakinra, siltuximab) for persistent CRS despite tocilizumab and dexamethasone ▪ Continue aggressive treatment until grade 1 CRS and then taper steroids off

Table 4: Prevention and treatment of neurotoxicity

Grade	Recommendations for ICANS
Supportive care	▪ Consider MRI brain to rule out cerebral edema ▪ Consider diagnostic lumbar puncture if severe, atypical, or refractory ICANS ▪ Consider anti-seizure prophylaxis (e.g. levetiracetam) for patients with active ICANS
Grade 1	▪ Hold treatment until symptoms resolve ▪ Consider dexamethasone 10mg IV → re-assess in 6 hours ▪ Tocilizumab only if concurrent CRS

Grade	Recommendations for ICANS
Grade 2	▪ Hold treatment until symptoms resolve ▪ Dexamethasone 10-20mg IV q6-12h ▪ Tocilizumab only if concurrent CRS
Grade 3	▪ Hold treatment until symptoms resolve ▪ Dexamethasone 10-20mg IV q6h → methylprednisolone 1g daily if refractory ▪ Tocilizumab only if concurrent CRS
Grade 4	▪ Hold treatment until symptoms resolve and consider permanently discontinuing treatment ▪ Dexamethasone 10-20mg q6h → methylprednisolone 1g daily if refractory ▪ Tocilizumab only if concurrent CRS ▪ Consider anakinra (preferred), intrathecal chemotherapy, siltuximab, ruxolitinib, etc. if refractory

Table 5: Prevention and treatment of other bispecific antibody toxicities

Grade	Recommendations
HLH/MAS	▪ Consider diagnostic evaluation for HLH/MAS for patients with late-onset or persistent CRS (e.g. >1 week) with associated organ dysfunction ▪ Consider treatment with tocilizumab, anakinra, and corticosteroids, and for life-threatening/refractory cases consider etoposide, ruxolitinib, emapalumab, etc.
Infections	▪ Recommend valacyclovir 500mg daily as HSV/VZV prophylaxis for all patients ▪ Recommend PJP prophylaxis, especially during periods of high steroid exposure (e.g. dose ramp-up) and for those with other risk factors for PJP ▪ Recommend HBV prophylaxis for at-risk patients ▪ Consider IVIg replacement for patients with recurrent and/or severe infections due to hypogammaglobulinemia
Neutropenia	▪ Neutropenia may be late onset and usually responds to G-CSF ▪ Temporary dose hold may be required in some cases but must be balanced with patient's disease control
Tumor flare	▪ Exercise caution for patients with bulky masses near the airway or other vital organs as tumor flare may occur during the first 1-2 cycles ▪ Severe cases can be managed by holding the bispecific antibody and administering corticosteroids +/- tracheostomy
Tumor lysis syndrome	▪ Recommend allopurinol prophylaxis and TLS monitoring in high-risk patients during the first 1-2 cycles

References

1. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Dec 15 2022;387(24):2220-2231.
2. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. *J Clin Oncol*. Apr 20 2023;41(12):2238-2247.
3. Lee DW, Santomaso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. Apr 2019;25(4):625-638.
4. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, et al. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. *Blood*. Jan 22 2024;

VIII. Supportive Care in the Treatment of Lymphoma

Allopurinol

300mg/d x10-14 days starting 1-3 days prior to cycle 1 chemotherapy for Burkitt or Lymphoblastic lymphoma. This should also be considered for rapidly progressive aggressive bulky lymphomas and in patients with impaired renal function.

Pre-Phase Therapy for DLBCL Patients >60 years of Age

Prednisone 100mg/d x 3-7 days prior to cycle 1 R-CHOP or R-CEOP.

Statin prophylaxis for prevention of anthracycline cardiotoxicity

Atorvastatin 40mg daily x 12 months is recommended for patients receiving an anthracycline who are >50 years old or have other cardiac risk factors¹

Neutropenia Prevention²⁻⁶

Primary or secondary prophylaxis to decrease the risk of febrile neutropenia and maintain chemotherapy dose intensity is indicated when treating with curative intent (e.g. preventing treatment delay/dose reduction). The recommendation for R-CHOP, CODOX-M/IVAC, HyperCVAD, or intensive salvage therapy regimens, with or without rituximab (e.g. DHAP, ICE, GDP, MICE, DICEP), in patients with aggressive Hodgkin or non-Hodgkin lymphoma older than 60 years of age, or poor prognostic factors (high IPI or IPS) is G-CSF 300µg subcutaneous on days 8 and 12 of a 14- or 21-day chemotherapy regimen².

For primary prophylaxis of febrile neutropenic infection for similar indications above or co-morbidities that increase risk of infectious complications such as chronic obstructive pulmonary disease, or secondary prevention after a prior episode of febrile neutropenia:

- G-CSF 300 or 480µg/day starting 3 days after chemotherapy completed until post-nadir ANC>1.0 (usually 7-10 days) (though most patients require only 2-5 days of G-CSF support)
- Must monitor CBC
- The alternative is one dose of pegfilgrastim (Neulasta) 6mg on day 4 (without CBC monitoring, but at a cost of ~\$2500/dose)

Erythropoietin

Erythropoietin is not recommended because of evidence suggesting increased mortality rates. Consider only for symptomatic anemia patients who cannot receive RBC transfusions (i.e., Jehovah's Witnesses, prior severe transfusion reactions or severe iron overload).

Antimicrobial Prophylaxis for Immunosuppressive Regimens⁷⁻⁹

- For patients receiving fludarabine, high dose cyclophosphamide, >5 days high dose corticosteroids every 21 days, bortezomib, and bendamustine, and for immune-compromised patients (i.e., HIV, post-organ transplant or autoimmune disease patients who develop hematologic cancers) use prophylaxis during and for 12 months post-treatment. CD4 count monitoring can be used to help determine if prophylaxis can be stopped earlier (should not be assessed until 3 or 6 months post-treatment). Patients with CD4 count > 200 / μL may have earlier discontinuation of antimicrobial prophylaxis.
- *Pneumocystis jiroveci* pneumonia (PCP) prophylaxis:
 - choice 1: Septra 1 regular strength tab daily
 - choice 2: dapsone 100mg every Monday/Wednesday/Friday (or 50 mg daily)
 - choice 3: pentamidine 300mg inhalation monthly
 - choice 4: atovaquone 1500 mg daily
- Shingles prophylaxis: valacyclovir 500mg daily

Immunizations

Patients should be encouraged to keep all immunizations up to date. The reactivation and/or seroreversion of viruses that patients have been previously vaccinated against, such as hepatitis B, is a major cause of morbidity and mortality in patients with hematologic malignancies treated with cytotoxic chemotherapy. Appendix G outlines the general principles and specific immunization schedules for recipients of blood and marrow transplantations. In addition, separate guidelines outlining influenza and pneumococcal immunization recommendations for all patients with cancer can be found at: www.albertahealthservices.ca/cancerguidelines.asp under the “Supportive Care” heading”

Recombinant adjuvant herpes zoster vaccine is commercially available however cancer patients were excluded in the pivotal phase 3 trials (ZOE-50 and ZOE-70). Studies with use in cancer patients are not yet published, but results suggest that vaccination responses are better for patients not on treatment or given prior to chemotherapy, as opposed to during chemotherapy¹⁰. Other hematological malignancy patients had better vaccine responses than Non Hodgkin's Lymphoma and CLL patients for reasons not yet identified¹¹. The AHS Hematology group consensus is that the recombinant adjuvant herpes zoster vaccine is not contraindicated in hematology patients. Patients may receive the vaccine if they have adequate immune function to mount a response, and are 6-9 months post Rituximab due to the reduced vaccine responses seen in rituximab-treated patients.

Family members and health care providers in contact with patients who have undergone a transplant should also be strongly encouraged to keep all immunizations up to date.

For patients who have experienced reactivation or seroreversion of hepatitis B virus, prompt administration of nucleoside/nucleotide analogues is essential¹². Entacavir or tenofovir following R-CVP or R-CHOP chemotherapy for lymphoma is recommended for all patients who have a positive hepatitis B surface antigen test.

References

1. Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. *Jama*. Aug 8 2023;330(6):528-536.
2. Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2005;23(28):6908-6918.
3. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. *Curr Med Res Opin*. 2007;23(9):2283-2295.
4. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25(21):3158-3167.
5. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. *Ann Intern Med*. 2007;147(6):400-411.
6. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. *The Cochrane database of systematic reviews*. 2008;(4):CD003189. doi(4):CD003189.
7. Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against *Pneumocystis jirovecii* pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review. *Transplant infectious disease : an official journal of the Transplantation Society*. 2017;19(2):10.1111/tid.12651. Epub 2017 Feb 15.
8. Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of *Pneumocystis jirovecii* pneumonia in patients with haematological and solid malignancies, 2014. *Intern Med J*. 2014;44(12b):1350-1363.
9. Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious Diseases Working P, et al. Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii* pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol*. 2013;92(4):433-442.
10. Vink P. Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical ID Week. Abstract 1349. <https://idsa.confex.com/idsa/2017/webprogram/Paper62593.html>
11. Oostvogels L. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial. IDWeek. Abstract 1344. <https://idsa.confex.com/idsa/2017/webprogram/Paper66049.html>
12. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. *Infection*. 2010;38(1):58-61.

IX. Follow-Up Care in the Treatment of Lymphoma¹⁻¹¹

The following late effects should be considered when patients are reviewed during follow-up:

- **Relapse.** Careful attention should be directed to lymph node sites. Routine surveillance CT scans are not indicated. Most relapses have been demonstrated to occur between scheduled clinics visits and tests, and are detected by patients themselves. Highly anxious patients who wish surveillance tests could be considered for occasional CXR and abdominal/pelvic ultrasounds (if thin), especially in the setting of indolent lymphoma and prior retroperitoneal and mesenteric disease.
- **Dental caries.** Neck or oropharyngeal irradiation may cause decreased salivation. Patients should have careful dental care follow-up and should make their dentist aware of the previous irradiation.
- **Hypothyroidism.** After external beam thyroid irradiation to doses sufficient to cure malignant lymphoma, at least 50% of patients will eventually develop hypothyroidism. All patients whose TSH level becomes elevated should be treated with life-long T4 replacement in doses sufficient to suppress TSH levels to low normal.
- **Infertility.** Multi-agent chemotherapy and direct or scatter radiation to gonadal tissue may cause infertility, amenorrhea, or premature menopause. However, with current chemotherapy regimens and radiation fields used, most patients will not develop these problems. All patients should be advised that they may or may not be fertile after treatment. In general, women who continue menstruating are fertile, but men require semen analysis to provide a specific answer.
- **Secondary neoplasms.** Although quite uncommon, certain neoplasms occur with increased frequency in patients who have been treated for lymphoma. These include AML, thyroid, breast, lung, and upper GI carcinoma, melanoma and cervical carcinoma *in situ*. It is appropriate to screen for these neoplasms by careful history, physical examination, mammography and Pap smears for the rest of the patient's life because they may have a lengthy induction period. Patients should be counseled about the hazards of smoking and excessive sun exposure, and should be encouraged to perform careful breast and skin examinations on a regular basis.

Table 1 outlines the minimum follow-up tests and examinations that should be performed on all patients after treatment for malignant lymphoma. Visits should be scheduled every 3-4 months for 2 years, then every 6 months up to 3 years, then annually.

Table 1. Minimum follow-up tests and examinations for patients with malignant lymphoma

Interval	Test
Every Visit	• Examination of lymph nodes, thyroid, lungs, abdomen, and skin • CBC & differential, LDH (consider ESR AlkP for Hodgkin disease) • Consider CXR during first 3 years for patients who previously had intrathoracic disease
Annually	• TSH (if thyroid was irradiated) • Mammogram for women after age 40 if irradiated (otherwise age 50) • Pap smear • Influenza immunization
Routine Body CT Scanning	• After 3 months of therapy and if abnormal, again after completion of all therapy • If a residual mass is seen on the CT after completion of all therapy, then consider a surveillance scan 6 months later. Otherwise, no further routine CT scans are required. PET scans are not performed for surveillance and are indicated only for staging and response assessment.

Data from large studies of patients with DLBCL treated on clinical trials confirm that Event Free Survival (EFS) at 24 months (lack of relapse or death 24 months after diagnosis) is representative of overall EFS because the majority of relapses occur within 12-24 months of diagnosis (ie. within 1 year of completing chemotherapy)¹². Thus, patients who are disease free 24 months from their diagnosis of aggressive lymphoma have a low risk of recurrence and should have their surveillance follow-ups transitioned back to their primary care physician. Late relapses are more frequent with indolent NHL but early diagnosis of relapsed iNHL is not associated with improved survival such that these patients are also appropriate to have surveillance under primary care. Transition of patients with indolent NHL should occur 12-18 months after completion of therapy for those who remain without evidence of active lymphoma. Detailed discharge and surveillance recommendations should be provided to the primary care team.

References

1. Maloney DG AF. *Lymphoma*. Cancer Patient Follow-Up. 1997:462-498.
2. Brigden M. Evidence-based follow-up testing of treated cancer patients – What does the literature support? . *Ann R Coll Physicians Surg Can*. 1999;32:281-90.
3. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(23):4386-4394.
4. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(18):3431-3439.
5. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(18):3440-3446.
6. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(5):897-906.
7. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2002;20(8):2101-2108.
8. Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2001;19(9):2472-2481.
9. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA*. 2003;290(4):465-475.
10. Deniz K, O'Mahony S, Ross G, Purushotham A. Breast cancer in women after treatment for Hodgkin's disease. *The Lancet Oncology*. 2003;4(4):207-214.
11. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2002;13 Suppl 1:138-147.
12. Maurer M, Ghesquières H, Jais J, Witzig T, Haioun C, Thompson C, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 04/01/2014 2014;32(10)

Appendix A. Information regarding Rituximab 375mg/m² IV or 1400mg SC for B-cell lymphoma treatment

- Indications:
 - All CD 20+ B cell lymphomas (indolent and aggressive)
 - PTLD and MCL
 - Monotherapy or with chemo
 - Maintenance q2m (MCL) and q3m (indolent and FL)
 - Stem cell mobilization and high dose conditioning regimens for ASCT.
- Not indicated:
 - Not CLL (Health Canada)
 - not for Ritux treatment of autoimmune cytopenias due to CLL or indolent lymphoma (hematoma risk)
- Timing of sc Rituximab relative to IV:
 - all first exposure to rituximab must be IV
 - before commencing SC the patient must have *completed* a full rituximab IV infusion dose, regardless if the patient had an infusion reaction or the grade of the reaction. (patient does not have to have 0 reaction to IV). If the patient did not complete* the full IV dose, the next rituximab dose must be by IV infusion. (Roche)x
- Pts may start with SC if:
 - going on to maintenance treatment and had SC prior
 - going on to mobilization, high dose chemo and had SC prior
 - undergoing re-treatment (even > 6 months) may start with SC if they had SC prior

I. Initial Therapy For Diffuse Large B-Cell Lymphoma

R-CHOP (standard risk):

- Rituximab 375mg/m² IV day 1 (premedications: Tylenol, Benadryl, Zantac, hydrocortisone 100mg), then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated well.
- Cyclophosphamide 750 mg/m² IV
- Adriamycin 50 mg/m² IV day 1
- Vincristine 2mg IV day 1
- Prednisone 100mg/day p.o. days 1-5
- *Cycles:* every 21 days

R-CHOEP (high risk, age <60 years)¹⁻³:

- Rituximab 375mg/m² IV day 1 (premedications: Tylenol, Benadryl, Zantac, hydrocortisone 100mg) then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated well.
- Cyclophosphamide 750 mg/m² IV

- Adriamycin 50 mg/m² IV day 1
- Vincristine 2mg IV day 1
- Etoposide 100mg/m² IV days 1-3 (or 200mg/m² p.o. days 2-3 instead of IV; round down to nearest 50mg multiple)
- Prednisone 100mg/day p.o. days 1-5
- G-CSF days 7-11 or neulasta day 4 of each cycle
- *Cycles:* every 14-21 days

R-CEOP (cardiac disease with LVEF <50%)¹⁻³:

- Rituximab 375mg/m² IV day 1 (premedications: Tylenol, Benadryl, Zantac, hydrocortisone 100mg) then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated well.
- Cyclophosphamide 750 mg/m² IV
- Vincristine 2mg IV day 1
- Etoposide 50mg/m² IV days 1-3 (or 100mg/m² p.o. days 2-3 instead of IV; round up to nearest 50mg multiple)
- Prednisone 100mg/day p.o. days 1-5
- *Cycles:* every 21 days

R-MACOP-B (not recommended unless patient needs to complete therapy in 3 months):

- Methotrexate 400mg/m² IV on weeks 2, 6, 10 (24 hours later: folinic acid 15mg q6 hours x 6 doses)
- Adriamycin 50 mg/m² IV weeks 1,3,5,7,9,11
- Cyclophosphamide 350 mg/m² IV weeks 1,3,5,7,9,11
- Vincristine 2mg IV weeks 2,4,6,8,10,12
- Bleomycin 10mg/m² weeks 4,8,12
- Prednisone 75mg/day p.o. daily, taper over last 15 days
- Septra for PCP prophylaxis
- Suggest adding rituximab 375mg/m² IV q14 days x 6 doses then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated well.

DA-EPOCH-R:

Prednisone is a tablet taken by mouth TWICE daily on Days 1, 2, 3, 4, 5 Rituximab is an intravenous (I.V.) infusion on Day 1 (time of infusion varies) Doxorubicin is an I.V. infusion given over 24 hours on Days 1, 2, 3, 4 Etoposide is an I.V. infusion given over 24 hours on Days 1, 2, 3, 4 Vincristine is an I.V. infusion given over 24 hours on Days 1, 2, 3, 4 Cyclophosphamide is an I.V. infusion given over two hours on Day 5 On Day 6, filgrastim (Neupogen®) is started subcutaneously once daily and continued every day until the white blood cell count returns to normal. Alternatively, some Doctors prefer to give one dose of pegfilgrastim (Neulasta®) after each cycle of dose-adjusted EPOCH-R Patients then have labs drawn twice weekly until the white blood cell count has recovered. Typically, etoposide, doxorubicin, and vincristine are mixed together in one intravenous infusion bag and each bag is infused over 24 hours on Days 1, 2, 3, and 4 of each cycle (96 hours total).

Day 1-4	Doxorubicin Vincristine	10 mg/m²/day 0.4mg/m²/day (no cap)	Intravenous infusion in an elastomeric infusor in sodium chloride 0.9% via a central line over 96 hours
Day 1-4	Etoposide	50 mg/m²/day	Intravenous infusion in 500ml sodium chloride 0.9% over 24 hours via a central line
Day 5	Ondansetron Cyclophosphamide	8mg 750mg/m²	Oral as a single dose prior to chemotherapy Intravenous bolus
Day 6	GCSF (Biosimilar)	300 micrograms	Subcutaneous injection once daily until neutrophil recovery (supply 7 doses)

Dose Adjustments according to nadir:

Doxorubicin, Etoposide and Cyclophosphamide ONLY.

Doses may be adjusted from Cycle 2 based on the previous cycle's neutrophil (ANC) nadir. This is monitored by obtaining TWICE WEEKLY CBC, i.e. days 9, 12, 15,18:

- If nadir ANC $\geq 0.5 \times 10^9/\text{l}$: **increase by 1 dose level**
- If nadir ANC $< 0.5 \times 10^9/\text{l}$ on 1 or 2 measurements: **same dose as last**

Cycle.

- If nadir ANC $< 0.5 \times 10^9/\text{l}$ on at least 3 measurements: **decrease by 1 dose level**
- If platelet nadir $< 25 \times 10^9/\text{l}$: **reduce by 1 dose level** regardless of ANC
- Life threatening infections: **decrease by 1 dose level**

Drug Dose Adjustments

Drugs	Drug Doses per Dose Levels				
	-2	-1	1 Cycle 1	2	3
	64% (64% x 0.8)	80% (100% x 0.8)	100% (starting dose)	120% (100% x 1.2)	144% (120% x 1.2)
Prednisolone (mg/m ² twice daily)	60	60	60	60	60
Rituximab (mg/m ² /day)	375	375	375	375	375
Doxorubicin (mg/m ² /day)	10	10	10	12	14.4
Vincristine (mg/m ² /day)	0.4	0.4	0.4	0.4	0.4
Etoposide (mg/m ² /day)	50	50	50	60	72
Cyclophosphamide (mg/m ² /day)	480	600	750	900	1080

Neurotoxicity:

If the patient complains of significant constipation or sensory loss in fingers and/or toes, consider dose reduction of vincristine:

- ☐ Reduce by 25% for grade 2 motor neuropathy

- Reduce by 50% for grade 3 motor or sensory neuropathy
- For patients who develop $\geq$ grade 3 ileus, treatment should be delayed until recovery and vincristine introduced at 75% of the normal dose thereafter. If $\geq$ grade 3 ileus recurs, vincristine should be discontinued

Additional medicines that may be prescribed:

Septra	480mg	Oral once daily
Valacyclovir	500mg	Oral once daily
Fluconazole	50mg	Oral once daily
Omeprazole	20mg	Oral once daily for 5 days
Metoclopramide	10mg	Oral four times daily as needed
Ondansetron	8mg	Oral as a single dose prior to chemotherapy, then twice daily as needed

Docusate/Senna (Senna-S®) to prevent constipation from vincristine

Consider intrathecal prophylaxis for patients with >1 extranodal site and elevated LDH

II. Initial Therapy For Indolent Histology Non-Hodgkin Lymphoma

B-R:

- Bendamustine 90 mg/m² IV day 1, 2
- Rituximab 375 mg/m² IV day 1 then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated.
- *Cycles:* repeated every 3-4 weeks depending on blood counts (usually administered every 28 days) for a maximum of 6 cycles

CVP:

- Cyclophosphamide 800 mg/m² IV day 1 (or 400 mg/m²/day p.o. days 1-5)
- Vincristine 2mg IV day 1
- Prednisone 100mg/day p.o. days 1-5
- *Cycles:* every 21 days

R-CVP:

- Rituximab 375mg/m² IV day 1 (premeds: Tylenol, Benadryl, Zantac, hydrocortisone 100mg), then Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated.
- Cyclophosphamide 750 mg/m² IV day 1
- Vincristine 2mg IV day 1
- Prednisone 100mg/day p.o. days 1-5
- *Cycles:* every 21 days

Maintenance Rituximab in First or Second Remission Following Chemotherapy + Rituximab:

- Follicular and other indolent B-cell lymphoma: rituximab 1400mg sc (or 375mg/m² IV if cannot tolerate sc) x 1 dose q3 months x 2 years (8 doses total)
- Mantle cell lymphoma option: rituximab 1400mg sc (or 375mg/m² IV if cannot tolerate sc) q2months until progression

Outpatient R-DHAP:

Cycle 1.

Day1: Rituximab 375mg/m² IV (if no rituximab in past 3months and cannot receive sc rituximab)

Day 2: 500mL NS pre, cisplatin 35 mg/m² in 500 mL NS/mannitol, 500 ml NS post, AraC 2g/m² in 500 mL NS.

Day 3: 500mL NS pre, cisplatin 35 mg/m² in 500 ml NS/mannitol, AraC 2g/m² in 500 mL NS. Total 5 hrs

Cycle 2 onwards.

Day1: Rituximab 1400mg sc, 500mL NS pre, cisplatin 35 mg/m² in 500 mL NS/mannitol, 500 ml NS post. Then AraC 2g/m² in 500 mL NS. Total 5 hrs

Day2: 500mL NS pre, cisplatin 35 mg/m² in 500 ml NS/mannitol, AraC 2g/m² in 500 mL NS. Total 5 hrs

Chlorambucil (options):

- 0.1-0.2 mg/kg/day for 4-8 weeks then usually reduce for maintenance
- 10-14 mg/m² for 5 to 7 days each 28 days
- 0.5 mg/kg days 1 and 15 q28d cycle

Fludarabine:

- 25mg/m² IV days 1-5 q28 days (days 1-3 only if frail elderly or renal dysfunction)
- 40mg/m² p.o. days 1-5 q28 days (round down to nearest multiple of 10mg) (d1-3 only if frail or renal dysfunction)

FND:

- Fludarabine 25mg/m² IV days 1-3 or 40mg/m² p.o. days 1-3
- Mitoxantrone 10mg/m² day 1
- Dexamethasone 40mg p.o. days 1-3
- Septra for PCP prophylaxis
- Cycles: every 28 days

III. Initial Therapy for Peripheral T-Cell Lymphoma

CHOP:

- Cyclophosphamide 750 mg/m² IV
- Adriamycin 50 mg/m² IV day 1
- Vincristine 2mg IV day 1
- Prednisone 100mg/day p.o. days 1-5
- *Cycles:* every 21 days

CHOEP¹⁻³:

- Cyclophosphamide 750 mg/m² IV
- Adriamycin 50 mg/m² IV day 1
- Vincristine 2mg IV day 1
- Etoposide 100mg/m² IV days 1-3 (or 200mg/m² p.o. days 2-3 instead of IV; round down to nearest 50mg multiple)
- Prednisone 100mg/day p.o. days 1-5
- G-CSF days 7-11 or neulasta day 4 of each cycle
- *Cycles:* every 21 days

VIPD (Nasal NK/T-cell lymphoma):

- Etoposide 100mg/m² days 1-3
- Ifosfamide 1.2g/m² days 1-3
- Cisplatin 33mg/m² days 1-3
- Dexamethasone 40mg days 1-4
- *Cycles:* 3 cycles after initial radiotherapy

GOLD (14 day cycle)⁴:

- Gemcitabine 1000mg/m² on day 1
- Oxaliplatin 100mg/m² on day 1
- L-asparaginase 10,000U/m² on days 1-5*
- Dexamethasone (20mg b.i.d.) on days 1-4

*An intradermal test was required prior to the administration of L-ASP

SMILE (28 day cycle)⁵:

- Methotrexate 2g/m² on day 1
- Leucovorin 15mg x 4 on day 2, 3, and 4
- Ifosfamide 1500mg/m² on day 2, 3, and 4
- Mesna 300 mg/m² x 3 on day 2, 3 and 4
- Dexamethasone 40mg/d on day 2, 3 and 4

- Etoposide 100mg/m² on day 2, 3 and 4
 - L-asparaginase 6000U/m² on day 8, 10, 12, 14, 16, 18 and 20
- GCSF should be given from day 6 and discontinued if the leukocyte count exceeds 5000/μL.
Antibiotic prophylaxis with sulfamethoxazole-trimethoprim is recommended.

IV. Hodgkin Disease Chemotherapy Regimens

Initial Therapy:

ABVD adriamycin 25 mg/m² IV days 1 and 14
bleomycin 10 mg/m² IV days 1 and 14
vinblastine 6 mg/m² IV days 1 and 14
dacarbazine 375 mg/m² IV days 1 and 14
Cycles: every 28 days

ChIVPP chlorambucil 6mg/m² p.o. days 1-14
vinblastine 6mg/m² IV days 1 and 8
procarbazine 100mg/m² p.o. days 1-14
prednisone 40mg/m² p.o. days 1-14
Cycles: every 28 days

BEACOPP (escalated)
bleomycin 10mg/m² IV day 8
etoposide 200mg/m² IV days 1-3
adriamycin 35mg/m² IV day 1
cyclophosphamide 1250mg/m² IV day 1
vincristine 1.4mg/m² IV day 8
procarbazine 100mg/m² p.o. days 1-7
prednisone 40mg/m² po days 1-14
G-CSF 300-480μg sc d9-19 (to ANC>1.5) or Neulasta d9
Cycles: every 21 days

MOPP nitrogen mustard 6mg/m² days 1 & 8
vincristine 1.4mg/m² IV days 1 & 8
procarbazine 100mg/m² po days 1-14
prednisone 40mg/m² po days 1-14
Cycles: every 28 days

COPP cyclophosphamide 650mg/m² IV days 1&8
vincristine 1.4mg/m² IV days 1 & 8
procarbazine 100mg/m² po days 1-14
prednisone 40mg/m² po days 1-14
Cycles: every 28 days

BEACOPP (baseline)
bleomycin 10mg/m² IV day 8
etoposide 100 mg/m² IV days 1-3
adriamycin 25mg/m² IV day 1
cyclophosphamide 650mg/m² IV day 1
vincristine 1.4mg/m² IV day 8
procarbazine 100mg/m² p.o. days 1-7
prednisone 40 mg/m² p.o. days 1-14

BEACOPDac (escalated)
bleomycin 10mg/m² day 8
etoposide 200mg/m² days 1-3
adriamycin 35mg/m² day 1
cyclophosphamide 1250 mg/m² IV day 1
vincristine 1.4mg/m² IV day 8
dacarbazine 250mg/m² IV days 2 and 3
prednisone 40 mg/m² p.o. days 1-14
G-CSF 300-480μg sc d9-19 (to ANC>1.5) or Neulasta d9
Cycles: every 21 days

V. Lymphoma Salvage Regimens

Aggressive Histology Hodgkin and Non-Hodgkin Lymphomas*:

DICE.

- Dexamethasone 10mg IV q6 hours days 1-4
- Ifosfamide 1g/m² (max 1.75g) over 15 minutes days 1-4
- Cisplatin 25mg/m² IV over 1hour days 1-4
- Etoposide 100mg/m² over 1 hour days 1-4

- Mesna 200 mg/m² over 5-10 min prior to first dose of ifosfamide, then 200 mg/m² IV at 4 hours and 400mg/m² p.o. (or 200 mg/m² IV) at 8 hours post-ifosfamide x 4 days
- *Cycles:* every 21-28 days

CEPP.

- Cyclophosphamide 600 mg/m² IV days 1 and 8
- Etoposide 70mg/m² days 1-3
- Procarbazine 60mg/m² p.o. days 1-10
- Prednisone 100mg/day p.o. days 1-10
- *Cycles:* every 28 days

GDP.

- Gemcitabine 1000mg/m² IV days 1 and 8
- Dexamethasone 40mg p.o. days 1-4
- Cisplatin 75mg/m² IV

DICEP.

- Dexamethasone 10mg IV q8 hours x 10 doses
- Cyclophosphamide 1.75 g/m² IV over 2 hours days 1-3
- Etoposide 350mg/m² IV over 2 hours days 1-3
- Cisplatin 35mg/m² IV over 2 hours days 1-3
- Mesna 1.75g/m² IV over 24 hours days 1-3
- Septra for PCP prophylaxis
- *Cycles:* Once only

**Add rituximab to salvage regimens for transplant eligible patients with relapsed B-cell lymphomas*

Indolent Histology Non-Hodgkin Lymphoma:

As above, plus:

Rituximab.

- 375mg/m² IV days 1,8,15, and 22 (Rituximab 1400mg sc from day 8 onwards if initial IV dose tolerated).
- Pre-medicate with hydrocortisone 100mg IV, Benadryl, Zantac, and Tylenol
- Infuse 50mg/hour initially, then increase by 50mg/hour increments q30 minutes as tolerated to a maximum of 400mg/hour
- Subsequent infusions can begin at 100mg/hour and increase by 100mg/hour increments as tolerated to maximum of 400mg/hour

FND.

- Fludarabine 25mg/m² IV days 1-3 or 40mg/m² p.o. days 1-3
- Mitoxantrone 10mg/m² day 1
- Dexamethasone 40mg p.o. days 1-3
- Septra for PCP prophylaxis
- *Cycles:* every 28 days

R-FCM.

- Fludarabine 25mg/m² IV days 1-3 or 40mg/m² p.o. days 1-3
- Cyclophosphamide 200mg/m² IV days 1-3
- Mitoxantrone 8mg/m² IV day 1
- Rituximab 375mg/m² IV day 1 (Rituximab 1400mg sc on day 1 from cycle 2 onwards if initial IV dose tolerated).
- *Cycles:* every 28 days

VI. Burkitt Lymphoma^{6,7}

Modified Magrath Regimen of R-CODOXM/R-IVAC (Blood 2014; 124:2913-2920)⁸: Regimen A (R-CODOX-M)

Days:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
rituximab 1400mg sc	x																		
cyclophosphamide 800mg/m ² IV	x	x																	
doxorubicin 50mg/m ² IV	x																		
vincristine 1.5mg/m ² IV cap 2mg	x														x				
allopurinol 300mg/day po	x	x	x	x	x	x	x	x	x	x									
methotrexate 3000mg/m ² IV over 2 hour IV**															x				
leucovorin 25mg IV @ 24 hours, then 25mg IV q6h until methotrexate<10 ⁻⁸ M																xx	xx	xx	xx
IT methotrexate 12mg	X																		
IT cytarabine 50mg *			X																
Peg-filgrastim 6mg			X																

*if CNS disease, give extra IT AraC 50mg d5 cycle 1 only

**HDMTX administered once urine pH>7, and diuresis established with hydration including D5-0.2%NS plus 2-3 amps sodium bicarbonate. Continue hydration and alkalinization until MTX cleared.

Regimen B (R- IVAC)

Days:	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
rituximab 375mg/m ² IV	X																	
cytarabine 2g/m ² IV q12h x 4 doses	X	xx																
ifosfamide 1500mg/m ² IV	X	x	x	x	x													
mesna 360mg/m ² IV q3 hours	xx	xx	xx	xx	xx	xx												
	x	x	x	x	x	x												

etoposide 60mg/m ² IV	X	x	x	x	x													
IT methotrexate 12mg					x													
Peg-filgrastim 6mg						x												

*if CNS disease, give extra IT AraC 50mg d3 cycle 1 only

Low risk patients:

- Single extra-abdominal mass <10cm, or completely resected abdominal disease and normal LDH
- Modified regimen A x 3 cycles (cytarabine IT day 1 and methotrexate IT day 3 each cycle)

High risk patients:

- All others
- Alternate regimen A with regimen B for a total of 2 each or 4 cycles total

Start next cycle once ANC>1.0 and platelets>50

VII. Primary CNS Lymphoma Protocol

A. Transplant Protocol for Transplant-Eligible for Patients: age < 75years, no significant co-morbidities.
All chemotherapy doses based on ideal body weight.

	Step 1				*Step 2			**Step 3			Step 4
Week	1	2	3	4	5	6	7	8	9	10	12-14
Rituximab 375mg/m ² IV d0, then 1400mg sc d4 & 14 high-dose methotrexate 3.5 g/m ² d1&15 procarbazine 100 mg/m ² d1-7	x		x								
rituximab 1400mg sc d1 cytarabine 3 g/m ² x d1&2 G-CSF 5-10 µg/kg d8-13 Apheresis ~d14 or 15					x						
Rituximab 1400mg sc d0 high-dose methotrexate 3.5 g/m ² d1 cytarabine 2 g/m ² twice daily days 2-3 all q21d for 2 cycles					x	x					
thiotepa 300 mg/m ² IV days -6,-5 busulfan 3.2 mg/kg IV days -4 to -2, ASCT day 0								x	x		X
											X

* Step 2 may begin either week 4 or 5 depending upon patient status and apheresis scheduling

**Step 3 may be omitted in patients who have achieved some response and are physically fit to proceed directly to ASCT on week 9.

Step 1. Induction: High-dose methotrexate/procarbazine q14 days x 2 cycles		
Day	Medications	Other Orders
ADMISSION 0	0900hr -Hydrocortisone 100mg IV, Benadryl 50mg IV, Zantac 50mg IV, Tylenol 650mg. 0900hr-Rituximab 375mg/m ² (1 st infusion protocol) 2000hr –IV lactated ringers @ 2 mL/kg/hour continue until methotrexate level <0.05 2200hr - sodium bicarbonate 1500 mg PO q6h continue until methotrexate level less than 0.05 µmol/L if urine pH <7, increase sodium bicarbonate to 6500 mg PO q4h	• Daily weights • Daily CBC & Diff, EP, Creat, glucose • ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg • LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hour days 1 and 15 0800hr - procarbazine 100mg/m ² po daily x 7days days 1-7 only (round down to nearest 50mg multiple) sodium bicarbonate 50 mmol IVPB q8h PRN if urine pH less than 7 continue until methotrexate level less than 0.05 µmol/L transfer 50 mL sodium bicarbonate injection (1 mmol/mL) into empty viaflex bag for administration. Give over one hour.	0700hr - Urine pH twice daily, call MD if <7.0
2-3	0800hr - folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 Continue hydration until methotrexate level <0.05	0500-0800hr – methotrexate Level daily (expect level < 10 d2, <1 d3, <0.1 d4, <0.05 d5)
4	0900hr- Rituximab 1400mg sc on cycle 1 only and continue folinic acid	0500-0800hr – methotrexate Level daily

5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember anticoagulant and anticonvulsant if patient is on these medications
---	---

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

Step 2. Rituximab/high-dose cytarabine x 1 cycle for stem cell collection after 2 cycles of methotrexate		
Day	Medications	Other Orders
1	0900hr -Premeds : Loratadine 10mg po, Tylenol 650mg p.o. -Rituximab 1400mg sc	- Weight - CBC & Diff, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
2 & 3	0800hr – Ondansetron or Granisetron, dexamethasone 10-12mg IV/po 0800hr – IV N/S 500mL/hour x 2 hours 1000hr – Cytarabine 3g/m ² IV over 3 hours daily if creat cl >60ml/min or 2g/m ² daily if creat cl 46-60ml/min or 1.5g/m ² daily if creat cl 31-45ml/min	1% Prednisolone eye drops, 2 tid x12 doses begin before first dose of cytarabine and continue until 48 hours after the last dose
9-14	1000hr – G-CSF 480-600 µg subcutaneous daily until apheresis completed (plan for apheresis approximately day 13-15, once ANC>5, Plt >75 and CD34>20)	Daily CBC & differential starting day 10

**Step 3. High-dose methotrexate/cytarabine consolidation q21 days x 1 cycles after stem cell collection		
Day	Medications	Other Orders
ADMISSION 0	16:00hr- Premeds : Loratadine 10mg po, Tylenol 650mg p.o. Rituximab 1400mg sc 2000hr – IV lactated ringers @ 2 mL/kg/hour until methotrexate level <0.05 2200hr - sodium bicarbonate 1500 mg PO q6h continue until methotrexate level less than 0.05 µmol/L if urine pH <7, increase sodium bicarbonate to 6500 mg PO q4h	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - ALT, Alk P, bili, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours sodium bicarbonate 50 mmol IVPB q8h PRN if urine pH less than 7 continue until methotrexate level less than 0.05 µmol/L transfer 50 mL sodium bicarbonate injection (1 mmol/mL) into empty viaflex bag for administration. Give over one hour.	07:00 - Urine pH bid, call MD if <7.0
2-3	080hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 -Continue hydration until methotrexate level <0.05 0800hr – Granisetron 2mg IV, dexamethasone 10mg IV 1000hr – Cytarabine 2g/m ² IV over 2 hours bid x2 days if CreatCl>60ml/min (reduce to 1.3g/m ² if creat cl 46-60ml/min or 1g/m ² if creat cl 31-45ml/min)	0500-08:00 – methotrexate level daily (expect <10 d2, <1 d3, <0.1 d4, <0.05 d5) 1% Prednisolone eye drops, 2 tid x12 doses begin before first dose of cytarabine and continue until 48 hours after the last dose
5	Discharge once methotrexate level <0.05 If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days (other meds as step 1 above)	
8-12	1000hr – G-CSF 480-600 µg subcutaneous daily until post-nadir ANC >1.5	Daily CBC & differential starting day 10

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

****NB: Step 3 may be omitted in patients who have achieved some response and are phsyically fit to proceed directly to ASCT on week 9.**

Step 4. *TBU/ASCT consolidation after response to methotrexate and high-dose cytarabine		
Day	Medications	Other Orders
ADMISSION Day -7	Allopurinol 300 mg p.o. daily until day 0 2200hr - N/S @ 100 mL/hour until day -4, then infuse only during busulfan administration days -4 to -2.	- Consult dietician, physiotherapy - Low bacteria diet 24 hour intake - Mouth protocol - Record intake and output - Valacyclovir 500mg/d
-6 & -5	0800 – thiotepa 300 mg/m ² IV over 3 hours x 2 days (IDEAL BSA) Reduce to 270mg/m ² if age 61-65years Reduce to 240mg/m ² if age 66-70years Reduce to 210mg/m ² if age >70years	0800hr – granisetron 2 mg IV daily x 8 days - EP daily x 31days - Shower/bath q6 hours x 3 days; avoid skin creams
-4 to -2	0900 - busulfan 3.2 mg/kg IV daily x 3 days (Ideal weight) Reduce to 2.9mg/kg if age 61-65years Reduce to 2.55mg/kg if age 66-70years Reduce to 2.25mg/kg if age >70years	- lorazepam 1mg qid prophylaxis x 4 days - CBC & differential daily x 31 days - ALT, Alk Phos, bili, alb, Ca, Mg, every Monday & Thursday - PT, PTT, every Monday

-1	Rest day	• mycostatin 500,000 units q2-4 hours
0	Autologous Blood Stem Cell INFUSION	
+7	G-CSF 300µg (if less than 70kg) or 480µg (if over 70kg) subcutaneous daily until post-nadir ANC > 1.5	
+14		• sepra RS 1 tab p.o. daily

B. MATRIX Non-Transplant Protocol for Transplant-Eligible for Patients who refuse transplant:

age < 70years, no significant co-morbidities, ECOG=0-2.

All chemotherapy doses based on ideal body weight.

	Step 1											
Week	1	2	3	4	5	6	7	8	9	10	11	12
Rituximab d0, 4	x			x			x			x		
high-dose methotrexate 3.5 g/m ² d1	x			x			x			x		
cytarabine 2g/ m ² q12h x 2 d2	x			x			x			x		
Thiotepa 30mg/ m ² d4	x			x			x			x		

Step 1. Induction: MATRIX x 4 cycles		
Day	Medications	Other Orders
ADMISSION 0	0900hr-Rituximab 375mg/m ² (1 st infusion protocol) 2000hr – IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200ml/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 3 hours	0700hr - Urine pH twice daily, call MD if <7.0
2-3	0800hr - folinic acid (leucovorin) 25 mg IV q6hr until MTX level < 0.05 Continue hydration until methotrexate level <0.05 1000hr –Cytarabine 2mg/m ² by 1 hour infusion q12 hr x 2 if CreatCl>60ml/min (reduce to 1.3g/m ² if creat cl 46-60ml/min or 1g/m ² if creat cl 31-45ml/min)	0500-0800hr – methotrexate level daily (expect level < 10 d2, <1 d3)
4	0900hr- Rituximab 1400mg subcutaneously 1000hr- Thiotepa 30mg/m ² by 30min infusion	0500-0800hr – methotrexate Level daily
5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

Methotrexate should be omitted if creat clearance < 50 mL/min or if renal dysfunction with prior cycle

Cytarabine should be reduced to q24hr if creat clearance < 50 mL/min or complications of myelosuppression

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches> 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches> 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

C. Transplant-Ineligible Patients: age ≥ 75 years, or significant co-morbidities, or patient refuses HDMTX.

	Step 1			Step 2								
Week	1	2	3	4	5	6	7	8	9	10	11	12
Rituximab 375mg/m ² day 0 Cytarabine 3g/m ² daily days 1&2 if creat cl >60ml/min or 2g/m ² days 1&2 if creat cl 46-60ml/min or 1.5g/m ² days 1&2 if creat cl 31-45ml/min Thiotepa 30mg/m ² on day 2	x											
Rituximab 1400mg sc day 1 Cytarabine 3g/m ² daily days 1&2 if creat cl >60ml/min or 2g/m ² days 1&2 if creat cl 46-60ml/min or 1.5g/m ² days 1&2 if creat cl 31-45ml/min Thiotepa 30mg/m ² on day 2				x			x			x		

Step 1. Induction: Rituximab high-dose cytarabine/thiotepa x 1 cycle		
Day	Medications	Other Orders
0 or 1	0900hr-Hydrocortisone 100mg IV, Benadryl 50mg IV, Zantac 50mg IV, Tylenol 650mg. 0900hr-Rituximab 375mg/m ² (1 st infusion protocol)	• Weekly CBC & differential, EP, creatinine, glucose ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
1	NS 1000ml IV hydration Granisetron 2mg po, dexamethasone 10mg IV *Cytarabine 3g/m ² daily on days 1&2 if creat cl >60ml/min or 2g/m ² daily on days 1&2 if creat cl 46-60ml/min or 1.5g/m ² daily on days 1&2 if creat cl 31-45ml/min	1% Prednisolone eye drops, 2 tid x12 doses begin before first dose of cytarabine and continue until 48 hours after the last dose
2	NS 1000ml IV hydration Granisetron 2mg po, dexamethasone 10mg IV *Cytarabine 3g/m ² daily on days 1&2 if creat cl >60ml/min or 2g/m ² daily on days 1&2 if creat cl 46-60ml/min or 1.5g/m ² daily on days 1&2 if creat cl 31-45ml/min Thiotepa 30mg/m ² on day 2	
7	Valtrex 500mg po daily and Septra 1 tab daily x6mo	
8-12	G-CSF 300 or 480µg sc daily x5d (or pegfilgrastim 6mg on day 4)	

Step 2. Rituximab High-dose Cytarabine/Thiotepa q21days x 3 cycles		
Day	Medications	Other Orders
1	Rituximab 1400mg sc NS 1000ml IV hydration Granisetron 2mg po, dexamethasone 10mg IV *Cytarabine 3g/m ² daily on days 1&2 if creat cl >60ml/min or 2g/m ² daily on days 1&2 if creat cl 46-60ml/min or 1.5g/m ² daily on days 1&2 if creat cl 31-45ml/min	• Weekly CBC & differential, EP, creatinine, glucose ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg 1% Prednisolone eye drops, 2 tid x12 doses begin before first dose of cytarabine and continue until 48 hours after the last dose
2	NS 1000ml IV hydration Granisetron 2mg po, dexamethasone 10mg IV *Cytarabine 3g/m ² daily on days 1&2 if creat cl >60ml/min or 2g/m ² daily on days 1&2 if creat cl 46-60ml/min or 1.5g/m ² daily on days 1&2 if creat cl 31-45ml/min Thiotepa 30mg/m ² on day 2	
8-12	G-CSF 300 or 480µg sc daily x5d (or pegfilgrastim 6mg on day 4)	

*If creat cl <30ml/min do not give cytarabine.

Calculated creatinine clearance= $N \times (140 - \text{Age}) \times \text{weight (kg)} / \text{serum creatinine in } \mu\text{mol/L}$ where *N = 1.23 males or 1.04 females

VIII. Secondary CNS Lymphoma Protocol

A) Transplant-eligible patients (age <65 years, no significant co-morbidities, no immune suppression) with isolated CNS relapse/progression following complete response of systemic lymphoma to RCHOP.

	Step 1								Step 2			Step 3		
Week	1	2	3	4	5	6	7	8	9	10	11	12	13	14
high-dose methotrexate 3.5 g/m ² d1	x		x		x		x							
Rituximab 375 mg/m ² d2	x		x		x									
procarbazine 100 mg/m ² x 7 days d1-7	x				x									
vincristine 1.4 mg/m ² d1	x		x											
rituximab 1400mg sc days 1,4									x					
dexamethasone 20 mg days 1-4									x					
cisplatin 35 mg/m ² days 1,2									x					
cytarabine 2 g/m ² x1 dose, days 1,2									x					
G-CSF 5-10 µg/kg day 8-13										x				
Apheresis day 13 or 14											x			
R-TbuM/ ASCT (ritux d-7 + thiotepa 250mg/m ² d -6,-5 busulfan 3.2 mg/kg day -4 to -2, melphalan 100 mg/m ² d-1, ASCT d 0													x	

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft.

Step 1. Induction: high-dose methotrexate/vincristine/procarbazine q14 days x 4 cycles		
Day	Medications	Other Orders
ADMISSION 0	2000hr - IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200mL/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours cycles 1-4 0800hr - procarbazine 100mg/m ² p.o. daily x 7days cycles 1 and 3 (round down to nearest 50mg multiple) 1000hr - vincristine 1.4mg/m ² IV only cycles 1 and 2	0700hr - Urine pH twice daily, call MD if <7.0
2-4	0800hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 Continue hydration until methotrexate level <0.05 1000hr – Rituximab 375mg/m ² IV (first 3 cycles HDMTX)	0500-0800hr – methotrexate level daily (expect level < 10 today)
5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

Step 2. Rituximab/DHAP x 1 cycle for stem cell collection after 4 cycles of methotrexate		
Day	Medications	Other Orders
1	0800hr - hydrocortisone 100mg IV, Benadryl , Zantac, Tylenol 0900hr - rituximab 1400mg sc 0900hr -IV 1L NS	- Weight - CBC & differential, EP, creatinine, glucose

Step 2. Rituximab/DHAP x 1 cycle for stem cell collection after 4 cycles of methotrexate		
Day	Medications	Other Orders
	0900hr – dexamethasone 20mg p.o./IV daily x 4 days 0900hr – Kyrtil 1mg IV or 2mg p.o. x 3-4 days 0900hr – aprepitant protocol p.o. x 3 days 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
2	0800hr – dexamethasone Kytril, Aprepitent continued 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	
4	Rituximab 1400mg sc	
8-13	1000hr – G-CSF 480-600µg subcutaneous daily until apheresis completed (plan for apheresis approximately day 13-15, once ANC>5, Plt >75 and CD34>20)	Daily CBC & differential starting day 10

Step 3. R-TBuM/ASCT consolidation after response to MTX and RDHAP Induction		
Day	Medications	Other Orders
ADMISSION Day -7	Allopurinol 300 mg p.o. daily until day 0 Premeds: Hydrocortisone 100mg IV, Benadryl 50mg IV, Zantac 50mg IV, Tylenol 650mg p.o. -rituximab 375mg/m ² IV (first dose long infusion protocol) 2200hr - D5½ N/S + 20 mEq KCL/L @ 125 mL/hour until day -1	- Consult dietician, physiotherapy - Low bacteria diet. 24hour intake - Mouth protocol; record intake and output
-6 & -5	0800hr – thiotepa 250 mg/m ² IV over 2 hours x 2 days (use ideal BSA)	0800hr – Granisetron 2 mg IV daily x 8 days - EP daily x 31days - Shower/Bath q6 hours x 3 days; avoid skin creams
-4 to -2	0900 - busulfan 3.2 mg/kg IV daily x 3 days (use Ideal weight)	- lorazepam prophylaxis x 4 days - CBC & differential daily x 31 days - ALT, Alk Phos, bilirubin, alb, Ca, Mg, every Monday & Thursday - PT, PTT every Monday
-1	10:00 -melphalan 100mg/m ² (actual BSA) IV over 5 minutes 10:15 – Lasix 20mg IV 10:30 - mannitol 20% 250 mL IVPB over 1 hour 11:30 - IV 1L NS @ 500 mL/hour for 3 hours 14:30 -IV 1L NS with 40 mEq KCL/L @ 125 mL/hour x 18 hours	- Mycostatin 500,000 units q2-4 hours - Septa RS 1 tab p.o. daily - Acyclovir 5 mg/kg twice daily IV or 400 mg p.o. four times daily
0	Autologous Blood Stem Cell INFUSION	
+7	G-CSF 300 µg (if less than 70kg) or 480µg (if over 70kg) subcutaneous daily until post-nadir ANC > 1.5	

B) Transplant-eligible patients (age <65 years, no significant co-morbidities, no immune suppression) with early Systemic and CNS lymphoma (prior to completing RCHOP x6): RCHOP and HDMTX x4 cycles then RDHAP for stem cell mobilization and collection, then R-TBuM/ASCT.

				Step 1							Step 2			Step 3			
Week	0	1	2	3	4	5	6	7	8	9	10	13	14	15	16	17	18
Methotrexate 3.5 g/m² q14d	X*		X**		X		X		X		X						
R-CHOP		X			X			X			X						
rituximab 1400mg sc days 1,4 dexamethasone 20 mg days 1-4 cisplatin 35 mg/m² days 1,2 cytarabine 2 g/m² x1 dose, days 1,2 G-CSF 5-10 µg/kg day 8-13 Apheresis day 13 or 14												x x x x	x	x			
R-TbuM/ ASCT (ritux d-7, thiotepa 250mg/m² d-6,-5 busulfan 3.2 mg/kg day -4 to -2, melphalan 100 mg/m² d -1, ASCT d 0																x	

*HDMTX prior to RCHOP#1 if CNS and systemic lymphoma both identified at time of initial diagnosis.

**If CNS lymphoma identified after RCHOP initiated but systemic disease responding to RCHOP, then plan for at least 4 doses HDMTX q14d with subsequent cycles RCHOP before proceeding to R-DHAP.

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft.

Step 1. Induction: RCHOP q21d as well as high-dose methotrexate q14 days x 4 cycles		
Day	Medications (HDMTX component)	Other Orders
ADMISSION 0	2000hr - IV D5W + 20meq KCL/L + 2 amps NaHCO3/L @ 200mL/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours cycles 1-4	0700hr - Urine pH twice daily, call MD if <7.0
2-4	0800hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 Continue hydration until methotrexate level <0.05	0500-0800hr – methotrexate level daily (expect level < 10 today)
5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

Step 2. Rituximab/DHAP x 1 cycle for stem cell collection after 4 cycles of methotrexate		
Day	Medications	Other Orders
1	0800hr - hydrocortisone 100mg IV, Benadryl , Zantac, Tylenol 0900hr - rituximab 1400mg sc 0900hr -IV 1L NS 0900hr – dexamethasone 20mg p.o./IV daily x 4 days 0900hr – Kytril 1mg IV or 2mg p.o. x 3-4 days 0900hr – aprepitant protocol p.o. x 3 days 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	- Weight - CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
2	0800hr – dexamethasone Kytril, Aprepitent continued 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	
4	Rituximab 1400mg sc	
8-13	1000hr – G-CSF 480-600µg subcutaneous daily until apheresis completed (plan for apheresis approximately day 13-15, once ANC>5, Plt >75 and CD34>20)	Daily CBC & differential starting day 10

Step 3. R-TBuM/ASCT consolidation after response to MTX and RDHAP Induction		
Day	Medications	Other Orders
ADMISSION Day -7	Allopurinol 300 mg p.o. daily until day 0 Premeds: Hydrocortisone 100mg IV, Benadryl 50mg IV, Zantac 50mg IV, Tylenol 650mg p.o. -rituximab 375mg/m ² IV (first dose long infusion protocol) 2200hr - D5½ N/S + 20 mEq KCL/L @ 125 mL/hour until day -1	- Consult dietician, physiotherapy - Low bacteria diet. 24hour intake - Mouth protocol; record intake and output
-6 & -5	0800hr – thiotepa 250 mg/m ² IV over 2 hours x 2 days (use ideal BSA)	0800hr – Granisetron 2 mg IV daily x 8 days - EP daily x 31days - Shower/Bath q6 hours x 3 days; avoid skin creams
-4 to -2	0900 - busulfan 3.2 mg/kg IV daily x 3 days (use Ideal weight)	- lorazepam prophylaxis x 4 days - CBC & differential daily x 31 days - ALT, Alk Phos, bilirubin, alb, Ca, Mg, every Monday & Thursday - PT, PTT every Monday
-1	10:00 - melphalan 100mg/m ² (actual BSA) IV over 5 minutes 10:15 – Lasix 20mg IV 10:30 - mannitol 20% 250 mL IVPB over 1 hour 11:30 - IV 1L NS @ 500 mL/hour for 3 hours 14:30 -IV 1L NS with 40 mEq KCL/L @ 125 mL/hour x 18 hours	- Mycostatin 500,000 units q2-4 hours - Septa RS 1 tab p.o. daily - Acyclovir 5 mg/kg twice daily IV or 400 mg p.o. four times daily
0	Autologous Blood Stem Cell INFUSION	
+7	G-CSF 300 µg (if less than 70kg) or 480µg (if over 70kg) subcutaneous daily until post-nadir ANC > 1.5	

C) Transplant-eligible patients (age <65 years, no significant co-morbidities, no immune suppression) with late relapse (prior RCHOP x6) with systemic and CNS lymphoma: HDMTX-Ifosfamide-etoposide x2 then RDHAP for stem cell mobilization and collection, then R-TBuM/ASCT

	Step 1							Step 2				Step 3		
Week	1	2	3	4	5	6	7	8	9	10	11	12	13	14
high-dose methotrexate 3.5 g/m ² d1	X			X			X							
Rituximab 375 mg/m ² d2	X			X										
Ifosfamide 1.5 g/m ² d3-5	X			X										
Etoposide 100 mg/m ² d3-5	X			X										
rituximab 1400mg sc days 1,4								x						
dexamethasone 20 mg days 1-4								x						
cisplatin 35 mg/m ² days 1,2								x						
cytarabine 2 g/m ² x1 dose, days 1,2								x						
G-CSF 5-10 µg/kg day 8-13									x					
Apheresis day 13 or 14										x				
R-TbuM/ ASCT (ritux d-7 + thiotepa 250mg/m ² d -6,-5 busulfan 3.2 mg/kg day -4 to -2, melphalan 100 mg/m ² d-1, ASCT d 0												X		

Step 1. Induction: R-IE and high-dose methotrexate x 2 cycles (HDMTX x3)

Day	Medications	Other Orders
ADMISSION 0	2000hr - IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200mL/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours cycles 1-4	0700hr - Urine pH twice daily, call MD if <7.0
2	0800hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 Continue hydration until methotrexate level <0.05 1000hr – Rituximab 375mg/m ² IV	0500-0800hr – methotrexate level daily (expect level < 10 today)
3-5	0800hr – Kytril 2mg IV, dexamethasone 10mg IV daily x 3d 0800hr – N/S IV 500mL/hour x 1 hour daily x 3d 0900hr – Mesna 0.5 g IV daily x 3d 0900hr - Ifosfamide 1.5g/m ² with 1g Mesna IV over 3 hours daily x 3d 1200hr – Mesna 0.5 g IV daily x 3d 1200hr – 1/2NS IV 250mL/hour x 4 hours daily x 3d 1200hr – Etoposide 100 mg/m ² IV daily x 3d 1600hr – Mesna 1.0 g IV daily x 3d 1000hr	
5 or 6	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches> 5ft.

Step 2. Rituximab/DHAP x 1 cycle for stem cell collection after 4 cycles of methotrexate		
Day	Medications	Other Orders
1	0800hr - hydrocortisone 100mg IV, Benadryl , Zantac, Tylenol 0900hr - rituximab 1400mg sc 0900hr -IV 1L NS 0900hr – dexamethasone 20mg p.o./IV daily x 4 days 0900hr – Kytril 1mg IV or 2mg p.o. x 3-4 days 0900hr – aprepitant protocol p.o. x 3 days 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	- Weight - CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
2	0800hr – dexamethasone Kytril, Aprepitent continued 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	
4	Rituximab 1400mg sc	
8-13	1000hr – G-CSF 480-600µg subcutaneous daily until apheresis completed (plan for apheresis approximately day 13-15, once ANC>5, Plt >75 and CD34>20)	Daily CBC & differential starting day 10

Step 3. R-TBuM/ASCT consolidation after response to MTX and RDHAP Induction		
Day	Medications	Other Orders
ADMISSION Day -7	Allopurinol 300 mg p.o. daily until day 0 Premeds: Hydrocortisone 100mg IV, Benadryl 50mg IV, Zantac 50mg IV, Tylenol 650mg p.o. -rituximab 375mg/m ² IV (first dose long infusion protocol) 2200hr - D5½ N/S + 20 mEq KCL/L @ 125 mL/hour until day -1	• Consult dietician, physiotherapy • Low bacteria diet. 24hour intake • Mouth protocol; record intake and output
-6 & -5	0800hr – thiotepa 250 mg/m ² IV over 2 hours x 2 days (use ideal BSA)	• 0800hr – Granisetron 2 mg IV daily x 8 days • EP daily x 31days • Shower/Bath q6 hours x 3 days; avoid skin creams
-4 to -2	0900 - busulfan 3.2 mg/kg IV daily x 3 days (use Ideal weight)	• lorazepam prophylaxis x 4 days • CBC & differential daily x 31 days • ALT, Alk Phos, bilirubin, alb, Ca, Mg, every Monday & Thursday • PT, PTT every Monday
-1	10:00 -melphalan 100mg/m ² (actual BSA) IV over 5 minutes 10:15 – Lasix 20mg IV 10:30 - mannitol 20% 250 mL IVPB over 1 hour 11:30 - IV 1L NS @ 500 mL/hour for 3 hours 14:30 -IV 1L NS with 40 mEq KCL/L @ 125 mL/hour x 18 hours	• Mycostatin 500,000 units q2-4 hours • Septra RS 1 tab p.o. daily • Acyclovir 5 mg/kg twice daily IV or 400 mg p.o. four times daily
0	Autologous Blood Stem Cell INFUSION	
+7	G-CSF 300 µg (if less than 70kg) or 480µg (if over 70kg) subcutaneous daily until post-nadir ANC > 1.5	

VIII. Secondary CNS Lymphoma Protocol

D) Transplant-ineligible patients (age >65 years, significant co-morbidities, or immune suppression) with isolated CNS relapse/progression following complete response of systemic lymphoma to RCHOP. (consider only for highly motivated patients who wish curative intent therapy. Otherwise palliation with IT chemotherapy, radiotherapy, or supportive care).

	Step 1		Step 2										Step 3
Week	1	2	3	4	5	6	7	8	9	10	11	12	15 or 16
Rituximab 375mg/m ² d0, 4 high-dose methotrexate 3.5 g/m ² d1 procarbazine 100 mg/m ² x 7 days d1-7	x												
Rituximab 375mg/m ² d0 high-dose methotrexate 3.5 g/m ² day 1 cytarabine 1.5-2 g/m ² bid days 2-3			x			x			x			x	
			x			x			x			x	
			x			x			x			x	
Ifosfamide 2g/m ² daily days 1-3													X

Step 1. Induction: high-dose methotrexate/procarbazine x 1 cycle		
Day	Medications	Other Orders
ADMISSION 0	0900hr-Rituximab 375mg/m ² (1 st infusion protocol) 2000hr – IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200ml/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours 0800hr - procarbazine 100mg/m ² p.o. daily x 7days only cycle 1 (round down to nearest 50mg multiple)	0700hr - Urine pH twice daily, call MD if <7.0
2-3	0800hr - folinic acid (leucovorin) 25 mg IV q6hr until MTX level < 0.05 Continue hydration until methotrexate level <0.05	0500-0800hr – methotrexate level daily (expect level < 10 d2, <1 d3)
4	0900hr- Rituximab 375mg/m ² (subsequent infusion protocol)on cycle 1 only and continue folinic acid)	0500-0800hr – methotrexate Level daily
5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches> 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

Step 2. High-dose methotrexate/cytarabine consolidation q21 days x 4 cycles		
Day	Medications	Other Orders
ADMISSION 0	1600hr- Rituximab 375mg/m ² (subsequent infusion protocol) on cycle 1 only and continue folinic acid) 2000hr – IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200mL/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - ALT, Alk P, bilirubin, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours	07:00 - Urine pH bid, call MD if <7.0
2-3	0800hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 -Continue hydration until methotrexate level <0.05 0800hr – Kytril 2mg IV, Decadron 10mg IV 1000hr – cytarabine 2g/m ² IV over 2 hours twice daily x 2 days; reduce to 1.5g/m ² if age >60 years or creatinine >100	0500-08:00 – Methotrexate Level daily (expect <10 d2, <1 d3, <0.1 d4, <0.05 d5)
5	Discharge once methotrexate level <0.05 If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days (other meds as step 1 above)	
8-12	10:00 – G-CSF 480-600 µg subcutaneous daily until post-nadir ANC >1.5	Daily CBC & diff starting d10

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft. Adjusted BW = IBW + [40% x (actual – IBW)]

Step 3. Ifosfamide consolidation after response to methotrexate and high-dose cytarabine		
Day	Medications	Other Orders
15 or 16	0800hr – Kytril 2mg IV, dexamethasone 10mg IV daily x 3d 0800hr – N/S IV 500mL/hour x 1 hour daily x 3d 0900hr – Mesna 1.0 g IV daily x 3d 0900hr – Ifosfamide 2g/m ² with 1g Mesna IV over 3 hours daily x 3d 1200hr – Mesna 0.5 g IV daily x 3d 1200hr – 1/2NS IV 250mL/hour x 4 hours daily x 3d 1600hr – Mesna 1.0 g IV daily x 3d	- weight (call MD if >2kg above day 1) - CBC & differential, EP, creatinine, glucose - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg

E) Transplant-ineligible patients (age >65 years, significant co-morbidities, or immune suppression) with early Systemic and CNS lymphoma prior to completing initial RCHOP x6. (consider only for highly motivated patients who wish curative intent therapy. Otherwise palliation).

				Step 1								Step 2			Step 3		
Week	0	1	2	3	4	5	6	7	8	9	10	13	14	15	16	17	18
Methotrexate 3.5 g/m ² q14d	X*		X*		X		X		X		X						
R-CHOP		X			X			X			X						
rituximab 1400mg sc days 1,4 dexamethasone 20 mg days 1-4 cytarabine 2 g/m ² x1 dose, days 1 and 2 G-CSF 5-10 µg/kg day 8-13												x x x					
Ifosfamide 2g/m ² daily days 1-3																X	
*HDMTX prior to RCHOP#1 if CNS and systemic lymphoma both identified at time of initial diagnosis. **If CNS lymphoma identified after RCHOP initiated but systemic disease responding to RCHOP, then plan for at least 4 doses HDMTX q14d with subsequent cycles RCHOP before proceeding to R-AraC.																	

* Male IBW = 50kg + 2.3kg x inches > 5ft, Female IBW = 45.5 kg + 2.3kg x inches > 5ft.

Step 1. Induction: RCHOP q21d as well as high-dose methotrexate q14 days x 4 cycles		
Day	Medications (HDMTX component)	Other Orders
ADMISSION 0	2000hr - IV D5W + 20meq KCL/L + 2 amps NaHCO ₃ /L @ 200mL/hour x 5 days	- Daily weights - Daily CBC & differential, EP, creatinine, gluc - ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg - LFTs, Ca, lipase, every Monday & Thursday
1	0800hr - Kytril 1mg IV 0800hr - methotrexate 3500mg/m ² IV over 2 hours cycles 1-4	0700hr - Urine pH twice daily, call MD if <7.0
2-4	0800hr- folinic acid (leucovorin) 25 mg IV q6 hours until methotrexate level < 0.05 Continue hydration until methotrexate level <0.05	0500-0800hr – methotrexate level daily (expect level < 10 today)
5	- Discharge once methotrexate level <0.05 - If level 0.01-0.05, discharge on leucovorin 5mg p.o. q6 hours x 2-3 days - Discharge meds: sepra DS 1 daily or dapsone 50mg daily x 6-9 months; consider dexamethasone taper if on dexamethasone - Remember coumadin/LMWH and dilantin if patient is on these medications	

Step 2. Rituximab/DHAP x 1 cycle for stem cell collection after 4 cycles of methotrexate		
Day	Medications	Other Orders
1	0800hr - hydrocortisone 100mg IV, Benadryl, Zantac, Tylenol 0900hr - rituximab 1400mg sc 0900hr -IV 1L NS 0900hr – dexamethasone 20mg p.o./IV daily x 4 days 0900hr – Kytril 1mg IV or 2mg p.o. x 3-4 days 0900hr – aprepitant protocol p.o. x 3 days 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	• Weight • CBC & differential, EP, creatinine, glucose • ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg
2	0800hr – dexamethasone Kytril, Aprepitent continued 1000hr – cisplatin 35mg/m ² IV over 2 hours with mannitol 25g and 500mL NS 1200hr- cytarabine 2g/m ² IV over 2 hours x 1 doses (1.5g/m ² if >60yr)	
4	Rituximab 1400mg sc	
8-13	1000hr – G-CSF 480-600µg subcutaneous daily until apheresis completed (plan for apheresis approximately day 13-15, once ANC>5, Plt >75 and CD34>20)	Daily CBC & differential starting day 10

Step 3. Ifosfamide consolidation after response to methotrexate and high-dose cytarabine		
Day	Medications	Other Orders
15 or 16	0800hr – Kytril 2mg IV, dexamethasone 10mg IV daily x 3d 0800hr – N/S IV 500mL/hour x 1 hour daily x 3d 0900hr – Mesna 1.0 g IV daily x 3d 0900hr – Ifosfamide 2g/m ² with 1g Mesna IV over 3 hours daily x 3d 1200hr – Mesna 0.5 g IV daily x 3d 1200hr – 1/2NS IV 250mL/hour x 4 hours daily x 3d 1600hr – Mesna 1.0 g IV daily x 3d	• weight (call MD if >2kg above day 1) • CBC & differential, EP, creatinine, glucose • ALT,AlkP,LDH,bilirubin,Alb,Ca,Mg

F) Transplant-ineligible patients (age >65 years, significant co-morbidities, or immune suppression) with late relapse (prior RCHOP x6) with relapsed systemic and CNS lymphoma.

This situation is unfortunately associated with extremely poor prognosis, and generally should be treated with palliative intent. Treatments could include IT chemotherapy, radiotherapy, decadron, or best supportive care.

Appendix B: General Radiotherapy Guidelines

Aggressive Non-Hodgkin Lymphomas:

30Gy/15-35Gy/20 is recommended in lymphoma subtypes and situations *except*:

1. Nasal NK/T cell lymphomas: 30Gy/10 or 40-50Gy +/- concurrent cisplatin
2. Testicular lymphoma, post-RCHOP: Scrotal radiotherapy 25-30Gy/10-15 fractions
3. Primary *or* secondary CNS lymphoma: Whole brain radiotherapy
 - o Palliative: 20Gy/5 - 35Gy/20 +/- 10Gy/5 boost *depending on age, KPS, anticipated life expectancy, status of extracranial disease?*
 - o Curative, post-methotrexate: 23.4Gy/13 fractions if in CR, or 45Gy/25 fractions (*?alternative 30Gy/15 + boost 15Gy/8 or 35 Gy/20 + boost 10 Gy/5?*) in PR

Indolent Lymphoma:

24Gy/12 - 30Gy/20 fractions is generally recommended for most subtypes and situations *except*:

1. Palliation: lower doses may be used for palliation such as 4Gy/2 fractions
2. Contiguous stage II disease, curative intent: higher doses up to 40Gy may be used
3. *Gastric MALT 30Gy/20*

Hodgkin Lymphoma:

20Gy/10 for early stage favorable, 30Gy/15 early stage unfavorable and advanced stage is recommended in lymphoma subtypes and situations *except for* nodular lymphocyte-predominant Hodgkin disease (NLPHD):

- o IFRT alone to 30Gy/15-35Gy/20 fractions

What is INRT/ISRT?⁹⁻¹¹:

- definitions are per ILROG guidelines and depends of whether radiation is sole treatment or part of combined modality regimen

Role of IMRT/VMAT/TOMO^{12,13}:

- role of IMRT/VMAT/TOMO over 3DCRT is at discretion of treating radiation oncologist- this is determined on a case by case basis
- the low dose bath is a consideration when using IMRT as it relates to potential long term risk of second malignancies

Role of PET in Planning¹⁴⁻¹⁷:

- this is outlined in the ILROG guidelines for HL, nodal HL and extranodal HL

Appendix C: Prognostic Models

ECOG Performance Status	
0	Fully active, able to carry on all pre-disease activities without restriction.
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g. light housework, office work).
2	Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.
3	Capable of only limited self-care. Confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.

International Prognostic Index (IPI) for DLBCL Following CHOP-Type Chemotherapy¹⁸

Factors	# of Factors	5 year PFS
Age > 60 years ECOG 2-4 Stage III/IV ENS > 1 Increased LDH	0-1	60%
	2-3	30%
	4-5	15%

Revised IPI for DLBCL Following R-CHOP Chemotherapy¹⁹

Factors	# of Factors	% of Patients	4 year PFS	4 year DSS	4 year OS
Age > 60 years ECOG 2-4 Stage III/IV ENS > 1 Increased LDH	0	11	96%	95%	95%
	1-2	48	81%	83%	79%
	3-5	41	55%	56%	55%

R-CHOP for DLBCL by Elevated LDH and Stage 3-4¹⁹

# of Factors	% of Patients	4 year PFS	4 year DSS	4 year OS
0	27	92%	90%	84%
1	38	78%	79%	77%
2	35	53%	56%	55%

An online prognostic calculator is available at:

<http://www.qxmd.com/calculate-online/hematology/prognosis-large-b-cell-lymphoma-r-ipi>

Modified IPI for Non-Bulky Stage I-IIA DLBCL Treated with CHOP x 3 cycles and IFRT

Factors	# of Factors	5 year PFS	10 year PFS
Age > 60 yrs ECOG 2-4 Stage II Increased LDH	0	94%	89%
	1-2	79%	73%
	3-4	60%	50%

Salvage Age-Adjusted IPI for Relapsed DLBCL²⁰

Factors	# of Factors	~ PFS for HDCT/ASCT Patients
Stage III/IV	0	70%
Elevated LDH	1	50%
ECOG 2-4	2	30%
	3	10%

Primary CNS Lymphoma (Memorial Sloan Kettering Cancer Center Model)²¹

Risk Group	mOS	5 year OS	mFFS	5 year FFS
Age < 50 years	5-8 years	50-60%	2-5 years	35-40%
Age >50 years, KPS ≥ 70%	2-3 years	15-35%	1.5 years	10-20%
Age >50 years, KPS < 70%	1 year	10%	0.5-1 year	5-10%

Simplified IELSG Primary CNS Lymphoma (Leon Berard Cancer Centre Model)²²

Factors	# of Factors	mOS	5 year OS
Age > 60 years	0	6 years	60%
Elevated LDH	1	4 years	40%
Deep Tumour	2	1 year	23%
o Cerebellum	3	0.5 years	0%
o Periventricular			
o Basal ganglion			
o Brainstem			

Follicular Lymphoma International Prognostic Index (FLIPI) Pre-dated Rituximab-Chemotherapy (Survival with Non-Rituximab Containing Therapy)²³

Factors	Prognosis	# Factors	% Patients	5 year OS	10 year OS
Age ≥ 60 years	Good	0-1	36	90%	70%
Stage III-IV	Intermediate	2	37	78%	50%
Increased LDH	Poor	3-5	27	53%	35%
Hb < 120 g/L					
5+ nodal sites					

An online prognostic calculator is available at:

<http://www.qxmd.com/calculate-online/hematology/follicular-lymphoma-international-prognostic-index-flipi>

FLIPI 2²⁴

Factors	Prognosis	# Factors	% Patients	3 year PFS	5 year PFS
Age > 60 years	Good	0	20	91%	80%
Marrow involvement	Intermediate	1-2	53	69%	51%
Increased B2M	Poor	3-5	27	51%	19%
Hb < 120 g/L					
Node >6cm longest diameter					

Hodgkin Lymphoma International Prognostic Score (IPS) for Advanced Disease²⁵

Factors	# of Factors	5 year FFS with ABVD
Age ≥ 45 years	0-1	80%
Male		
Stage IV	2	70%
Albumin < 40 g/L		
Hb < 105 g/L	3	60%
WBC $\geq 15 \times 10^9$ /L		
Lymphocyte $< 0.6 \times 10^9$ /L or $< 8\%$ WBC	4-7	50%

An online prognostic calculator is available at:

<http://www.gxmd.com/calculate-online/hematology/hasenclever-hodgkins-prognosis-score-ips>

Prognosis of Hodgkin Lymphoma Relapsed After Prior Chemotherapy²⁶

Factors	# of Factors	2nd Line Chemo	HDCT/ASCT
Time to relapse < 1 year	0	70%	100%
Relapse stage III-IV	1	60%	70%
Hb < 105 female, 120 male	2	30%	50%
	3	0%	50%

* 5yr OS by second line therapy.

* Freedom from second failure was 50% for 0-1 factor, 35% for 2 factors, and 15% for 3 factors.

Mantle Cell Lymphoma (MIPI)²⁷

Points	Age	ECOG	LDH	WBC
0	< 50	0-1	< 0.67 ULN	< 6.7
1	50-59	-	0.67-0.99 ULN	6.7-9.99
2	60-69	2-4	1-1.49 ULN	10.0-14.99
3	70+	-	≥ 1.5 ULN	≥ 15.0
Points	Age	ECOG	LDH (ULN 235)	WBC
0	< 50	0-1	< 157	< 6.7
1	50-59	-	157-235	6.7-9.99
2	60-69	2-4	235-352	10.0-14.99
3	70+	-	≥ 352	≥ 15.0
Risk		# Points	~Median OS	~5 year OS
Low		0-3	6 years	60%
Intermediate		4-5	4 years	40%
High		6-11	2 years	20%

An online prognostic calculator is available at:

<http://www.gxmd.com/calculate-online/hematology/prognosis-mantle-cell-lymphoma-mipi>

Post-Transplantation Lymphoproliferative Disease (PTLD) Prognostic Scoring Systems:

1. Evens *et al.*, 2010²⁸

Score 1 point for each: hypoalbumenia, bone marrow involvement, CNS involvement

# of Factors	Overall 3 year PFS	Overall 3 year OS
0	84%	93%
1	66%	68%
2-3	7%	11%

Patients who received rituximab-based therapy as part of their initial treatment had a 3-year PFS of 70% and an OS of 73% compared with a 3-year PFS of 21% ($p<0.0001$) and an OS of 33% ($p=0.0001$) for patients who did not receive rituximab.

2. Leblond *et al.*, 2001²⁹

Risk Group	PS	and/or	# of Sites	mOS
low-risk	PS < 2	and	1	>5 years
intermediate risk	PS ≥ 2	or	2 or more	3 years
high risk	PS ≥ 2	and	2 or more	1 month

Waldenström Macroglobulinemia

Study	Prognostic Factors	Stratification	Survival
Gobbi <i>et al.</i> , 1994 ³⁰	Hb<9 g/dL Age >70 years Weight loss Cryoglobulinaemia	0-1 factor 0-2 2-4 factors	mOS 80 months mOS 48 months
Morel <i>et al.</i> , 2000 ³¹	Age ≥ 65 years Albumin <40 g/L 1 cytopenia (1-point) >1 cytopenia (2-points)	0-1 factor 2 factors 3-4 factors	5 year survival 87% 5 year survival 62% 5 year survival 25%
Dhodapkar <i>et al.</i> , 2001 ³²	β2M >3 mg/L Hb <12 g/dL IgM >40 g/L	β2M<3 mg/L + Hb≥12 g/dL β2M<3 mg/L + Hb<12 g/dL β2M≥3 mg/L + IgM<40 g/L β2M>3 mg/L + IgM>40 g/L	5 year survival 87% 5 year survival 63% 5 year survival 53% 5 year survival 21%
Merlini <i>et al.</i> , 2003 ³³	Age≥60 years Hb<100 g/L Albumin <35 g/L	<60 years, Hb≥100, Alb≥35 ≥60 years, Hb <100, Alb<35 Other combinations	mOS 178 months mOS 33 months mOS 84 months

CLL Prognostic Score from MD Anderson Cancer Center

Factors	# of Factors	# of Patients	5 year OS
Age >60 years	0	364	96%
B2M >2 mg/L	1	623	79%
Alb < 35	2	497	69%
Creatinine > 1.6	3	70	30%
17p mutations	4-5	10	16%

CLL International Prognostic Score: Bahlo 2015ASCO, J Clin Oncol 33, 2015 (suppl; abstr 7002)

Factors	Points	Risk Group	5 year OS
Age >65 years	1	Low (0-1 points)	93% (~90%)
Clinical Stage >1	1	Intermediate (2-3 points)	79% (~80%)
IGHV unmutated	2	High (4-6 points)	64% (~60%)
B2M >3.5 mg/L	2	Very high risk (7-10 points)	23% (~25%)
17p deletion or TP53 mutations	4		

The full analysis set was collected from eight phase 3 trials in France, Germany, the United Kingdom, the United States, and Poland (n=3,472 patients, median age 61 years (27-86 yrs)). 89% of patients had received treatment for CLL and median overall survival (OS) was 95 months. The model was externally validated in a third dataset comprising 845 patients with newly diagnosed CLL from the Mayo Clinic; 39% had received treatment for CLL. The final model of multivariate analysis identified 5 independent predictors for OS: *TP53* (17p) mutation (deleted and/or mutated; hazard ratio [HR]: 4.2); *IGHV* mutation status (unmutated, HR: 2.6); B2M (>3.5 mg/L; HR: 2.0); clinical stage (Binet B/C or Rai I-IV, HR: 1.6); and age (>65 years, HR: 1.7). Using weighted grading, a prognostic score from 0 to 10 was derived that separated the patients into four different groups: low risk (score 0-1), intermediate risk (score 2-3), high risk (score 4-6), and very high risk (score 7-10). At 5 years, significantly different rates of OS were observed for the low to the very high risk group, 93%, 79%, 64%, and 23%, respectively ($P<0.001$; C-statistic $c=0.72$ [95% CI: 0.69, 0.76]). The multivariable model was confirmed on the internal validation datasets; in addition, the four risk groups were reproduced with on the Mayo dataset, with 5-year OS rates of 97%, 91%, 68% and 21%, respectively ($P<0.001$; C-statistic $c=0.79$ [95% CI: 0.74, 0.85]).

Appendix D: Lymphoma Response Criteria

Response	Definition	Nodal Masses	Spleen, Liver	Bone Marrow
CR	Disappearance of all evidence of disease	(a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT	not palpable, nodules disappeared	Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immuno-histochemistry should be negative
PR	Regression of measurable disease and no new sites	$\geq 50\%$ decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT	$\geq 50\%$ decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen	Irrelevant if positive prior to therapy; cell type should be specified
SD	Failure to attain CR/PR or PD	(a) FDG-avid or PET positive prior to therapy; PET positive at prior sites of disease and no new sites on CT or PET (b) Variably FDG-avid or PET negative; no change in size of previous lesions on CT		
Relapsed Disease or PD	Any new lesion or increase by $\geq 50\%$ of previously involved sites from nadir	Appearance of a new lesion(s) > 1.5 cm in any axis, $\geq 50\%$ increase in SPD of more than one node, or $\geq 50\%$ increase in longest diameter of a previously identified node > 1 cm in short axis Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy	$> 50\%$ increase from nadir in the SPD of any previous lesions	New or recurrent involvement

Abbreviations: CR=complete response, FDG-PET=(18)F-fluorodeoxyglucose positron emission tomography, CT=computed tomography, PR=partial response, SPD=sum of the product of the diameters, SD=stable disease, PD=progressive disease.

LYMPHOMA RESPONSE CRITERIA³⁴

Complete Response (CR)

The designation of CR requires the following:

1. Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
- 2a. Typically FDG-avid lymphoma: in patients with no pretreatment PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted as long as it is PET negative.

- 2b. Variably FDG-avid lymphomas/FDG avidity unknown: in patients without a pretreatment PET scan, or if a pretreatment PET scan was negative, all lymph nodes and nodal masses must have regressed on CT to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their long axis and more than 1.0 cm in their short axis before treatment must have decreased to ≤ 1.0 cm in their short axis after treatment.
3. The spleen and/or liver, if considered enlarged before therapy on the basis of a physical examination or CT scan, should not be palpable on physical examination and should be considered normal size by imaging studies, and nodules related to lymphoma should disappear. However, determination of splenic involvement is not always reliable because a spleen considered normal in size may still contain lymphoma, whereas an enlarged spleen may reflect variations in anatomy, blood volume, the use of hematopoietic growth factors, or causes other than lymphoma.
4. If the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy. The biopsy sample on which this determination is made must be adequate (with a goal of >20 mm unilateral core). If the sample is indeterminate by morphology, it should be negative by immunohistochemistry. A sample that is negative by immunohistochemistry but that demonstrates a small population of clonal lymphocytes by flow cytometry will be considered a CR until data become available demonstrating a clear difference in patient outcome.

Partial Response (PR)

The designation of PR requires all of the following:

1. At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. These nodes or masses should be selected according to all of the following: they should be clearly measurable in at least 2 perpendicular dimensions; if possible they should be from disparate regions of the body; and they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.
2. No increase should be observed in the size of other nodes, liver, or spleen.
3. Splenic and hepatic nodules must regress by $\geq 50\%$ in their SPD or, for single nodules, in the greatest transverse diameter.
4. With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
5. Bone marrow assessment is irrelevant for determination of a PR if the sample was positive before treatment. However, if positive, the cell type should be specified (e.g., large-cell lymphoma or small neoplastic B cells). Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders. When the bone marrow was involved before therapy and a clinical CR was achieved, but with no bone marrow assessment after treatment, patients should be considered partial responders.

6. No new sites of disease should be observed.
7. Typically FDG-avid lymphoma: for patients with no pre-treatment PET scan or if the PET scan was positive before therapy, the post-treatment PET should be positive in at least one previously involved site.
8. Variably FDG-avid lymphomas/FDG-avidity unknown: for patients without a pre-treatment PET scan, or if a pre-treatment PET scan was negative, CT criteria should be used.
9. In patients with follicular lymphoma or mantle-cell lymphoma, a PET scan is only indicated with one or at most two residual masses that have regressed by more than 50% on CT; those with more than two residual lesions are unlikely to be PET negative and should be considered partial responders.

Stable Disease (SD)

Stable disease is defined as the following:

1. A patient is considered to have SD when he or she fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (see Relapsed Disease [after CR]/Progressive Disease [after PR, SD]).
2. Typically FDG-avid lymphomas: the PET should be positive at prior sites of disease with no new areas of involvement on the post-treatment CT or PET.
3. Variably FDG-avid lymphomas/FDG-avidity unknown: for patients without a pre-treatment PET scan or if the pre-treatment PET was negative, there must be no change in the size of the previous lesions on the post-treatment CT scan.

Relapsed Disease (after CR)/ Progressive Disease (after PR or SD)

1. Lymph nodes should be considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be considered abnormal if its short axis is more than 1.0. Lymph nodes $\leq 1.0 \times \leq 1.0$ cm will not be considered as abnormal for relapse or progressive disease.
2. Appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size. Increased FDG uptake in a previously unaffected site should only be considered relapsed or progressive disease after confirmation with other modalities. In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT are mostly benign. Thus, a therapeutic decision should not be made solely on the basis of the PET without histologic confirmation.
3. At least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered

progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must increase by $\geq 50\%$ and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis.

4. At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.
5. Lesions should be PET positive if observed in a typical FDG-avid lymphoma or the lesion was PET positive before therapy unless the lesion is too small to be detected with current PET systems (<1.5 cm in its long axis by CT).
6. Measurable extranodal disease should be assessed in a manner similar to that for nodal disease. For these recommendations, the spleen is considered nodal disease. Disease that is only assessable (e.g., pleural effusions, bone lesions) will be recorded as present or absent only, unless, while an abnormality is still noted by imaging studies or physical examination, it is found to be histologically negative.
7. In clinical trials where PET is unavailable to the vast majority of participants, or where PET is not deemed necessary or appropriate for use (e.g., a trial in patients with MALT lymphoma), response should be assessed as above, but only using CT scans. However, residual masses should not be assigned CRu status, but should be considered partial responses.

Revised Criteria for Response Assessment

Response and site	PET-CT-Based Response	CT-Based Response
Complete Lymph nodes and extralymphatic sites	Complete metabolic response Score 1,2, or 3* with or without a residual mass on 5PI It is recognized that in Waldeyer's ring or extranodal sites with high physiologic uptake or with activation within spleen or marrow (eg. with chemotherapy or myeloid colony-stimulating factors), uptake may be greater than normal mediastinum and/or liver. In this circumstance, complete metabolic response may be inferred if uptake at sites of initial involvement is no greater than surrounding normal tissue even if the tissue has high physiologic uptake.	Complete radiologic response (all of the following) Target nodes/nodal masses must regress to ≤ 1.5 cm in LDI No extralymphatic sites of disease
Nonmeasured lesion Organ enlargement New lesions Bone marrow	Not applicable Not applicable None No evidence of FDG-avid disease in marrow	Absent Regress to normal None Normal by morphology; if indeterminate, IHC negative
Partial Lymph nodes and extralymphatic sites	Partial metabolic response Score 4 or 5 with reduced uptake compared with baseline and residual masses(es) of any size At interim, these findings suggest responding disease At end of treatment, findings indicate residual disease	Partial remission (all of the following) $\geq 50\%$ decrease in SPD of up to 6 target measurable nodes and extranodal sites When a lesion is too small to measure on CT, assign 5 mm x 5 mm as the default value When no longer visible, 0 x 0 mm For a node > 5 mm x 5 mm, but smaller than normal, use actual measurement for calculation Absent/normal, regressed, but no increase Spleen must have regressed by > 50% in length beyond normal
Nonmeasured lesions Organ enlargement New lesions Bone marrow	Not applicable Not applicable None Residual uptake higher than uptake in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or an interval scan.	None Not applicable
No response or stable disease Target nodes/nodal masses, extranodal lesions	No metabolic response Score 4 or 5 with no significant change in FDG uptake from baseline at interim or end of treatment	Stable disease < 50% decrease from baseline in SPD of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met
Nonmeasured lesions Organ enlargement New lesions Bone marrow	Not applicable Not applicable None No change from baseline	No increase consistent with progression No increase consistent with progression None Not applicable
Progressive disease Individual target nodes/nodal masses Extranodal lesions	Progressive metabolic disease Score 4 or 5 with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment	Progressive disease requires at least 1 of the following PPD progression: An individual node/lesion must be abnormal with: LDI > 1.5cm and Increase by $\geq 50\%$ from PPD nadir and An increase in LDI or SDI from nadir 0.5 cm for lesions ≤ 2 cm 1.0 cm for lesions > 2 cm In the setting of splenomegaly, the splenic length must increase by > 50% of the extent of its prior increase beyond baseline (eg. a 15-cm spleen must increase to > 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline
Nonmeasured lesions	None	New or recurrent splenomegaly New or clear progression of preexisting nonmeasured lesions

Response and site	PET-CT-Based Response	CT-Based Response
New lesions	New FDG-avid foci consistent with lymphoma rather than another etiology (eg. Infection, inflammation). If uncertain regarding etiology or new lesions, biopsy or interval scan may be considered	Regrowth of previously resolved lesions A new node > 1.5 cm in any axis A new extranodal site > 1.0 cm in any axis; if < 1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphoma Assessable disease of any size unequivocally attributable to lymphoma
Bone Marrow	New or recurrent FDG-avid foci	New or recurrent involvement

Abbreviations: 5PS, 5-point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC immunohistochemistry; LDi, longest transverse diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; PPD, cross product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product of the perpendicular diameters for multiple lesions.

* A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim scan. However, in trials involving PET where de-escalation is investigated, it may be preferable to consider a score of 3 as inadequate response (to avoid undertreatment). Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal lesions selected to be clearly measurable in two diameters. Nodes should preferably be from disparate regions of the body and should include, where applicable, mediastinal and retroperitoneal areas. Non-nodal lesions include those in solid organs (eg. liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable disease should be considered not measured. These sites include any nodes, nodal masses, as truly assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that cannot be confirmed and followed by imaging. In Waldeyer's ring or in extranodal sites (eg, GI tract, liver, bone, marrow), FDG uptake may be greater than in the mediastinum with complete metabolic response, but should be no higher than surrounding normal physiologic uptake (eg. with marrow activation as a result of chemotherapy or myeloid growth factors).

iPET 5PS: 1, no uptake above background; 2, uptake $\leq$ mediastinum; 3, uptake > mediastinum but $\leq$ liver; 4, uptake moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.

Appendix E: New Lymphoma Patient Data Sheet

Identification:

Name _____ DOB (d/m/y) _____
 AHN _____ ACB# _____
 Gender: male female Age at Diagnosis _____

Diagnostic Information:

Date Diagnosis (d/m/y) _____ Surgical accession # _____
 Biopsy type: open surgical core needle fine needle bone marrow blood
 Diagnosis: _____

Stage: I II III IV B sx: yes no Bulk > 10cm: yes no
 Marrow +ve: yes no Other Extranodal Sites: _____
 LDH elevated: yes no ECOG Status: 0 1 2 3 4

Prognosis Score by Histology:

Large Cell Lymphoma: #IPI Factors: 0 1 2 3 4 5
 Circle if present: Age > 60yr Stage III/IV LDH > ULN ECOG 2-4 ≥ 2 Extranodal Sites
Follicular: #FLIPI Factors: 0 1 2 3 4 5
 Circle if present: Age ≥ 60 yr Stage III/IV LDH > ULN Hb < 120g/L ≥ 5 Nodal Sites
Hodgkin: #IPS Factors: 0 1 2 3 4 5 6 7
 Circle if present: Age ≥ 45 yr Stage IV Male Lymphocyte < 0.6 (or < 8% WBC) Albumin < 40 g/L
 Hb < 105g/L WBC ≥ 15

Initial Treatment:

Therapy	Plan	Regimen / Radiation Site	Start Date d/m/y
Chemotherapy	yes no		
Maintenance Rituximab	yes no		
Radiotherapy	yes no		
Stem Cell Transplant	yes no		


First Relapse Information:

Relapse/progression after treatment 1: yes no Date relapse (d/m/y) _____
 2nd Treatment: Regimen _____ Radiation yes no HDCT/ASCT yes no


Survival Information:

Dead: yes no Date death or last follow-up (d/m/y) _____
 Cause of death: lymphoma other (specify) _____

Ann Arbor Staging Nodal Sites



FLIPI Nodal Sites



Revised-International Prognostic Index for

Diffuse Large B-Cell Lymphoma Following R-CHOP Chemotherapy

Factors:

	#Factors	%pts	4yr PFS
• Age > 60yr	0	11	95%
• ECOG 2-4	1-2	48	80%
• Stage III/IV	3-5	41	55%
• ENS > 1			
• ↑ LDH			

FLIPI (Follicular Lymphoma International Prognostic Index)

Factors

Survival with Non-Rituximab Containing Therapy

	Prognosis #	%pt	5yr	10yr
• Age ≥ 60yrs	Good 0-1	36	90%	70%
• Stage 3-4	Intermed 2	37	75%	50%
• Increased LDH	Poor 3-5	27	50%	35%
• Hb < 120g/l				
• 5+ nodal sites				

Primary CNS Lymphoma Prognostic Index

	Overall Survival		Failure-Free Survival	
Adverse Factors	mOS	5yr OS	mFFS	5yr FFS
Age < 50 yrs	5-8 yrs	50-60%	2-5yrs	35-40%
Age > 50 yrs KPS ≥ 70%	2-3 yrs	15-35%	1.5 yrs	10-20%
Age > 50 yrs KPS < 70%	1 yr	10%	0.5-1yr	5-10%

Hodgkin Lymphoma International Prognostic Score for Advanced Stage Disease

Ann Arbor Staging System

Stage I	Single lymph node region (I) or one extralymphatic organ (IE)
Stage II	≥2 lymph node regions (II) or local extralymphatic extension plus lymph nodes (IIE), same side of diaphragm.
Stage III	Lymph node regions both sides of diaphragm, either alone (III) or with local extralymphatic extension (IIIE)
Stage IV	Diffuse involvement of one or more extralymphatic organs or sites.

ECOG Performance Status

0	Fully active, able to carry on all pre-disease activities without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
2	Ambulatory, capable of all self-care but unable to carry out any work activities. Up and about >50% waking hours.
3	Capable of only limited self-care. Confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.

Appendix F: Ideal Body Weight

Height (cm)	Males – Weight (kg)			Females – Weight (kg)		
	Small Frame	Medium Frame	Large Frame	Small Frame	Medium Frame	Large Frame
145				47.1	51.0	55.4
146				47.3	51.3	55.8
147				47.6	51.7	56.2
148				47.9	52.1	56.7
149				48.2	52.5	57.1
150				48.5	52.9	57.5
151				48.9	53.4	58.1
152				49.3	53.8	58.7
153				49.8	54.4	59.2
154				50.3	55.0	59.7
155	57.3	59.6	63.3	50.7	55.6	60.3
156	57.7	59.9	63.7	51.2	56.1	60.9
157	58.0	60.3	64.1	51.7	56.6	61.5
158	58.4	60.7	64.5	52.3	57.0	62.1
159	58.8	61.0	65.0	52.8	57.6	62.7
160	59.1	61.4	65.5	53.4	58.2	63.4
161	59.5	61.8	66.0	53.9	58.7	64.0
162	59.8	62.2	66.5	54.4	59.2	64.6
163	60.2	62.7	67.0	55.0	59.7	65.2
164	60.5	63.1	67.6	55.5	60.2	65.9
165	60.9	63.6	68.1	56.0	60.8	66.5
166	61.3	64.1	68.7	56.5	61.4	67.1
167	61.7	64.6	69.4	57.1	61.9	67.8
168	62.2	65.2	70.0	57.7	62.5	68.4
169	62.6	65.7	70.7	58.2	63.0	69.0
170	63.1	66.3	71.3	58.8	63.5	69.6
171	63.5	66.8	71.9	59.3	64.0	70.2
172	64.0	67.3	72.5	59.8	64.6	70.7
173	64.4	67.8	73.2	60.3	65.2	71.2
174	64.9	68.4	73.7	60.8	65.7	71.8
175	65.3	68.9	74.3	61.4	66.2	72.3
176	65.7	69.5	75.0	61.9	66.8	72.8
177	66.2	70.0	75.6	62.5	67.3	73.4
178	66.7	70.6	76.2	63.1	67.8	73.9
179	67.2	71.2	76.9	63.6	68.4	74.5
180	67.8	71.8	77.5	64.1	69.0	75.0
181	68.4	72.4	78.2	64.7	69.6	75.6
182	69.0	73.1	78.9	65.2	70.1	76.1
183	69.6	73.7	79.6			
184	70.2	74.4	80.4			
185	70.8	75.2	81.3			
186	71.4	75.8	82.0			
187	72.1	76.4	82.8			
188	72.7	77.0	83.6			
189	73.4	77.8	84.5			
190	74.1	78.7	85.4			
191	74.8	79.5	86.3			

References

1. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood*. 2004;104(3):634-641.
2. Gang AO, Strom C, Pedersen M, d'Amore F, Pedersen LM, Bukh A, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. *Ann Oncol*. 2012;23(1):147-153.
3. Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, Pfluger KH, Vrieling T, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *Ann Oncol*. 2008;19(3):545-552.
4. Guo HQ, Liu L, Wang XF, Lin TY, Yao SN, Yao ZH, et al. Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. *Mol Clin Oncol*. 2014;2(6):1172-1176.
5. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *J Clin Oncol*. 2011;29(33):4410-4416.
6. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. *J Clin Oncol*. 1996;14(3):925-934.
7. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. *Ann Oncol*. 2011;22(8):1859-1864.
8. Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. *Blood*. 2014;124(19):2913-2920.
9. Girinsky T, Ghalibafian M. Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. *Semin Radiat Oncol*. 2007;17(3):206-222.
10. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. *Radiother Oncol*. 2006;79(3):270-277.
11. Yahalom J. Hodgkin's and non-Hodgkin's lymphoma radiotherapy indications, field and dose decisions and implementation: refresher course. . Paper presented at: American Society for Therapeutic Radiology and Oncology 47th Annual Meeting; October 16-19, 2005., 2005; Denver, Colorado.
12. Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? *Int J Radiat Oncol Biol Phys*. 2006;64(1):218-226.
13. Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. *Int J Radiat Oncol Biol Phys*. 2005;62(1):198-206.
14. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. *Cancer Treat Rev*. 2006;32(4):245-260.
15. Bujenovic S. The role of positron emission tomography in radiation treatment planning. *Semin Nucl Med*. 2004;34(4):293-299.
16. Kahn ST, Flowers C, Lechowicz MJ, Hollenbach K, Johnstone PA. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. *Int J Radiat Oncol Biol Phys*. 2006;66(4):961-965.
17. Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. *Semin Radiat Oncol*. 2007;17(3):190-197.
18. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med*. 1993;329(14):987-994.
19. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. 2007;109(5):1857-1861.
20. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. *Blood*. 2003;102(6):1989-1996.
21. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. *J Clin Oncol*. 2006;24(36):5711-5715.

22. Ghesquieres H, Sunyach MP, Drouet Y, Sebban C, Chassagne C, Jouanneau E, et al. Long-Term Follow-Up of 132 Immunocompetent Primary Central Nervous System Lymphomas Treated at Leon Berard Cancer Centre: Proposition of a New Prognostic Model. *Blood*. 2007;110(11):521-521.
23. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. *Blood*. 2004;104(5):1258-1265.
24. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. *J Clin Oncol*. 2009;27(27):4555-4562.
25. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med*. 1998;339(21):1506-1514.
26. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. *J Clin Oncol*. 2002;20(1):221-230.
27. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood*. 2008;111(2):558-565.
28. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. *J Clin Oncol*. 2010;28(6):1038-1046.
29. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. *J Clin Oncol*. 2001;19(3):772-778.
30. Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, et al. Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. *Pituitary*. 2010;13(1):68-77.
31. Durando X, Thivat E, Gilliot O, Irthum B, Verrelle P, Vincent C, et al. Temozolomide treatment of an adult with a relapsing medulloblastoma. *Cancer Invest*. 2007;25(6):470-475.
32. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. *J Clin Endocrinol Metab*. 1997;82(3):876-883.
33. Deutsch M, Thomas PR, Krischer J, Boyett JM, Albright L, Aronin P, et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. *Pediatr Neurosurg*. 1996;24(4):167-167.
34. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol*. 2007;25(5):579-586.

Development and Revision History

This guideline was developed by a multidisciplinary working group comprised of members from the Alberta Provincial Hematology Tumour Team, external participants identified by the Working Group Lead, and a methodologist from the Guideline Resource Unit. The draft guideline was externally reviewed and endorsed by members of the Alberta Provincial Hematology Tumour Team who were not involved in the guideline's development, including surgical oncologists, radiation oncologists, medical oncologists, hematologists, nurses, pathologists, and pharmacists. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in March 2006.

Maintenance

A formal review of the guideline will be conducted in 2024. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

2-CDA, 2-chlorodeoxyadenosine; ABVD, adriamycin + bleomycin + vinblastine + dacarbazine; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase (test); ALL, acute lymphoblastic leukemia; ALT, alanine transaminase (test); AML, acute myeloid leukemia; ATCL, adult T-cell lymphoma; BCNU, carmustine; BEACOPP, bleomycin + etoposide + adriamycin + cyclophosphamide + vincristine + procarbazine + prednisone; BEAM, BCNU + etoposide + cytarabine + melphalan; BL, Burkitt lymphoma; BMT, bone marrow transplant; B-R, Bendamustine-rituximab; CALGB, Cancer and Leukemia Group B; CAP, cyclophosphamide + adriamycin + prednisone; CBV, cyclophosphamide + BCNU + etoposide; CEC, cyclophosphamide + lomustine + vindesine + melphalan + prednisone + epidoxirubicin + vincristine + procarbazine + vinblastine + bleomycin; CEPP, cyclophosphamide + etoposide + procarbazine + prednisone; ChIVPP, chlorambucil + vinblastine + procarbazine + prednisone; CHOP, cyclophosphamide + adriamycin + vincristine + prednisone; CHOEP, cyclophosphamide + adriamycin + vincristine + etoposide + prednisone; CL, chronic lymphocytic leukemia; CMED, cyclophosphamide + etoposide + methotrexate + dexamethasone + leucovorin + G-CSF; CNS, central nervous system; CODOX-M, cyclophosphamide + vincristine + adriamycin + methotrexate; COPP, cyclophosphamide + vincristine + procarbazine + prednisone; CR, complete remission; CS, clinical stage; CSF, cerebrospinal fluid; CT, computed tomography scan; CTCL, cutaneous T-cell lymphoma; CVAD,

cyclophosphamide + vincristine + adriamycin + dexamethasone; CVP, cyclophosphamide + vincristine + prednisone; DHAP, dexamethasone + cytarabine + cisplatin; DICE, dexamethasone + ifosfamide + cisplatin + etoposide + mesna; DICEP, dexamethasone + cyclophosphamide + etoposide + cisplatin + mesna + Septra; DLBCL, diffuse large B-cell lymphoma; DLCO, diffusing capacity of the lung for carbon monoxide; EBER, Epstein-Barr virus encoded ribonucleic acid; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; ENS, extracapsular neoplastic spread; ENT, ear, nose, and throat; ESHAP, etoposide + methylprednisolone + cytarabine + cisplatin; ESR, erythrocyte sedimentation rate; FC, fludarabine + cyclophosphamide; FEV1, forced expiratory volume in one second; FISH, fluorescent in situ hybridization; FLIPI, Follicular Lymphoma International Prognostic Index; FND, fludarabine + mitoxantrone + dexamethasone; FVC, forced vital capacity; G-CSF, granulocyte-colony stimulating factor; GDP, gemcitabine + dexamethasone + cisplatin; GHSG, German Hodgkin Study Group; GMALL, German multicentre adult acute lymphoblastic leukemia protocol; H&E, hematoxylin and eosin stain; HAART, highly active antiretroviral therapy; HAMA, human anti-mouse antibodies; HDCT, high dose chemotherapy; HL, Hodgkin lymphoma; HP-Pac, lansoprazole + clarithromycin + amoxicillin; HSCT, hematopoietic stem cell transplantation; HVS, hyperviscosity syndrome; ICE, ifosfamide + carboplatin + etoposide; IELSG, International Extranodal Lymphoma Study Group; IFRT, involved field radiation therapy; IMRT, intensity-modulated radiation therapy; IPI/IPS, International Prognostic Index/Score; IV, intravenous; IVAC, ifosfamide + mesna + etoposide + cytarabine; IVE, ifosfamide + vincristine + etoposide; KPS, Karnofsky Performance Status Scale; LDH, lactate dehydrogenase test; LPL, lymphoplasmacytic lymphoma; LVEF, left ventricular ejection fraction; MACOP-B, methotrexate + adriamycin + cyclophosphamide + vincristine + bleomycin + prednisone; MALT, mucosa-associated lymphoid tissue; MDS, myelodysplastic syndrome; MEP, mitomycin C + etoposide + cisplatin; MTD, maximum transthoracic diameter; MTX, methotrexate; MUGA, multiple gated acquisition scan; NHL, non-Hodgkin lymphoma; NK, natural killer; NLPD, nodular lymphocyte predominant Hodgkin disease; OS, overall survival; PCNSL, primary central nervous system lymphoma; PCP, Pneumocystis jiroveci pneumonia; PET, positron emission tomography; PFS, progression-free survival; PFT, pulmonary function test; POMP, mercaptopurine + vincristine + methotrexate + prednisone; PR, partial response; PTCL, peripheral T-cell lymphoma; PTLD, post-transplant lymphoproliferative disorder; PUVA, psoralen + ultraviolet A radiation; R, rituximab; R-CHOP, rituximab + cyclophosphamide + adriamycin + vincristine + prednisone; R-CVP, rituximab + cyclophosphamide + vincristine + prednisone; R-FCM, fludarabine + cyclophosphamide +

mitoxantrone + rituximab; RIT, radioimmunoconjugate therapy; RR, response rate; RT, radiotherapy; SBFT, small bowel follow-through (test); SCT, stem cell transplant; SD, stable disease; SLE, systemic lupus erythematosus; SLL, small lymphocytic lymphoma; SOT, solid organ transplant; STNI, subtotal nodal irradiation; TBUc, thiotepa + busulfan + cyclophosphamide; TBI, total body irradiation; TRM, Transplant-related mortality; TSH, thyroid stimulating hormone; UGI, upper gastrointestinal series (test); VIPD, etoposide + ifosfamide + cisplatin + dexamethasone; WHO, World Health Organization; WM, Waldenström macroglobulinemia.

Disclaimer The recommendations contained in this guideline are a consensus of the Alberta Hematology Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2024) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of CancerCare Alberta's evidence-based clinical practice guidelines and supporting materials comes from the CancerCare Alberta operating budget; no outside commercial funding was received to support the development of this document. All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

Citation

Cancer Care Alberta, Alberta Health Services (2024). Clinical Practice Guideline on Lymphoma, Version 20]. Accessed [Month, Year]. Available from: www.ahs.ca/guru